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The introduction will begin with a brief discussion of the current status of the drug discovery process, 
followed by a discussion on why newer approaches are necessary, and how a “biofocussed 
chemoprospecting” approach can lead to more efficient hit-generation in drug discovery. This will 
be followed by a detailed discussion on specific efficiency parameters for library design and effective 
compound selection as the core of this approach. The principle and approach of biofocussed 
chemoprospecting thereby emerges; it developed further by describing specific examples of 
compound libraries. Finally, the detailed goals of the thesis research will be shown to follow from 
these analyses. Thus, this introduction should guide the reader from current status of drug discovery 




1.  Biofocussed chemoprospecting approach 
This chapter serves as an introduction to the current status of drug discovery processes and  
timelines, the need to find new approaches of basic research, and how biofocussed 
chemoprospecting can provide a way forward for efficient drug discovery. This includes discussion 
of a typical drug discovery process, followed by discussion of different types of biochemical 
screening, their role in drug discovery and the importance of linking the screening approaches with 
synthetic chemistry accessibility. This leads to “chemoprospecting”, the approach introduced and 
followed here. These discussions are expected to bridge the reader to the more specific introduction 
on chemical libraries for chemoprospecting, to be discussed in chapter 2.  
1.1. Need for faster and cheaper drug discovery approaches  
New drug discovery and development is typically a long process involving enormous 
resources in terms of time, money, labour and intellect. If we consider the drug discovery 
process as a sequence from the original idea to the market launch, it can take from 8 to 12 
years of time, and more than 1 billion USD, to develop a single new chemical entity (NCE) 
into a marketable drug.1,2 In fact, according to an estimate3 from the Tufts Center for the 
Study of Drug Development (CSDD), the average drug discovery investment has risen to 
over 2.6 billion USD per approved drug. Moreover, in recent years, the rise in the cost of 
drug discovery has been accompanied by the high attrition rates and an overall decline in 
pharma R & D productivity, raising the risks of investment.4–6 Further, most 
pharmaceutical research is carried out with target based approach, which (despite being a 
low-risk approach) necessitates significantly improved therapeutic activity from existing 
molecules – often requiring longer and larger clinical trials, in turn increasing the cost and 
time before market-launch, resulting high drug prices of new drugs.  
A drug discovery research project must pass through several stages before a drug can be 
launched to market.7 The period before the preclinical testing is considered basic research 
in which only a small number of compounds out of thousands of molecules are selected for 
further research. This basic research phase can take up to 5 years. After this phase, the 
possibilities to minimize cost and time are limited, as each stage must be carried out in 
compliance with extensive regulatory guidelines. This shows the need to adopt newer 
approaches in basic research phase (especially for hit-finding and lead-optimization) that 
can make the drug discovery process faster, cheaper and more efficient. In addition to 
streamlining the process, new approaches also promise improvements in the quality of the 
results, as it been observed8,9 that improved and more focused preclinical research may 
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lessen the possibility of drug discovery failure. The following chapters will throw more 
light on this and how “Chemoprospecting” approach offers a good alternative to current 
approaches. 
1.2.  Bioactivity screening 
The primary goal of any drug discovery process is to elicit a specific biological response 
that can translate into corresponding therapeutic activity. This can be analyzed by 
measuring the effect of compounds in question on the biological responses in bioactivity 
screening. Thus, bioactivity screening has a central role in any drug discovery model. The 
screenings may be phenotypic screening or target specific screening.  
 Phenotypic screening 
Phenotypic screening is useful to identify the effect of compounds on specific cellular 
activity. Hence, such screening is useful when the objective of the research is to identify 
whether compounds exert any therapy relevant activity at all, independent of whether the 
drug-target at the core of the activity mechanism is known. High throughput phenotypic 
screening10–13 has generally involved in vitro (biochemical or cellular) assays since the 
1980s, in contrast to earlier reliance on in vivo (i.e. animal models) phenotypic assays. They 
identify effects of compounds on specific cellular activity, depending on the assay readout. 
Usually, the assays are performed on well characterized cell lines and a specific read-out 
parameter, such as cell-growth or particular protein production. For more complex analysis 
with parallel measurement of more than one parameters, high content screening14,15 is also 
used.  
 Target specific screening 
Target specific screening is the logical approach when the objective of the research is to 
identify the effect of compounds on a specific cellular or extracellular target, usually an 
enzyme or receptor. Such assays are always in vitro assays, and are carried out on isolated 
targets, generally as activity or binding assays.16 As indicated by the names, activity assays 
measure the activity of a target as a function of compound concentration, while binding 
assays measure the binding of a compound to the often immobilized target, independent of 
its activity effects.  
Table 1 provides an overview of phenotypic and target specific screening approaches. 
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Table 1. Comparison of phenotypic and target specific screenings 
Criteria Phenotypic screening Target specific screening 
In vitro / In vivo 
Can be both, but mostly in vitro in 
initial stage of drug discovery 
In vitro 
Subject Cells or Cell lines 
Specific target such as 
enzyme / receptor 
Read-out 
Growth / growth inhibition / cell 
count / protein expression / 
effect on cellular organnels etc. 












Yes, target identification and 
validation is required, often it 
proves to be a bottleneck 
No, assays are done on the 




Assays are done on cells, so 
results are indicative of the 
activity at cellular level 
Critically depends factors 
such as on absorption, pH 
and stability inside the cell 
and cellular organelles 
Correlation with 
in vivo activity 
Generally good correlation, 
except where distribution and 
metabolism affect severely. 
Very unpredictable 
 
1.3. Hit-finding approaches and library design 
As described above, bioactivity screening is the core of any drug discovery project. The 
overall goal is to achieve valuable therapeutic activity by eliciting a suitable phenotypical 
response due to target interactions. For medicinal chemists, the means to achieve the 
specific biological response is usually to select—somehow—a promising set of small 
chemical molecules, from the vast “chemical space” of possible molecules, and optimize 
them. The typical hit-finding and lead optimization process involves screening a large 
number of molecules with an assay simple enough to enable high throughput testing, 
choosing the most promising hits, and optimizing them based on hypotheses of the best 
properties for clinical trials. The fundamental requirement for this process is the supply of 
the molecules for screening, which may be either natural or synthetic. Based on the source 
and choice of molecules, and corresponding bioactivity screening approaches, there are 
several conventional methods for hit-discovery and lead optimization: (1) target-based 
approaches (structure- or fragment based), (2) a scaffold-based approach, or (3) 
bioprospecting (Figure 1). The bioprospecting approach relies on natural product extracts 
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and purified biomolecules to provide the molecules for screening, while all other 
approaches rely largely on synthetic chemistry.   
 
Figure 1. Different approaches in drug discovery research 
 Target based approaches 
Target based approaches use validated and “druggable” targets. Druggable targets are ones 
that have chemical characteristics that are compatible with high affinity binding at sites 
where binding should cause the desirable therapeutic effect. Usually, high throughput 
screening is used to identify “hit” molecules, which is followed by computational studies 
and combinatorial/parallel synthesis approaches to modify the molecules for further 
testing. Target based approaches are relatively low-risk, as only the hits that act on known 
and validated drug targets are considered for further development. Hence, target based 
approaches have been followed most17 in both academia and industries in the past decade.  
A significant limitation of target-based approaches is over-exploitation of a target. It often 
reduces the target value, both from a biological and from a market perspective. 
Biologically, this is especially true for chronic use for resistance-prone diseases such as 
cancer or antimicrobial therapy. From a market perspective, the use of the same target and 
hence the same mechanism of action requires that new drug candidates must show 
significant improvement over the existing molecules that act on the same target, which in 
turn requires longer and larger clinical trials, making the drug development slower and 
costlier.  
A. Structure based  
A structure based approach is possible when the interactions of known active 
compounds/leads are known in detail, enabling the design of specific modifications to the 
target binding interactions.17–19 It is a relatively recent approach, starting in the 1980s as 
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protein crystallography was increasingly efficient due to improvements of recombinant 
protein production methods, X-ray sources, and crystallography techniques. Now, with the 
support of high-speed computation, high-throughput X-ray crystallography techniques, and 
extensive databases of known structures, opportunities exist to analyze and/or predict drug-
target interactions for many types of targets. Despite the availability of target structures, 
however, de novo structure-based drug design is relatively less frequent, due to the still 
limited ability to predict binding strengths. 
B. Fragment based  
The fragment based approach is based on the idea that different fragments of a molecule 
interact at different sites inside the binding pocket of a protein. It is a type of structure 
based approach. In this approach, different fragments binding to the residues inside the 
active site of the target are identified, and then a lead molecule is built with the fragments 
in such a way that would enable spatial arrangement of the fragments in proximity of the 
respective residues.20–22 Generally, the lead molecules are built by anchoring the fragments 
as substitutions around suitable chemical scaffolds. This provides an opportunity for 
introducing newer, simpler and easily synthesized scaffolds. However, the interactions of 
the fragments anchored around a scaffold in the biological system may deviate significantly 
from that observed from the fragment crystal structure, or as predicted computationally. 
Small changes in the number of rotational bonds, atom-specific conformational changes 
such as amino-nitrogen inversion, and conformational changes in saturated rings may also 
cause significant differences in interactions at the active site. Therefore, the fragment based 
approach is robust when the key fragment properties that are important for binding allow 
for such changes. Because fragment binding geometries are only approximately reproduced 
in the larger molecules, diverse methods relevant to pocket identification and verification 
of fragment binding, such as NMR spectroscopy, may be utilized in the fragment based 
approach.23 
 Scaffold based  
The scaffold based approach is a conventional approach of drug discovery and 
development. It is based on analyzing the structural similarities of active molecules and 
developing their variants.24–27 Initially, compounds from diverse scaffolds are screened. 
Based on the structures of active compounds, common scaffolds are recognized and kept 
constant, while a library of compounds is created around the scaffold by variations in its 
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appendages (substitutions), enabling specific design to reproduce desired pharmacophoric 
features. Exploratory diversification at this stage may be called “hit explosion”. A 
significant advantage of this approach is that it can be used independent of knowledge of 
the target structure. Without a target structure, this approach can be used to create SAR and 
QSAR hypotheses, though usually ambiguous, that predict the suitability of diverse 
substituents (and corresponding pharmacophoric features) at variable sites of the scaffold. 
If the target structure is known, that knowledge greatly reduces the ambiguity of the SAR 
hypotheses with concomitant improvement in the choice of substituents that may facilitate 
better interactions. 
A specific scaffold based approach is also known as Plexxikon approach, which combines 
use of a conventional scaffold based approach iteratively with X-ray crystallography in 
order to evaluate the effectiveness of substitutents and thereby to find a hit.27  
 Bioprospecting  
For thousands of years, humankind has used natural biodiversity for therapeutic purposes. 
Bioprospecting is simply a modern version of this, with a more systematic approach to 
investigate potentially large numbers natural compounds, for a potentially large diversity 
of therapy applications; natural biodiversity is huge.28–30 A common practice in 
bioprospecting is to use high-throughput screens to identify bioactivity first on crude 
extracts of natural products. The extracts showing bioactivity are then purified further, 
aiming to identify individually the active natural compound or compounds, which is 
followed by the derivatization and further testing. Usually the high throughput screening 
in bioprospecting take place on both phenotypic screens as well as target-based screens.  
A general limitation of bioprospecting is lack of direct identification of target and 
mechanism of action in phenotypic screening. When biological activity is observed via 
phenotypic screening, it often turns out to be difficult to identify the drug target and 
mechanism of action, especially when it is novel. However, this difficulty also leads to the 
greatest advantage of the methods: it allows the discovery of novel targets, novel 
mechanisms of actions, and new scaffolds. It can be a challenge to isolate the active 
constituent of an active extract in amounts sufficient to carry out structure elucidation. 
Moreover, the chemical synthesis of the natural compound for scale-up and derivatization 
is often a bottleneck for library synthesis for drug-development, as well as for commercial 
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production. Hence, while bioprospecting approach is beneficial for novelty, it is also 
disadvantageous for practical commercial application. 
In general, library design requires careful balance of synthetic feasibility, structural 
diversity and diversity of physicochemical properties for efficient hit finding. It has been 
observed that, while size is important, diversity in the library is also necessary, depending 
on its type.31–33 Further, replacing random diversity with a biogenic biased selection of 
compounds also greatly enhances the efficiency.34 
1.4. Biofocussed chemoprospecting: A hybrid approach 
From above approaches, it would be apparent that each approach has its own spectrum of 
advantages and disadvantages. Hence, it was important to us to develop a hybrid approach 
that fits to the constraints of a PhD research project, maximizing the potential value, while 
minimizing the disadvantages and uncertainties that can be tolerated in larger scale 
enterprises.  
With some 30000 encoding genes in the human genome, and a much larger diversity among 
pathogens, there would seem to be a huge number of potential drug targets. Thus, it is 
remarkable—even stunning—that there are only 324 drug targets, in total, for all FDA 
approved drugs35,36. There is a huge potential for the discovery of new drug-targets and 
therapeutic mechanisms. Bioprospecting approaches are certainly useful in this respect. 
Nevertheless, to alleviate its synthetic chemistry bottlenecks, a bioprospecting inspired 
scaffold-based approach may be chosen, synthesizing libraries of compounds with bio-like 
scaffolds for screening. This hybrid approach can be called “biofocussed 
chemoprospecting”. In other words, it can be described as a type of diversity oriented 
synthesis37 of bio-relevant scaffold based libraries, from a small set of starting materials, 
and using them to screen for novel types of bioactivity. From a synthetic chemistry point 
of view, this approach not only uses diversity-oriented synthesis to create diversity from 




2. Efficiency parameters for chemoprospecting approach 
With a background about biofocussed chemoprospecting as a hybrid approach for faster, cheaper 
and efficient drug discovery in chapter 1, we will now discuss specific aspects of the approach, such 
as scopes of diversification and tailoring of library properties. This chapter intends to explain to the 
readers how such libraries can be designed while carefully considering and balancing the efficiency-
parameters. This reading is expected to prepare the ground for the specific examples of 
chemoprospecting libraries chosen for this research project (to be discussed in chapter 3) and to 
facilitate the explanation of the specific statement of purpose / goals of the project in chapter 4. 
2.1. Biofocus 
The core idea of the approach is to adapt chemical synthesis to bioprospecting, but at the 
same time to keep advantages of synthetic efficiency to avoid the supply bottleneck of 
natural products. In other words, chemoprospecting libraries were designed for ease of 
synthesis but also with a focus on “bio-like” properties, i.e. maintaining close similarity 
with biomolecules. Hence, the actual relevance to biomolecules, or “biofocus”, was 
considered the most important criterion, among many, in the selection of the scaffolds. 
2.2. Structural diversification potential 
While biofocus is the primary aim for good activity potential, the diversification potential 
of the scaffold is essential for synthesis of a library with good potential for the discovery 
of novel activities.31,37 There are four different levels where diversification needs 
consideration.  
 Skeletal diversification 
Diversity oriented synthesis aims for syntheses of more than one scaffold from same 
starting materials. It can be achieved with the use of one type of compound as the precursor 
for another type of compound (not just simple derivative, but structurally different class), 
or by using different reaction conditions of same precursors; both create different scaffolds. 
Skeletal diversification provides an opportunity to target more than one class of 
biomolecules, and thereby a much broader range of targets/cellular pathways. This level of 
diversity is further expanded by other levels. 
 Appendage diversification 
For each scaffold, appendages (substitutions) at different positions provide another level 
of diversification. The potential of diversification increases exponentially with number of 
the appendage-sites and available variations for any given appendage site. For a scaffold 
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with only 3 variable substitution positions, and each position with just 5 variations, the total 
number of possible compounds using a small set of 5 substituents would be as many as 5 
* 5 * 5 =125.  
As with the concept behind the fragment-based approach to drug discovery, the 
substitutions anchored on a scaffold are the most important part of molecule, as they are 
the ones that interact with the biological target; the choice of such fragments determines 
not only diversity but also the likelihood of good target interactions. 
 Functional group diversification 
The functional groups, either as parts of a scaffold or as appendages, represent 
characteristic pharmacophoric features, and determine the total ligand-receptor interaction. 
Diversity of functional groups in a library provides an opportunity for different kinds of 
interactions, and therefore better chances of finding hits. Hence, the substitutions should 
be carefully chosen from fragments important for interactions with drug-targets, 
corresponding to the fragments that can form hydrogen bonding, π-π stacking, hydrophobic 
interactions, metal-π interactions, etc. 
 Stereochemical diversification 
The binding of ligand to its drug target critically depends on three-dimensional spatial 
arrangement of atoms. Use of different stereoisomers can provide access to different 
residues/coordinates at the active site. Because the three-dimensional structure changes 
drastically with a change from e.g. an “S” configuration to an “R” configuration at a single 
chiral center, the bioactivity profile can change completely, as in case of quinine (an 
antimalarial drug) vs quinidine (an anti-arrhythmic drug). The presence of chiral centers in 
a scaffold thus provides additional scope for stereochemical diversity. 
2.3. Diversity of properties and drug likeness 
The discussion of structural diversity in the previous section (2.2), alluded to the diversity 
of physicochemical and pharmacophoric properties important for the structural interactions 
with target molecules. The total set of properties relevant for chemical library design 
include others, such as molecular weight, partition coefficient, number of rotatable bonds, 
in addition to ones that may involve specific interactions, such hydrogen bond 
donor/acceptor capacities. In fact, such properties can be used as quantifiable parameters 
to assess the library diversity. The “appending” substitutions can serve as the means to 
introduce such properties on an anchoring scaffold. An efficient selection of compounds 
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would show such parameter values scattered across a broad range of combinations. A 
library designed this way, although including only an extremely small subset of the 
theoretical possibilities in numerical terms, would still provide diversity reasonable enough 
to represent the scaffold. This is analogous to “sparse matrix” types of searches to identify 
key parameters from a large set of variables. 
It has been a recent tradition to evaluate “drug likeness” based on a set of physicochemical 
properties, such as molecular weight, lipophilicity, functional groups, no. of hydrogen bond 
donor, no. of hydrogen bond acceptor, polar surface area, etc.38–40 Various sets of “rules” 
have been derived from empirical data in order to focus research efforts on “drug like” 
compounds. Lipinski’s rule of five41 (also known as Pfizer’s rule of five) is an example. 
The Lipinski’s rule has been largely followed “religiously” by medicinal chemists across 
the world. Its variant such as “rule of 3” has also been employed for fragment compounds.42 
Recently, a new measure of drug likeness based on a concept of desirability called 
Quantitative Estimate of Drug likeness (QED) has also been proposed.43  
However, depending on the source of empirical data, such rules may focus on properties 
of relevance for a specific target area or therapeutic type, such as bioavailability, toxicity 
and other pharmacokinetic factors. For example, the criteria may be valid only for orally 
administered drugs. Further, the criteria are defined for human cells as target only; hence, 
these criteria may be irrelevant44 or nearly so when the target cells are not human cells, as 
with as antibiotics. In the wake of recently developed drugs, such as kinase inhibitors, 
questions have been raised on the validity of such criteria.45,46 For this work, the traditional 
drug likeness criteria were considered secondary to bio-likeness, and attempts were made 
to design the libraries in a way that most drug likeness criteria would be satisfied. 
2.4. Ease of synthesis 
With the aim to ease synthetic chemistry bottleneck typical of bioprospecting approaches, 
ease of synthesis is an important criterion for library design. From synthetic chemistry 
viewpoint, ease of synthesis can roughly be measured as the number of steps to synthesize 
a final compound of the series. Hence, it is important to choose those scaffolds as libraries 
that can be synthesized with a small number of steps, while providing good scope for 
diversification. It is of course also important to consider the nature of chemical reactions 
and the safety of reagents as parameters relevant to ease of synthesis.  
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2.5. Cost and availability of starting materials 
The importance of cost as a criterion for library design depends on the available budget, 
but universally becomes a consideration for any practical application. As a model of 
chemoprospecting research, it is interesting to assess the cost of library synthesis. For 
simple estimation, the costs of the starting compounds may be used, ignoring the costs of 
solvents, isolation or structure analysis (which may vary widely).  
The cost of a reagent is inevitably determined by its availability (natural or synthetic), and 
demand. Thus, for hit-finding purposes, it will generally be preferable to choose starting 
materials that are available commercially as non-specialized compounds.  
2.6. Summary of principle 
In summary, we aimed to develop the libraries of compounds that would combine similarity 
to biomolecules with physicochemical criteria for “drug likeness” and give good diversity 
at low cost. Each library would possess a scaffold with more than one variable position, 
each allowing a good range of substitutions to diversify the pharmacophoric properties. 
Preferably, the synthesis of libraries would be easy with simple and small number of 
reaction steps, using cheap and safe reagents that are commercially available in wide 
variety, and preferably avoiding harmful/dangerous reagents.   
3. Libraries for biofocussed chemoprospecting 
After discussions on how chemoprospecting provides a hybrid approach for drug discovery in 
chapter 1, and on the efficiency parameters of biofocussed chemoprospecting library design in 
chapter 2, this chapter will now provide the specific examples of the chemoprospecting libraries 
designed, synthesized and tested as a part of the PhD research. 
3.1. Biomolecules as the starting points 
As discussed in previous chapters, bio-relevance was the primary criteria for our 
chemoprospecting library design. Following this, we considered two very important 
biomolecules–peptides and tartaric acid–as the starting points (Figure 2). 
Peptides are versatile in nature. Hence, the molecules having structural similarity with 
peptides may be expected to show activity on biological systems. In order to create our 
libraries, we decided to synthesize simple peptide derivatives with minor modification from 
natural peptides. The simplest peptide structure is a dipeptide, which can be either linear 
or cyclic. A cyclic dipeptide would be piperazine-2,5-dione. One of the two nitrogen atoms 
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may be substituted with an alkyl/aryl substitution to introduce fragments with diverse 
pharmacophoric features. Such substituted piperazine-2,5-diones can be synthesized from 
corresponding N-substituted linear dipeptide esters, which in turn could be synthesized 
from starting materials such as aldehyde, amino acid and amino acid esters. Thus, 
congruent with the concept of diversity oriented synthesis, use of the same starting 
materials can provide two different libraries based on peptides: N-substituted dipeptide 
esters and piperazine-2,5-diones. 
Tartaric acid is a naturally occurring compound, which can be viewed as an open chain 
form of ribose. The similarity with ribose can be used to mimic ATP structure, and hence 
may be expected to show some activity on the ATP-binding targets. Thus, this provided us 
with another library: Tartaric acid bisamides. 
 
Figure 2. Biofocussed chemoprospecting libraries from biomolecules as starting points 
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3.2. N-substituted dipeptide esters (NSDs) 
 Peptides and peptidomimetics 
Peptides are chains of amino acid monomers linked together by covalent peptide (amide) 
bonds formed by coupling of carboxylic acid group of one amino acids and amino group 
of another amino acid. Proteins are made of one or more chains of peptides. Based on the 
number of monomers present, the peptides are called dipeptides (2 monomers), tripeptides 
(3 monomers), tetrapeptides (4 monomers) and so on. Peptide molecules having monomers 
between 2 to approximately 20 are collectively known as oligopeptides.  
Peptidomimetics are molecules that mimic peptide structure47,48; they are often derivatives 
of natural peptides or are synthesized using scaffolds similar to natural peptide 
components.49 Owing to the similarity with peptides, peptidomimetics are expected to 
affect peptide binding targets, such as proteases and peptide receptors. Such targets maybe 
found relevant to diverse pathophysiological conditions including cancer, arthritis, 
pancreatitis, Alzheimer’s disease, and others.50  
 N-substituted dipeptide ester as scaffold 
The potential of using peptide-like structures as a library for chemoprospecting is self-
evident. Dipeptides are the simplest peptides, and linear dipeptide esters can also serve as 
precursors of cyclic dipeptides i.e. piperazine-2,5-diones. Consequently, N-substituted 
derivatives of dipeptide esters (Figure 3) were chosen for one of libraries of this research.  
 
Figure 3. N-substituted dipeptide ester scaffold 
The scientific literature describes some previous examples51–53 of structurally related N-
substituted dipeptide esters (henceforth NSDs). However, they differed from the 
compounds chosen here. Their synthetic route involved reductive amination of amino acid 
esters, followed by peptide coupling with N-protected amino acids. This strategy resulted 
in dipeptide esters with substitutions on the peptide bond nitrogen. However, our scaffold 
allows N-alkyl substitution on the terminal nitrogen, at the end of the chain (Figure 4), 




Figure 4. Difference between N-substituted dipeptides from previous reports and our scheme 
Advantages of the scaffold 
Selection of the NSD scaffold offered certain advantages. The peptidomimetic scaffold is 
“bio-like” and is suitable for chemoprospecting library synthesis. The scaffold offers of 4 
sites for variation. Further, there are two chiral centers in the scaffold, which means that 
the scaffold offers effectively 6 stereospecific sites to introduce 4 chemical groups, 
providing high potential for diversification. The opportunity of introducing 4 desired 
fragments at 6 stereospecific positions can be important to tailor the physicochemical and 
pharmacophoric properties, which is a very important benefit for chemoprospecting, as 
well as for optimization after hit-finding. A significant benefit of this scaffold is also that 
it can be synthesized from simple, cheap and safe-to-use starting materials such as 
aldehydes, amino acids and amino acid esters, which are available commercially with good 
diversity.  
3.3. Piperazine-2,5-diones (2,5-diketopiperazines, DKPs) 
 Marine bioprospecting background 
Marine biodiscovery and bioprospecting is one of the most important areas of Norwegian 
research. In the course of the research on marine bioprospecting and biodiscovery, many 
marine species have been studied by UiTø and MabCent. As a part of such studies, the 
antimicrobial and antifouling activity of extracts of Synoicum pulmonaria, and isolation 
and characterization of the active molecules, such as synoxazolidinones A, B, C., 
pulmonarins A and B etc. have been described.54,55 Synoxazolidinone A and B have been 
observed to have antimicrobial activity while synoxazolidinone C also possesses anticancer 
cytotoxic activity in addition.56,55 Similarly, ianthelline from an arctic Sponge Stryphnus 
fortis has been established to possess anticancer activity via kinase inhibition activity.57 
Further, anti-inflammatory and anti-oxidant activity of barettin from a marine sponge 
Geodia barrette has also been reported.58 Many hybrid variants of synoxazolidinones, 
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ianthelline and barettin have been synthesized and tested for antimicrobial and anticancer 
activity. Among those, the compounds containing a simplified 6-member piperazine-2,5-
dione (2,5-diketopiperazine, referred to as “DKP” henceforth) ring structure (as in barettin) 
were synthesized55, replacing the  5-member 4-oxazolidinone ring (e.g. synoxazolidinones) 
did not affect the antifouling activity.  




 Use of the DKP scaffold as an anchor of important fragments 
The above examples demonstrated that DKP could prove a good anchoring scaffold for 
introduction of suitable substitutions, such as various amino acid side chains or aromatic 
substitutions as in synoxazolidinones, barettin, ianthelline and other analogues. In line with 
our chemoprospecting approach, the DKP derivatives would then be available for various 
bioactivity assays. Thus, as shown in Figure 5, the evolution of a marine biodiscovery 
process eventually came to include chemoprospecting using the DKP library. 
 DKP as a bioactive scaffold 
DKP as a scaffold has been well established59,60 for its therapeutic potential. An interesting 
case61 is the development of tadalafil, a DKP containing PDE5 inhibitor, from a hydantoin 
lead. Merck patented62 piperazine and DKP derivatives as tachykinin receptor antagonists, 
while Novo Nordisk and Boehringer patented63 DKP derivatives as MC4 receptor agonists 
for anti-obesity treatment. A series of pyridyl-2,5-diketopiperazines have been shown64 to 
be orally bioavailable potent oxytocin antagonists.   
Apart from the therapeutic areas mentioned above, the DKP scaffold has also been used as 
an effective core for anticancer drug development. In the pursuit to develop DNA binding 
agents, DKP derivatives similar to anthracyclin derivatives such as daunorubicin and 
doxorubicin were also developed65,66 and their anti-cancer activities were established. 
Exploiting the zinc binding property of thiol group, various thiol containing DKP 
derivatives have been developed67–69 as matrix metalloproteinase inhibitors. Qiao et al.70 
reported DKP derivatives as dual inhibitors of farnesyltransferase and 
geranylgeranyltransferase-1. While these derivatives were similar to our designed library, 
the library compounds had substitutions only at one carbon. In contrast, our library was not 
designed against any specific target and included diverse substitutions on both carbons. 
 Benefits of the DKP scaffold 
 




In addition to the similarity with previously reported compounds, the DKP scaffold (Figure 
6) offered a few benefits also. 
1) It is possible to introduce chemically 3 substitutions (R1, R2, R3) at 5 possible 
stereospecific spaces, allowing to address greater possibilities of interactions 
inside active site. It is also possible to exploit the 2nd nitrogen to introduce a 4th 
substitution if required.  
2) DKP occurs in two conformational states59,71–73, flat or slightly puckered boat 
conformations. There is only a minor energy difference between both 
conformations, which allows DKP scaffold to interchange its conformation 
between both conformational states. From medicinal chemistry point of view, it 
is interesting as this enables DKP scaffold to address an even greater diversity 
of pharmacophores with minor changes in structure. 
3) The polarity of the overall structure heavily depends on the selection of 3 
substitutions. Hence, the scaffold allows necessary flexibility for 
pharmacokinetic considerations for drug-development.  
4) The most common starting materials for synthesis of the scaffold are aldehydes, 
amino acids and amino acid esters. These starting materials are cheap, and 
readily available in a wide variety. They are also easily accessible from other 
class of compounds for introduction of specific substitutions when required. 
3.4. Tartaric acid bisamides (TABs) 
 ATP binding proteins as possible drug targets 
ATP is one of the most important biomolecule in nature, often considered as a universal 
energy-currency inside a cell. ATP serves multiple roles in cellular functions such as 
metabolism, active-transport, cell-signaling and synthesis of other biomolecules including 
DNA and RNA. With such a wide-range of functions, it is apparent that ATP binds to 
multiple cellular targets, such as kinases and ATPases, and these targets can be exploited 
to elicit significant therapeutic activities.74,75  
 The rationale behind the tartaric acid bisamide (TABs) scaffold 
As shown in Figure 7, tartaric acid can be viewed as an open chain analogue of ribose, with 
the vicinal diol of tartaric acids as similar to 2’- and 3’- hydroxyl groups of ribose. The 
stereospecific considerations can be explored with use of different stereoisomers of tartaric 
acid. Further, the conversion of both carboxyl groups of tartaric acid to amides can be a 
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versatile approach to introduce favourable substitutions at both ends. From the varieties of 
commercially available amines and accessibility of amines from other classes, the scaffold 
may be developed into a new class of compounds for ATP-binding targets. 
 
Figure 7. Tartaric acid bisamides as open chain analogues of ATP 
 Benefits of TAB scaffold 
Compared to NSD or DKP scaffolds, TAB is a smaller scaffold, which makes TABs more 
like fragments that can be further extended via substituted fragments on both variable 
positions. Moreover, stereospecific vicinal diol functionality provides more potential to 
tailor physicochemical and pharmacophoric properties. This is compatible with importance 










4. Statement of purpose / Goals 
Based on the principle of the “biofocussed chemoprospecting” approach described in 
previous chapters, the overall goals of the research work were defined as follows: 
Goal: Design and synthesis of diverse chemical libraries based on bio-relevant scaffolds 
with "appropriate" properties (foci) and their bioactivity studies. 
Subgoals:  
 To employ a hybrid approach – biofocussed chemoprospecting - to minimize 
limitations of conventional approaches of hit-finding and lead determination, such 
as bioprospecting and scaffold based approaches, while maximizing their 
efficiency/opportunities. 
 Determine scaffolds and substitutions for compound-libraries fulfilling desired 
criteria. 
 Design easy and short synthetic routes with conventional, customized, or novel 
methods, followed by the synthesis of libraries and assessment of the protocols.  
 Test the synthesized libraries at different platforms for bioactivities including 
phenotypic assays and cell-based assays. Create target hypotheses for the 
































In the introduction part, a brief outline of biofocussed chemoprospecting libraries was given as a 
theoretical treatise with examples of three libraries inspired from biomolecules. In this part, the 
practicalities of this approach will be demonstrated using the same libraries, with details on library 





5. Library I: N-substituted dipeptide esters (NSDs) 
This chapter first describes synthesis of N-substituted dipeptide ester library, followed by the 
cheminformatics analysis of library properties regarding the efficiency parameters described in the 
introduction part. The discussion will then focus on bioactivity studies and initial target identification 
approaches. These comprise especially assays on cancer cell lines and proteomics analysis with the 
SILAC method, protease profiling, target-prediction efforts using cheminformatics fingerprinting 
based models and BioPrint® profiling. Overall, this chapter describes the N-substituted dipeptide 
esters library as a practical example of a biofocussed chemoprospecting library.   
5.1. Synthesis 
 Approach for synthesis 
As described in chapter 3, the N-substituted dipeptide esters can be synthesized from 
common commercially available starting materials, such as aldehydes, amino acids and 
amino acid esters. As a dipeptide ester scaffold, a peptide coupling protocol would also be 
the most convenient approach. In order to introduce substitutions on the terminal nitrogen, 
the amino acid may be alkylated before the peptide coupling. The retrosynthetic analysis 
can be explained as below in Scheme 1. 
 




Following the retrosynthetic analysis, the two-step synthetic scheme (Scheme 2) was 
designed. Unlike the previously reported examples discussed in chapter 3, we chose to 
carry out reductive amination of amino acids to generate N-substituted amino acid, 
followed by its peptide coupling with an amino acid ester.  
 
Scheme 2. Synthesis scheme for N-substituted dipeptide esters 
As typical peptide coupling requires many steps of protection and deprotection, it is 
common to carry out peptide couplings using solid phase synthesis. In our case, for 
couplings using uronium coupling agents such as HBTU, the reactivity difference76 
between the 2o-amine (of N-alkylated amino acid) and the 1o-amine (of amino acid ester) 
provided an opportunity to skip protection-deprotection steps. Therefore, the solid phase 
synthesis, as in previous examples, was no longer required. Thus, using a slightly different 
strategy for synthesis, we avoided the need of protection and deprotection steps, decreasing 
the number of steps and making the synthesis easier, cheaper and more compliant with our 
approach.  
 Selection of R1, R2 and R3 substitutions 
As described in the introduction part, appending substitutions play a major role in 
determining physicochemical properties of final compounds. For efficient library 
synthesis, it was important to select the substitutions that can provide sufficient diversity 
with respect to such properties at low cost.  
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As per the synthetic strategy, R1 comes from an aldehyde, while R2 and R3 come from 
amino acid and amino acid esters. Aldehydes were selected among diverse aromatic 
carbocycles or heterocycles such as phenol, pyridine, thiophene, furan, indole etc. Amino 
acids and amino acid esters were chosen to be either natural ones (L-isomers) or their 
enantiomers (D-isomers), except for proline which is an imino acid. Further, acidic or basic 
amino acids were excluded in order to make synthesis simpler. Hence, out of 19 natural 
amino acids (excepting the imino acid proline) we selected neutral amino acids and their 
esters such as:  
- Glycine (polar amino acid with no substitution)  
- Alanine (relatively non-polar amino acid with small methyl substitution)  
- Phenyl alanine (hydrophobic aromatic substitution without any HBD or HBA) 
- Tyrosine (partially hydrophobic aromatic substitution with hydrogen bond donor 
and acceptor groups) and  
- Tryptophan (large hydrophobic aromatic heterocyclic substitution) 
Except for L-phenylalanine (ethyl ester), all amino acid esters used were methyl esters.  
 N-monoalkylation via reductive amination 
N-monoalkylation of amino group is a common method to create a C-N bond. There are 
many ways to achieve N-alkylation, including simple nucleophilic substitution of halides, 
using alcohol with palladium catalyst in presence77 or absence78 of hydrogen, reductive 
amination, the Buchwald-Hartwig reaction etc. Though the nucleophilic substitution is 
simple and straightforward, multiple alkylation and quaternary salt formation are its main 
limitations.  
Reductive amination is a common method for N-monoalkylation of amino acids. The 
reductive amination of amino acids has been reported with reagents such as sodium 
borohydride79–81, sodium cyanoborohydride82–84, 1,2,3-triazole-boranes85. Typically, the 
reaction takes place in two steps, whereby the first step requires imine formation between 
aldehyde and amino acid. As the imine formation is reversible, one reagent is generally 
used in excess to drive the equilibrium towards the imine side, which is then converted to 
amine by reducing agents such as borohydrides and boranes.  
Using a protocol81 reported by Verardo et al. (protocol A in Scheme 3), different aldehydes 
were reacted with amino acids (Table 2) in methanol. After allowing imine formation, they 
were reduced with sodium borohydride. To drive the equilibrium in the forward direction, 
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a 1.4 equivalent amount of aldehyde was taken. The reactions were mostly clean, with only 
a few exceptions. As the products were highly polar, it was not possible to isolate the 
impure products. As all products were also more or less water-soluble, the water-soluble 
salts were not separated and the products were used in crude form for the next step. Hence, 
it was not possible to calculate yields. 
 
Scheme 3. Synthesis of N-substituted amino acids via reductive amination 
Table 2. Table for reductive amination reaction (Step-1) 
Aldehyde Amino acid Protocol Product Product structure 
 
Glycine Aa A1 
 
 
L-Alanine A A2 
 
 





L-Cysteine Ab A4 
 
 
L-Phenylalanine A A5 
 
 
L-Phenylalanine A A6 
 
 
L-Phenylalanine A A7 
 
 
L-Phenylalanine A A8 
 
 
L-Phenylalanine Ab A9 
 
 
L-Phenylalanine A A10 
 
 
Glycine A A11 
 
 
L-Alanine A A12 
 
 





L-Alanine B A14 
 
 
D-Alanine B A15 
 
 
L-Asparagine Bb A16 
 
 
L-Glutamine Bb A17 
 
aExtremely hygroscopic product, could not be dried for long to remove acetone 
bImpure products – not used further 
The reaction of indole-3-carboxaldehyde with phenylalanine was not clean. Hence, the 
reactions of indole-5-carboxaldehyde and 4-(1H-imidazol-1-yl)benzaldehyde were carried 
out using a different protocol (protocol B in Scheme 3), using sodium cyanoborohydride 
to allow a longer reaction time for imine formation and selective reduction of imines 
driving the equilibrium to forward direction.  
 Peptide coupling 
A typical peptide coupling protocol involves activation of carboxylic acid using singly or 
in combination, coupling reagents such as HBTU, PyBOP, 3o-amine like 
diisopropylethylamine (DIPEA), in aprotic solvents like DMF and then adding amine to 
form the amide product. After completion, the reaction mixture is usually washed with 
citric acid solution to remove excess amines and water soluble impurities, and is extracted 
with ethylacetate or DCM. The crude reaction mixture thus obtained is subjected to 




Scheme 4. Peptide coupling reaction for synthesis for NSDs 
In our case (Scheme 4), the NSDs were synthesized using a modified peptide coupling 
protocol (Table 3). Most of the products were highly or partially soluble in water. 
Moreover, the products also contained an active 2o-amine group that would react with 
acids. Hence, the reaction mixtures could not be washed with aqueous citric acid solutions 
in order to remove reagents like excess DIPEA. Thus, it was necessary to substitute DIPEA 
with a 3o-amine, which can be evaporated when in excess. So, triethylamine (TEA) was 
used. Instead of a high boiling point solvent like DMF, a low boiling point aprotic solvent 
acetonitrile was used. R4 was kept as a methyl group for all compounds except B28, which 
contained ethyl group as R4. 





Product Product structure 
Isolated 
Yield % 
A1 GlyOMe B1 
 
73a 
A2 GlyOMe B2 
 
49a 
A3 GlyOMe B3 
 
67a 





A2 L-TrpOMe B5 
 
53a 
A3 D-TrpOMe B6 
 
53 
A2 L-TyrOMe B7 
 
58 
A5 GlyOMe B8 
 
55 
A7 D-TrpOMe B9 
 
47a 
A7 L-AlaOMe B10 
 
45 





A8 L-TrpOMe B12 
 
43 
A8 L-TyrOMe B13 
 
48b 
A8 GlyOMe B14 
 
68b 
A8 L-AlaOMe B15 
 
63b 
A10 GlyOMe B16 
 
61 
A10 L- AlaOMe B17 
 
54 





A10 L-TyrOMe B19 
 
46 
A5 D-TrpOMe B20 
 
50 
A11 L-TrpOMe B21 
 
43 
A11 D-TrpOMe B22 
 
39 
A11 GlyOMe B23 
 
59 
A11 L-TyrOMe B24 
 
64a 
A14 D-TrpOMe B25 
 
50 





A10 D-TrpOMe B27 
 
52 
A10 L-PheOEt B28 
 
47 
A10 D-PheOMe B29 
 
53 
A7 L-TrpOMe B30 
 
54 
A3 L-TrpOMe B31 
 
48 
A10 L-ThrOMe B32 
 
44 
a5-10 % cyclic dimer was formed 
bProduct has very low UV activity 
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 Cyclic dimer formation as a self-condensation product 
After the carboxylic group of amino acid is activated by a coupling agent like HBTU, it 
can react with both 1o- and 2o-amines. As Scheme 5 shows, if the activated carboxylic 
group reacts with 2o-amine (instead of the 1o-amine of amino acid esters, which would give 
an NSD product) of another molecule of the same starting material, it leads to a cyclic 
dimer as a self-condensation product. However, the rate of reaction for coupling with 1o-
amine is much faster than that with the 2o-amine. While designing the reaction scheme, we 
attempted to utilize the difference in order to avoid protection and deprotection steps. It 
was observed that in some reactions, the self-condensation product was still formed in 
small amounts, even as the dipeptide product was the major one.  
 
Scheme 5. Cyclized dimer formation as a result of self-condensation of N-substituted amino acids 
As the cyclized dimer product is a symmetrical DKP derivative, this side-product formation 
was considered an opportunity to generate a new series. Hence, when such dimer product 
was formed as a side product, it was also isolated along with the desired NSD product. 
However, as we had expected, such self-condensation product formation was not common. 
When it did not form as a side product, the reactions were set up according to the same 
protocol, but without addition of amino acid ester (Table 4). The rationale was to facilitate 
the self-condensation in absence of 1o-amine.  
From the perspective of synthesizing a new series, the strategy worked quite well, as it was 
possible to synthesize several compounds with this method. It is important to note that 
specific reactions were set up only when self-condensation did not occur as a side-reaction, 
implying that the self-condensation was not easy in such cases. Hence, the seemingly poor 











































5.2. Library properties  
 Diversifiability 
The starting materials for this series such as aldehydes and amino acids are commercially 
available in wide varieties. Amino acid esters are also commercially available or easily 
accessible from corresponding amino acids. This implies that, consistent with the idea of 
chemoprospecting, there is a huge diversification potential for this library. A latest Sigma-
Aldrich (Sigma-Aldrich, St. Louis, MO, USA) catalogue mentions 1244 aldehydes and 551 
amino acids. Even if we consider 1200 aldehydes, 500 amino acids and 500 corresponding 
amino acid esters (only methyl esters), the number of total theoretically accessible 
compounds becomes 1200 * 500 * 500 = 300 million compounds! 
The computation required to evaluate such a huge chemical space exhaustively with respect 
to different properties, is prohibitively expensive, so we decided to create its small subset 
as a virtual library and then to analyze this virtual library computationally to study the 
distributions of various properties for these compound sets.  
As Mao et al. have noted86, an overwhelming majority of approved drug molecules contain 
at least one aromatic ring. Additionally, the presence of at least one aromatic group in a 
compound can be helpful in chromatographic isolation. However, not all amino acids and 
amino acid esters are aromatic. Hence, out of more than 1200 varieties of aldehydes, 22 
aromatic / heterocyclic aldehydes were chosen as R1. All the aldehydes were chosen from 
simple aromatic carbocycles or heterocycles such as phenol, thiophene, furan, pyridine, 
indole, quinoline, imidazole etc. Similarly, out of more than 500 varieties of amino acids 
and amino acid esters, only natural isomers (L-isomer) and their unnatural enantiomers (D-
isomer – except for achiral glycine) were chosen as R2 and R3 respectively (Table 5). Being 
an imino acid, both isomers of proline were excluded from amino acids and amino acid 
esters. Using the JChem software suite (ChemAxon, Budapest, Hungary), a virtual library 
of 22 * 37 * 37 = 30118 compounds was generated. The virtual library was subjected to 
computational analysis. 
Table 5. Aldehydes, amino acids and amino acid esters chosen for virtual library generation. 
No. Aldehydes Amino acids Amino acid esters 
1 4-pyridaldehyde Glycine Glycine methyl ester HCl 
2 3-pyridaldehyde L-Alanine L-Alanine methyl ester HCl 
3 2-pyridaldehyde L-Serine L-Serine methyl ester HCl 
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4 4-hydroxybenzaldehyde L-valine L-valine methyl ester HCl 
5 3-hydroxybenzaldehyde L-leucine L-leucine methyl ester HCl 
6 2-hydroxybenzaldehyde L-isoleucine L-isoleucine methyl ester HCl 
7 Thiophene-2-carboxaldehyde L-tyrosine L-tyrosine ethyl ester HCl 
8 Thiophene-3-carboxaldehyde L-phenylalanine L-phenylalanine ethyl ester HCl 
9 Furan-2-carboxaldehyde L-cysteine L-cysteine ethyl ester HCl 
10 Furan-3-carboxaldehyde L-threonine L-threonine methyl ester HCl 
11 Imidazole-4-carboxaldehyde L-methionine L-methionine methyl ester HCl 








L-asparagine L-asparagine tert-butyl ester HCl 
15 4-anisaldehyde L-glutamine L-glutamine methyl ester HCl 
16 3-anisaldehyde L-aspartic acid L-aspartic acid dimethyl ester HCl 
17 2-anisaldehyde L-glutamic acid 





L-arginine L-arginine methyl ester diHCl 
19 Quinoline-3-carboxaldehyde L-lysine L-lysine methyl ester diHCl 
20 Isoquinoline-5-carboxaldehyde D-Alanine D-Alanine methyl ester HCl 
21 Indole-3-carboxaldehyde D-Serine D-Serine methyl ester HCl 
22 Indole-5-carboxaldehyde D-valine D-valine methyl ester HCl 
23   D-leucine D-leucine methyl ester HCl 
24   D-isoleucine D-isoleucine methyl ester HCl 
25   D-tyrosine D-tyrosine methyl ester HCl 
26   D-phenylalanine D-phenylalanine methyl ester HCl 
27   D-cysteine D-cysteine methyl ester HCl 
28   D-threonine D-threonine methyl ester HCl 
29   D-methionine D-methionine methyl ester HCl 
30   D-tryptophan D-tryptophan methyl ester HCl 
31   D-histidine D-histidine methyl ester diHCl 
32 
  D-asparagine 
monohydrate 
D-asparagine methyl ester HCl 
33   D-glutamine D-glutamine methyl ester HCl 




D-glutamic acid dimethyl ester 
HCl 
36   D-arginine D-arginine methyl ester diHCl 




The diversity of the virtual library of NSDs was analyzed with respect to various 
physicochemical parameters such as molecular weight, AlogP, number of rotatable bonds 
and polar surface area. It can be observed in Figure 8 that the virtual library shows 








Figure 8. Distribution of a few properties for the virtual library of NSDs 
 Ease of synthesis 
As explained in the introduction, the ease of synthesis can be approximately correlated with 
the number of steps (quantitatively) and safety parameters of the reagents and reaction 
conditions. The NSD library can be synthesized from commercially available materials in 
just two steps. Both steps are very safe, easy to scale-up and do not necessarily require 
work-up. The first step does not require purification as well, as the crude reaction mixture 
is sufficient for the second step. The second step is prone to side product formation and it 
needs isolation with column chromatography.  
Considering multistep synthesis as a “norm” in library synthesis for drug discovery, it can 
be safely concluded that the overall ease of synthesis is significantly high for the NSD 
library.    
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 Cost and availability of starting materials 
The cost and availability of starting materials can make a significant impact on overall 
budget of research work. The starting materials for NSDs are aldehydes, amino acids and 
amino acid esters. They are cheap and commercially available in wide varieties.  
 
Figure 9. The plot shows 3D representation of virtual library of NSDs with respect to molecular 
weight, AlogP and cost. The red marks signify the synthesized library and represent the extent of 
diversity achieved by the chemoprospecting. 
In order to estimate the cost, an estimation was made for all 22 aldehydes, 37 amino acids 
and 37 amino acid esters. As a standard, the necessary amount of compounds to carry out 
reaction at 1 mmol scale was calculated considering the mole equivalents. Based on the 
amount, the prices for each starting material was generated based on commercial 
catalogues of Aldrich (and other suppliers if the compound was not available at Aldrich). 
From the cost of each starting material, the costs for all 30118 compounds from virtual 
library were estimated. The estimated costs include only the cost of aldehyde, amino acid 
and amino acid esters. They do not include the isolation, purification or characterization 
costs because such calculations would be unpredictable and can show huge variation from 
one reaction to another. 
40 
 
The plot in Figure 9 shows distribution of compounds on three parameters: molecular 
weight, clogP and cost of starting materials. It is evident from the plot that the synthesized 
compounds are scattered along the two property axes while remaining strongly skewed 
towards cheaper side, implying that good diversity was achieved at low cost. 
5.3. Bioactivity studies and target-search 
The NSD library was tested for various bioactivities on multiple platforms such as viability 
assays on cancer cell lines, anti-microbial assays, anti-oxidant activity assay, and detailed 
profiling on targets such as kinases, proteases and CEREP BioPrint® profile. Significant 
and promising activities were observed on cancer cell lines, on prolyl oligopeptide (POP) 
and on multiple targets in BioPrint® profile. No other significant activities were observed. 
The detailed observations of bioactivity assays are included in the appendix part. 
 Viability loss on cancer cell lines 
At MarBio, NSD compounds were tested on various cancer cell lines such as A2058 
melanoma, HT29 colon cancer, MCF7 breast cancer and MRC lung cells. The results are 
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Figure 10. Cell viability assays on cancer cell lines for NSD series 
Table 6. Viability loss of cell lines treated with seven active compounds (50 µM) 
Compound A2058 MCF7 HT29 MRC5 
B31 105 112 101 107 
B28 99 78 74 99 
B30 106 110 32 98 
B18 90 101 -6 75 
B11 59 81 -5 -3 
B17 104 104 -1 23 
B19 19 51 5 -5 
As shown in Table 6, seven NSD compounds (Figure 11) have been identified that cause 
significant loss of viability on at least one cancer cell line. Notably, compound B27 and 
compound B6 (stereoisomers of active compounds B18 and B31 respectively, both with R-
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highlights the importance of chirality analogous to natural amino acid for the loss of 
viability (Figure 12). 
   
    
Figure 11. NSD compounds showing viability loss on cell lines  
Upon morphological analysis of cells, compound B18 was observed to cause 
morphological change in the A2058 melanoma cells from concentrations as low as 5 µM 
in 4 hour exposure (Figure 13). The affected cells changed their shape from angular to 
round and did not remain immobilized at the bottom of the well. At higher concentrations 
such as 30 µM, the morphological change was immediate (within 5 minutes). Compound 
B27, an inactive stereoisomer of B18, did not cause any morphological change at 30 µM, 
confirming that the morphological change was associated with the loss of viability.   
      
       
Figure 12. Compounds B18 and B31 (both S,S) causes viability loss, while their stereoisomers B27 
and B6 (both S,R) are inactive, indicating that chirality analogous to natural amino acids is vital for 





Figure 13. Effect of active compound B18 and its stereoisomer B27 on morphology of A2058 
melanoma cells. B18 causes change in the shape of cells at concentrations as low as 5 µM in 4 
hours, while B27 does not cause any viability loss.  
In order to understand the underlying mechanism via which the N-substituted dipeptide 
esters cause loss of viability, proteomics analysis was has been carried out using SILAC 
method, which will be discussed in section 5.3.2.  
Structure activity relationship (SAR) for loss of viability  
Even though the drug-target was not identified, a rough SAR was generated for R1, R2 and 
R3 substitutions and their effect on viability loss on cancer cell lines. These were based on 
available variations of substitutions of tested compounds and were as described below: 
SAR for R1: Aromatic carbocyclic or heterocyclic substitutions appear beneficial. The 
aromatic ring may contain hydrogen bond donor and acceptor groups.  
SAR for R2: A hydrophobic aromatic ring is beneficial. Absence of substitution or small 
aliphatic groups are counter-productive. 
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SAR for R3: Hydrophobic aromatic rings are beneficial. Polar hydrogen bond donor groups 
may decrease the activity. Absence of substitutions or substitutions with unnatural chirality 
result in complete loss of activity, which suggests that conformational state analogous to 
natural peptides is vital for the activity. 
 Quantitative proteomics analysis with SILAC studies 
As described in section 5.3.1, seven compounds from NSD series showed significant loss 
of viability on cancer cell lines, starting from as low as 5 µM concentration in 4 hours. 
However, the drug target and underlying mechanism for the loss of viability is not known. 
A broad profiling of active compounds on kinases and proteases did not provide any 
conclusive target. Even though BioPrint® profiling did provide some interesting new 
targets, those targets do not appear relevant to the observed viability loss. Hence, a 
quantitative proteomics analysis was carried out using SILAC methods in order to 
understand change in protein expression driving the viability loss.  
Principle: SILAC (Stable Isotope Labeling with Amino acid in Cell-culture) is a method 
for quantitative proteomics studies, which uses automated HPLC system coupled with 
tandem mass spectrometry to separate and identify specific cellular proteins.87,88 Heavy 
amino acids (containing isotopes 2H, 13C, and/or 15N) are present in media used to grow 
cells. As the cells grow, the heavy amino acid(s) are incorporated into its proteins. Thus, 
the cellular proteins from the cells grown in a heavy media have higher molecular weight 
than the proteins from the cells grown in a normal media, while the other properties, such 
as cellular functions or HPLC retention time, remain essentially the same. This difference 
in molecular weight separates the protein from heavy-media treated cells from the proteins 
from normal media treated cells when subjected to mass spectrometry after HPLC 
purification. The relative amount of proteins can thus be measured quantitatively to 
measure upregulation or downregulation of proteins.. 
Method: In a typical experiment, one group of cells (test or control) are grown in the heavy-
media, while the other group (control or test) are grown in the normal media, . The test 
cells are subjected to the factors under study, while control cells are kept untreated. After 
treatment, the cells are lysed, and the protein mixtures are resolved on SDS-PAGE gel and 
digested to generate smaller “signature” peptides, which represent known peptide 
fragments for corresponding parent proteins. At this stage, peptides obtained from test and 
control cells are mixed, and the mixture is subjected to HPLC (or UPLC) purification as 
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per a pre-optimized automated protocol. The HPLC output is then subjected to tandem MS 
analysis, where signature peptide fragments are identified. For quantitative analysis, the 
log2 ratio between “Heavy” and “Light” labelled proteins in the sample are compared to 
identify significant upregulation and downregulation of proteins, which in turn would 
provide information regarding involved pathways. 
 
Figure 14. A2058 cells treated with B18 show morphological change at 5 µM concentration but not 
at lower concentrations such as 3 µM or 1 µM. 
As the morphological change occurs as a result of numerous cellular events initiated by an 
affected cellular pathway caused by binding of compound to the specific drug target, it may 
be expected that the specific drug target and pathway are affected at much lower 
concentration than the concentration causing the morphological change. In our case, A2058 
cells treated with B18 showed morphological change at a 5 µM concentration, while 
concentrations lower than 5 µM, such as 3 µM and 1 µM did not cause any observable 
change (Figure 14). Hence, for SILAC studies, A2058 melanoma cells were treated with 
B18 for 4 hours at 3 different concentrations: 0.5 µM, 2.5 µM and 5 µM. For each 
concentration, test and control samples were grown in heavy media and normal media 
respectively. 
Results: The primary results of SILAC studies give an interesting insight into the cellular 
events driving the loss of viability. The histograms in Figure 15 shows that the overall log2 
ratio (test/control) for the majority of proteins increases from less than zero to ~0.7 as per 
raw data with increasing concentration of B18. This suggests that increasing concentration 
of B18 results in stress conditions, which results in overall higher metabolic activity as 
cells react to the stress, e.g. prepare for apoptosis or other responses. Hence, the ratios were 
normalized for analysis of upregulation and downregulation of proteins, and the proteins 
showing significant change between test and control samples were analyzed for their 
involvement in cellular signaling pathways. The detailed data has been included in the 




Figure 15. Histogram showing distribution of proteins in terms of amount ratio (test/control) for 
raw (left) and normalized (right) data. The ratio H/L are the log2 ratio between Heavy (test) and 
Light (control) labelled proteins. 
It would be too early to conclusively establish the specific target or pathway from the 
primary results of SILAC studies. However, with the aim to understand the initial change 
in proteomics profile, the proteins showing significant upregulation (59 proteins) or 
downregulation (31 proteins) in both 0.5 µM and 2.5 µM samples were identified. The 
genes corresponding to such proteins were associated with specific cellular pathways with 
the help of Panther Database.89,90 From this, the following four pathways were identified 
to be associated with one or more upregulated proteins as well as downregulated proteins:  
1) FAS signaling pathway 
2) Inflammation mediated by chemokine and cytokine signaling pathway 
3) Huntington disease pathway 
4) Cytoskeletal regulation by Rho GTPase 
The Panther database was not able to associate some genes to any pathway, therefore, it 
cannot be ruled out that these four pathways may manifest an aftereffect of the activity of 
the compound on its target. Nevertheless, the identification of these pathways serves as an 




 Protease profiling 
The role of proteases has been well-established in cancer biology.91,92 As the NSD 
compounds are peptidomimetic dipeptide esters, their potential to show activity on peptide-
binding targets is evident. In order to explore this potential, compound B28-which showed 
significant activity on cancer cell lines-was subjected to protease profiling assays against 
38 proteases at BPS bioscience, San Diego, USA. The compound B28 showed selective 80 
% inhibition of prolyl oligopeptidase (POP) enzyme at 50 µM concentration. Its IC50 value 
was measured to be 6.0 µM (Figure 16). Following this, other related compounds, including 
B18, which also showed strong activity against cancer cell lines, were also subjected to 
assays on POP, but neither of them showed very significant inhibition at 100 µM (Table 
7). This also means that the loss of viability observed on cancer cell lines is not due to POP 
inhibition. However, at the same time, the activity on POP also indicates that the NSD 











































Figure 16. Inhibition of POP by compound B28 at 50 µM (left) and its IC50 studies (right). 
Table 7. Assays on prolyl oligopeptidase (POP) 
Compound Structure IC50, (POP inhibition) 
B28 
 
































IC50 > 100 μM, 
(23 % at 100 μM) 
B19 
 
IC50 > 100 μM, 
(39 % at 100 μM) 
B29 
 
IC50 > 100 μM, 
(9 % at 100 μM) 
B16 
 
IC50 > 100 μM, 
(6 % at 100 μM) 
B17 
 
IC50 > 100 μM, 
(10 % at 100 μM) 
BST-L2-30 
 
IC50 > 100 μM, 
(27 % at 100 μM) 
B18 
 
IC50 > 100 μM, 




 Cheminformatics fingerprinting based target-prediction 
Multiple methods93–100 have been and continue to be developed for the in silico prediction 
of drug-target interactions using cheminformatics based fingerprinting analysis. Though 
the accuracy of such methods remains debatable, such methods help in narrowing down 
the list of probable targets. Among these models, we used a machine learning model98 
developed by Mervin et al. based on Bayesian methods using activity data (ChEMBL) and 
inactivity data (PubChem), and 2D fingerprinting of the compounds. Five representative 
compounds from N-substituted dipeptide esters library were subjected to the target 
prediction. The predictions were encoded as probability estimates that the compound binds 
to the target. 
Table 8. Cheminformatics fingerprinting based target-prediction as probability estimates 
Targets Uni.No B5 B11 B18 B19 B28 
Cathepsin B P07858 ++ ++ ++ ++ ++ 
Cathepsin L1 P07711 ++ ++ ++ ++ ++ 
Calpain-1 catalytic subunit P07384 + ++ ++ ++ ++ 
Neprilysin P08473  ++ ++ ++ ++ 
Endothelin-converting enzyme 1 P42892 ++ ++ ++ ++  
Integrin alpha-4 P13612  ++ ++ ++ ++ 
Prolyl oligopeptidase (POP) P48147      
Table 8 shows the target most likely to be inhibited, along with the predictions for prolyl 
oligopeptidase (POP). The method predicted (++ = near certainty, + = likely, blank = 
unlikely) binding of NSDs to cathepsin B and other related proteases. However, as 
described earlier, the protease profiling did not reveal any such significant activity on 
cathepsins or other related targets except µM level binding affinity of B28 to POP, which 
was predicted to be unlikely. 
Overall, analogous to the results reported by Urich et al.101 for protein kinases, this 
cheminformatics fingerprinting based prediction correlates with the measurements within 
the enzyme type, but not for the specific enzymes themselves. This may be attributed to 
the fact that cheminformatics based methods take into consideration mostly 2D structures, 
which neither includes information on 3D interactions with targets nor it identifies the most 
important structural features to give higher importance for probability calculation. These 
observations, however, may be useful for development of more a more inclusive and 
holistic cheminformatics fingerprinting based model. 
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 Multiple receptor binding 
A broader Bioprint® profiling of compound B18 at Eurofins CEREP revealed significant 
new bioactivities on multiple targets as shown in Table 9. Further detailed studies in a 
larger scale are underway to establish primary SAR. 
Table 9. BioPrint® profile of B18 shows strong binding to multiple receptor and enzyme targets 
Assay 
% Inhibition of Control 
Specific Binding (50 μM) 
Follow up study 
NK2 (h) 102 Antagonist, IC50 = 3.1 μM, Kb = 400 nM 
kappa  (KOP) 98 Agonist, EC50 = 2.3 μM 
COX2(h) 93  
COX1(h) 92  
motilin (h) 90  
delta  (DOP) (h) 90 Antagonist, 37 % inhibition at 5 μM 
mu  (MOP) (h) 90 Weak agonist, EC50 = 47 μM 
A3 (h) 84  
V1a (h) 84  
CCK1 (CCKA) (h) 83  
PPARγ  (h) 80  
Ca2+ channel  (L, diltiazem 
site)  (benzothiazepines) 
79  
MT1 (ML1A) (h) 77  
FP (h) 77  
NK1 (h) 76  
Considering that, most of these targets are peptide receptors; the activities are promising 
and optimizable. The strong activities on opioid receptors and cyclooxygenase are 
particularly interesting owing to their common therapeutic potential in treatment of pain. 
Moreover, strong activity on opioid receptors and neurokinin receptors also provides an 
opportunity in psychotherapeutics. In the follow-up studies, the compound B18 has been 
established to be agonist on κ (kappa) – opioid receptor with EC50 = 2.3 µM, a weak agonist 
on µ (mu) – opioid receptor with EC50 = 47 µM (20 times weaker agonist than on κ) and 
an antagonist on δ (delta) - opioid receptor with 37 % inhibition at 5 µM. This subtype 
selectivity is intriguing, especially from therapeutic point of view. The compound was also 
found to be antagonist on NK2 receptors with IC50 = 3.1 μM and Kb = 400 nM, further 




Figure 17. The docking of B29 inside Mu-opioid receptor (PDB: 5C1M) suggested that interactions 
with Asp147 and His54 may be important. Moreover, π-π stacking with His297 was also predicted. 
As the N-substituted dipeptide scaffold provides six sites for stereospecific substitution, it 
should be possible to develop compounds with desired selectivity on a particular 
therapeutic class. For example, as shown in Figure 17 docking studies on opioid receptors 
suggest strong binding of B27 and B29 to opioid receptors (compounds that have been 
inactive on tested cancer cell lines). Overall, the existence of an expanded set of therapeutic 
targets, including anti-cancer activities, CNS disorders and pain relief, enables 
optimization separately for each therapeutic or target class. 
 
6. Library II: Piperazine-2,5-diones (DKPs) 
This chapter describes the synthesis of a piperazine-2,5-dione library, followed by a cheminformatics 
analysis of library properties with respect to the efficiency parameters described in the introduction 
part. Then, the results of bioactivity studies are given, especially assays on cancer cell lines and 
inhibition of BRSK1 enzyme has been discussed. Finally, a comparative docking study on Rho-kinase 
is detailed-as a test of the reliability of the method.   
6.1. Synthesis 
 Synthetic protocol for DKPs 
Though the synthesis of DKPs is possible to carry out in various ways59,60,102, the synthesis 
via cyclization of dipeptide remains the most common protocol. Moreover, the synthesis 
via cyclization of dipeptide also enables the introduction of stereospecific substituents, a 
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benefit not easily available in other methods. For example, for the synthesis of a library 
similar to the one we considered, Qiao et al.70 used an N-alkylation route using 
haloacetylhalide, which limited the possibility of diverse substitutions to only one carbon. 
To achieve substitutions on the other carbon, one would require a corresponding haloacid 
halide, which is not easily accessible. On the other hand, for the synthesis of cysteine based 
DKPs, Szardenings et al.67,68 used dipeptide-route via simple solid phase synthesis to 
generate stereospecific S-cysteine and R-cysteine based similar DKPs with other 
substitutions on the other carbon and one nitrogen. However, this route also necessitated 
the use of protected amino acids along with usual protection-deprotection steps as in solid 
phase peptide synthesis.  
In line with our efforts to use diversity oriented synthesis for chemoprospecting, the N-
substituted dipeptide ester library worked as a precursor for the DKP library. Further, our 
approach enabled introduction of stereospecific substitutions at both α-carbons, and 
protection-deprotection steps. Thus, our approach achieved both advantages over previous 
protocols 
 Synthesis of library using microwave assisted cyclization 
The most common protocol for synthesis of DKPs is the cyclization of dipeptide esters. 
However, the reaction requires the transformation of the orientation of the amide bond from 
trans to energetically less favourable cis orientation. Hence, a high activation energy barrier 
necessitates long times at high temperatures for completion.  
The use of microwave radiation as a source of energy in organic synthesis is not new. The 
absorption of microwaves takes place in the polar covalent bonds of a molecule, resulting 
into rapid increase in rotational and translational energies of a molecule. This in turn 
increases the probability of successful collisions or folding of reactant molecules. Hence, 
microwave assisted reactions usually complete much faster than the reactions with only 
conventional heating do. As the cyclization of N-substituted dipeptide esters is also a 
reaction that requires high temperature and long time, we evaluated the use of a microwave-
assisted protocol to achieve the cyclization in faster and efficient manner.  
One of such microwave assisted protocols52 for cyclization of boc-protected dipeptide 
esters appeared quite promising due to its simplicity and use of only water as a solvent 
without any other reagent. The protocol used boc-protected dipeptide esters. The Boc-
deprotection occurs in situ, generating a 1o-amine group as nucleophile, which then reacts 
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with carbonyl carbon of the ester group, and DKP is formed with the alkoxy group of ester 
leaving as an alcohol. However, the protocol also had a few limitations/problems: 
1) Most of diketopiperazines have no substitution on any nitrogen (denoted as R3 in 
the scheme in the mentioned article). In case of substituted ones, the substitution is 
only methyl and not any greater than that. 
2) Even though the article mentions, “water as solvent, 200 °C, 300 W, and 5 min 
reaction time resulted in the best”, the table of synthesized compounds mentions the 
temperature to be 250 oC. (Table-2, step-b in the article).  
3) The conditions mentioned were not possible to achieve. The publication mentions 
150 psi pressure (~ 10 atm), 250 oC and 250 W. It was observed that 10 atm pressure 
was reached at 180 oC and the remaining reaction stayed at 172-175 oC. In 
subsequent reactions, the pressure limit was increased up to maximum 20 atm to 
achieve 250 oC, however, this time pressure limit reached 20 atm just at 225 oC and 
the remaining reaction took place at 220-225 oC. 
 
Scheme 6. Microwave assisted cyclization of N-substituted dipeptide esters to DKPs 
We sought to correct and customize the protocol (Scheme 6) to synthesize diverse DKPs 
containing larger substitutions with 2o-amine as the nucleophile (Table 10). Moreover, 
most of our compounds were more or less soluble in water, hence the aqueous work-up 
procedure could not be used.  
Table 10. Microwave assisted cyclization of N-substituted dipeptide esters to DKPs 
Step-2 
product 
Time Product Product structure 
Isolated 
Yield % 





B2 30 min D2 
 
76 
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B12 1 h + 2 h D11 
 
22 
B13 1 h + 2 h D12 
 
37b 





















B18 1 h + 1 h D17 
 
55 





B21 30 min D19 
 
61 
B22 30 min D20 
 
65 
B23 30 min D21 
 
72 
B24 30 min D22 
 
59 
aDegradation was observed. 
bVery low UV activity may have resulted in low isolated yield. 
Overall, the yields were moderate. With the introduction of more and bigger substitutions, 
the decrease in the yield and increase in the necessary time for reaction completion was 
notable. A strong steric effect of substitutions in cyclization reaction was thus evident. A 
detailed study of such effects can be useful to determine synthesizability, and thereby in 
library design. In order to get a clear idea regarding such effects, theoretical studies were 
carried out for both stages of the reaction, namely cis/trans isomerization and cyclization 
led by nucleophilic attack of amino nitrogen on carbonyl carbon of ester group. The 
theoretical studies have been described in a separate section “Theoretical Studies”, from 
page 77. 
6.2. Library properties 
 Diversifiability 
As DKPs are cyclized products of N-substituted dipeptide esters, the DKP series has a 
diversification potential similar to that for NSDs. Both series have the same starting 
materials, and hence the theoretical chemical space for DKPs and NSDs have the same 
size. Considering this similarity, the virtual library of total 30118 DKPs with same R1, R2 
and R3 as in NSDs was created and all compounds were analyzed for different 




Like the NSD library described earlier, the DKP virtual library was analyzed with respect 
to various physicochemical parameters such as molecular weight, AlogP, number of 
rotatable bonds etc. It can be observed from Figure 18 that the DKP virtual library shows 








Figure 18. Distribution of a few properties for the virtual library of piperazine-2,5-diones. Red dots 
denote the synthesized compounds. 
 Ease of synthesis 
The DKP library can be synthesized with a three-step synthesis method from commercially 
available starting materials, including aldehyde, amino acid and amino acid esters. As 
described earlier, the first step does not require purification, while the second step and third 
step require column chromatography. All three steps are quite safe and no harmful reagent 
is required. Hence, overall the ease of synthesis is quite high.  
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 Cost and availability of starting materials 
As this library represents the cyclized product of N-substituted dipeptide library, the cost 
of the starting materials for DKP library remains the same as that for the N-substituted 
dipeptide library.  
6.3. Bioactivity studies 
The piperazine-2,5-diones library was tested for various bioactivities on multiple platforms 
such as viability assays on cancer cell lines, anti-microbial assays, anti-oxidant activity 
assay, and detailed profiling on kinases. One compound showed significant inhibition of a 
cancer cell line, while another compound showed significant inhibition of a kinase. No 
other significant activities were observed. The detailed observations of bioactivity assays 
are included in the appendix. 
 Inhibition of cancer cell lines 
D14 was found to cause loss of viability on A2058 melanoma cell line with 74 % viability 
loss at 50 µM and IC50 = 43 µM (Figure 19). However, no other compound showed such 
significant activities on A2058 or other cell lines.  
    
Figure 19. Active compounds from piperazine-2,5-diones series 
 BRSK1 inhibition 
The kinase profiling of a DKP compound D8 showed 92 % inhibition of BRSK1 at 100 
µM. This was not reproduced to that extent in follow-up testing, which showed instead 46 
% inhibition and thus an IC50 near 100 µM. This revealed BRSK1 (also known as SAD1 
or SAD-b) as a possible target that can be explored by the DKP series and its further 
development. As D8 is a small sized molecule with molecular weight less than 300, it can 
be reasonably considered a fragment type hit for further BRSK1 oriented drug-
development (Figure 19). 
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BRSK1 (Brain Specific Kinase 1) is an isoform of brain specific kinases (also known as 
SAD kinases). It has been shown103 to be important for neuronal polarization. BRSK1 is 
activated104 by LKB1 (Liver Kinase B1, also known as STK11) by phosphorylation in 
cerebral cortex. Once activated, BRSK1 then phosphorylates105 microtubule associated 
proteins, which finally elicit polarization. BRSK1 has also been associated with 
presynaptic vesicle clustering and axon termination106 as well as with regulation107 of 
neutrotransmitter release. Recently, the relationship between tau-dependent 
neurogeneration by BRSK1108 has also been established.  
Apart from its role in polarization of neurons and presynaptic regulations, BRSK1 has been 
recognized109–111 as an important regulator of centrosome replication, which also explains 
its role in the check-point response to the DNA damage112 induced by UV or chemical 
mutagenesis. Such an important role in cell-cycle makes BRSK1 as an interesting drug 
target for cancer drug development. 
With such an important role, from a pharmaceutical point of view, BRSK1 is a relatively 
new yet interesting target. BRSK1, as modifier of the PTEN/AKT pathway and the 
methods of use were patented113 in 2006, which expires by 2026. Considering 10-15 years 
as a typical drug-development time-line, 9 years from now is also a convenient window for 
BRSK1 targeted drug development 
6.4. Docking studies of synthesized compounds to Rho kinases 
 Rho kinases and their biological importance 
Rho-associated protein kinase (ROCK) belongs to the AGC kinase family of serine-
threonine kinases, expressed throughout human body as two subtypes, namely ROCK1 and 
ROCK2. More specifically, ROCK1 is expressed more in liver, kidney, testis and spleen, 
while ROCK2 is expressed more in brain, skeletal muscles and other tissues.114,115 
Being an important cell-regulator and wide distribution throughout the human body, ROCK 
has been shown to contribute to various pathophysiological conditions. The biological roles 
of ROCK116 in various body-functioning such as in the functioning of skeletal and smooth 
muscles117–120, determination of cell-permeability121,122 insulin signaling123, neurological 
disorders124 has been well documented. A very important role of ROCK has been 
established in the cardiovascular system125–128 where it is involved in various cellular 
processes such as nitric oxide synthesis, atherosclerotic lesion, angiotension generated 
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hypertrophy, cardiovascular inflammation, hypertension, stroke etc. Similarly, ROCK is 
also associated with cancers129,130 contributing to cell-permeability and invasion.  
With such a diverse activity profile, ROCK has attracted much attention in recent years as 
an important drug target. Many ROCK specific inhibitors131–135 belonging to diverse 
chemical classes have also been reported. Among them, Fasudil has been approved for 
treatment of cerebral vasospasm.  
 Similarity of synthesized DKP derivatives with patented Rho inhibitor 
piperazines 
ROCK shares significant similarity136 with other AGC kinases such as protein kinase A 
and specific inhibitors of Rho kinase have also been studied137 for their activity on PKA 
using Rho kinase mutant model in PKA as surrogate models.  
The literature survey revealed that N-substituted piperazine derivatives135 have been 
developed and patented as specific Rho kinase inhibitors.  
 
Figure 20. Similarities between patented piperazine derivatives and synthesized DKP derivatives 
Because of the structural similarity between patented piperazine derivatives and 
synthesized DKP derivatives (Figure 20), we considered the possibility of Rho kinase 
inhibition by synthesized library. Accordingly, we decided to carry out docking studies as 
a primary indicative tool for possible inhibition. However, in order to determine the 
predictivity of docking results, we decided to carry out an initial docking study of known 
Rho kinase inhibitors and PKA inhibitors on different structures of Rho kinase, PKA, and 
their hybrid structures.  
 Initial docking of known inhibitors on Rho, PKA and hybrid structures 
Following protein structures from the PDB were included for the docking studies: 
 ROCK1 structures: 2ESM, 2F2U, 3NCZ, 3V8S, 4W7P 
 5 fold mutant of Rho kinase on PKA (PKA5R) structures: 2GNH, 2GNI, 2GNF  
62 
 
 3 fold mutant of Rho kinase on PKA (PKA3R) structures: 2GNJ, 2GNL  
 PKA structures: 1STC, 1SVG, 1Q8W 
Along with above structures, two homology models were also created using Schrodinger 
software suite and were included in docking.  
 Homology models: PKA (1Q8W) based on ROCK1 (3NCZ), ROCK1 (3NCZ) 
based on PKA (1Q8W) 
As known inhibitors, following ligands were extracted from one of their native protein-
ligand complexes and were subjected to LigPrep application prior to docking. 
 Fasudil, Hydroxyfasudil, Y27632, H1152P, 3NC from PDB ID: 3NCZ, 3ND from 
PDB ID: 3NDM, Indazole compound 18 from PDB ID: 3V8S, RKI1342 from PDB 
ID: 3TV7, YB-15-QD37 from PDB ID: 4W7P, Staurosporine 
The docking results were studied to compare the predicted docking pose vis-à-vis the 
crystal structure pose of the compound in the same enzyme, considering the crystal 
structure pose as a most energetically favourable pose. The results are summarized in 
Figure 21. 
 Although only a small fraction of docking experiments reproduced the experimental 
binding pose in its entirety (dark green), somewhat over half reproduced at least the 
hinge binding interactions (dark and light green), and a clear majority predicted at 
least some hinge binding (yellow and greens).  
 The failure of staurosporine to dock successfully in any target except its parent 
structure (and here only with XP precision docking) is notable. Because 
staurosporine, with its extended planar and aromatic structure, significantly expands 
the binding site,138 docking requires adequate prediction of flexibility prediction for 
the target, as has been noted previously.139 
 The target 1SVG also usually failed to predict hinge binding. Here, due to definition 
of the pocket grid based on the extent of the native ligand, the more extended 
inhibitor of 1SVG led to a pocket that included more residues distant from the hinge. 
Several of these created a hydrophobic/aromatic site that the docking algorithm 
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checked box = parent ligand-protein pair 
Dark green colour = Docking pose similar to a reported crystal structure 
Light green colour = Docking pose with only hinge binding portion similar to a reported 
structure 
Yellow = hinge interactions but incorrect hinge binding mode 
Red colour = no interactions (all distances >4A) at hinge 
Black colour = Ligand did not dock at all. 
Figure 21. Docking of known inhibitors on Rho kinase, PKA and hybrid structures. Each target 
structure (in rows) was used with (top half of row) and without (bottom half of row) minimization. 
Inhibitors with multiple possible charge or protonation states have multiple columns. 
 Although the minimization of the target molecule often significantly changed the 
outcome, there is no overall correlation with respect to the quality of the prediction.  
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 The proton assignment could be decisive: Unfavorable assignment of the 
protonation state of indazole-18 search prevented correct docking.  
The homology models performed diversely: the ROCK1 model (based on 1Q8W was as 
good as the best ROCK1 structures, while the PKA homology model was quite poor. 
 Docking of synthesized compounds with PKA, Rho and hybrid 
structures 
From the above study, it was apparent that protein structures 1SVG and 1STC structures, 
as parameterized, were unreliable for docking. Hence, docking of synthesized compounds 
was carried out on all structures except these two. A standard protocol to use of energy 
minimized protein structures was followed. Moreover, all native ligands extracted from 
protein structures were also included for the docking studies in order to make a possible 
comparison with docking scores of synthesized compounds.  
The docking results showed that ligands 3ND and 3NC (from native ligands) were quite 
good binders to most structures. Known inhibitors of Rho kinase also docked well. In 
comparison, the synthesized compounds showed relatively poor docking score. Only a few 
compounds such as D18 showed docking score within around 1-2 units range of the scores 
for 3NC and 3ND, while for others, the docking scores were poorer.  
Overall, the docking results were not very positive for the synthesized compounds with 
respect to binding with Rho kinase.  
 
7. Library III: Tartaric acid bisamides (TABs) 
This chapter first describes different methods used for synthesis of tartaric acid bisamides. This 
synthesis also led to a faster protocol for cyclic tartrimide derivatives. This is followed by 
cheminformatics analysis of library properties as per the efficiency parameters described in the 
introduction part. A brief account on bioactivity studies is also included. 
7.1. Synthesis 
 Designing the synthetic route to tartaric acid bisamides (TABs) 
As the target structure was a bisamide with two different amides at both ends, reaction of 
both carboxylic acid centers with two different amines was necessary. However, it was not 
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possible to react both carboxylic acid centers with two different amines simultaneously. 
Hence, it was necessary to use a multi-step approach.  
 
Scheme 7. Synthetic route to tartaric acid bisamides 
The general approach for synthesis was a three step scheme (Scheme 7), where the first 
step involved synthesis of O,O-diacetyl tartaric acid anhydride. The reaction of the 
anhydride with an amine would give O,O-diacetyl monoamide derivatives, which upon 
reaction with another amine followed by alkaline hydrolysis would afford the desired 
tartaric acid bisamides. 
 Synthesis of O,O-diacetyl tartaric acid anhydride (E) 
 
Scheme 8. Synthesis of O,O-diacetyl tartaric acid anhydride 
Following a reported protocol140,141, O,O-diacetyl tartaric acid anhydride was synthesized 
by refluxing tartaric acid with acetic anhydride and catalytic amount of sulfuric acid for 
10-15 min in 69 % yield (Scheme 8). The pure product was isolated on gram scale after 
crystallization followed by washing with benzene and ether. 
 Synthesis of O,O-diacetyl tartaric acid monoamide (F) 
The anhydride was reacted with amines to afford O,O-diacetyl tartaric acid monoamide. 
The use of 2 equivalents of amines141,142 resulted in salt formation due to reaction of excess 
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amine with the free carboxylic acid group of monoamide product. Therefore, only slight 
excess of anhydride (1.05 equivalent) was used (Scheme 9). Initially, the 1o-amines were 
used to generate corresponding 2o-amides. However, later on when the follow-up steps 
could not succeed with 2o-amides, 3o-amides were synthesized via reactions of 2o-amines 
with the anhydride (Table 11). 
 
Scheme 9. Synthesis of tartaric acid monoamides 
Table 11. Synthesis of O,O-diacetyl tartaric acid monoamides 






rt, 2 hr 88 % 
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rt, 1 hr 92 % 
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rt, 1 hr 98 % 
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rt, 1 hr 98 % 
F6 
 
1 day No reaction 
F6 
 
60 oC, 6 hr No reaction 
 
 Attempts of peptide coupling 
In order to synthesize tartaric acid bisamides from the monoamides, first peptide coupling 
was tried, as shown in Scheme 10. The same protocol, which was used for N-substituted 
dipeptide library, was initially used here. However, the reactions were not successful as the 
crude reaction mixture showed degradation and no discernible product formation. The 




Scheme 10. Attempts of peptide coupling with monoamide 
It appeared that the monoamide might be sensitive to the peptide coupling protocols as the 
reaction with tryptophan methyl ester (often used in the N-substituted dipeptide series) was 
also unsuccessful. 
Table 12. Peptide coupling attempts with O,O-diacetyl tartaric acid monoamides 
No. R1-N(H) R2-NH Reaction conditions 
1 
  
HBTU (1.2 equiv), rt, TEA 
(4.8 equiv), ACN, 30 min 
2 
  
DCC (2.1 equiv), 80 oC, 
ACN, 3 h 
3 
  










HATU (1.2 equiv), rt, TEA 




HATU (1.2 equiv), 
60 oC, TEA (4.8 equiv), 




HBTU (1.2 equiv), rt, TEA 




HBTU (1.2 equiv), rt, TEA 









HBTU (1.2 equiv), rt, 





Initially, the peptide coupling reactions were carried out with only monoamides generated 
from 1o-amines. After the efforts with 2o-amides proved to be unsuccessful, monoamides 
from 2o-amines like morpholine were synthesized. However, peptide-coupling reactions on 
these were also unsuccessful (Table 12). 
 Attempts of peptide coupling after deprotection 
The failure of peptide coupling reactions was unexpected. However, we found an example 
in literature where the tartaric acid monoamides had been reported143 to undergo ketene 
formation in presence of thionyl chloride. We hypothesized that activation of the 
carboxylic acid group with coupling reagents might also lead to ketene formation, which 
might be a reason for the failure of the protocol because a ketene intermediate could lead 
to different reaction pathways. If that were the case, the deacetylated monoamide might 
show some different result. Hence, a hydrolysis reaction was performed as shown in 
Scheme 11. 
 
Scheme 11. Hydrolysis of diacetyl tartaric acid monoamide 
The O,O-diacetyl monoamide was hydrolyzed using 28 % aq. ammonium hydroxide144 
solution. The hydrolysis reaction was not clean. The product was highly polar which did 
not elute out of silica or alumina column. Thus, it was an unsuccessful attempt of isolating 
deacetylated monoamide product.  
 Attempts of acid-chloride synthesis from 2o-amide – tartrimide 
formation 
As the peptide coupling was unsuccessful, and the deacetylation product could not be 
isolated, formation of the acid chloride intermediate was chosen as the strategy for the 
required amide bond formation. Hence, the reaction of monoamide was carried out with 
thionyl chloride at reflux145,146, followed by addition of a secondary amine, morpholine 




Scheme 12. Scheme for acid chloride synthesis, which resulted in tartrimide formation 
However, when the reaction was carried out, the mass spectrum of the crude reaction did 
not show any peak for desired product (Table 13). Instead, a single peak for dehydrated 
product was observed, which implied that instead of acid chloride formation, the 
monoamide might have cyclized in the presence of thionyl chloride via ketene 
intermediate.143 Later, this was confirmed in a different protocol using thionyl chloride as 
solvent, and a new series of tartrimide was developed (Please see section 7.1.8) 
Table 13. Attempts for synthesis of acid chlorides from monoamides 




Peak for cyclized tartrimide observed 




Peak for cyclized tartrimide observed 
on MS, not isolated 
The result indicated that the 2º-amides were susceptible to cyclization and tartrimide 
formation. Therefore, it was preferable to use 3º-amides generated via reaction of 
anhydride with 2o-amine for the acid chloride route.  
 Tartaric acid bisamide (G) synthesis via acid-chlorides 
After it was realized that monoamides with fully substituted amide groups were better 
starting materials than the monoamides with 1o-amine, a modified acid chloride route 
(Scheme 13) was used for synthesis of target bisamides. Instead of taking 4 equiv. of 
thionyl chloride in THF, thionyl chloride was used as solvent, and the reactions were 
carried out at room temperature. The use of thionyl chloride as solvent resulted in side-
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reactions that generate a yellow colour. In order to minimize it, small scale reactions were 
carried out (only to monitor the completion, not to isolate product – first four entries in 
Table 14) and the optimum duration for the acid chloride formation was found to be 30 
min. On completion, the reaction mixture was evaporated to dryness at room temperature 
using argon flow. After complete evaporation of thionyl chloride, dry THF was added as 
solvent for the next step, followed by amine.  
 
Scheme 13. One-pot three-step method for synthesis of tartaric acid bisamides via acid chlorides  
Initially, an attempt was made to isolate the diacetyl bisamide products (step-2 products) 
with column chromatography. However, on isolation, it was realized that the thionyl 
chloride evaporation causes deacetylation of one or both acetyl groups, resulting in a 
mixture of four compounds (with both acetyl groups present, with either of two acetyl 
groups and with both acetyl groups removed), which was not possible to separate. Hence, 
the isolation and purification of pure product could be done only after hydrolysis. 
As per this protocol, after the first step, the solvent is evaporated with argon flow to 
dryness. Then the second step is carried out with new solvent and reagents. After the second 
step, the solvent is again evaporated to dryness under reduced pressure, followed by 
addition of new solvent, which is again evaporated after reaction completion. It was only 
after the third step that the crude reaction mixture was subjected to isolation and 
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purification. Thus, this protocol works satisfactorily as a one-pot three-step method for 
synthesis of tartaric acid bisamides. 
Table 14. Synthesis of tartaric acid bisamide derivatives via acid chloride route 




























30 min 27 %  
G2 
  
30 min 21 %  
G3 
  
30 min 31 %  
G4 
  










30 min No reaction  
 
 Tartrimide (H) synthesis 
Tartrimides are an important class of tartaric acid derivatives, used as an intermediate for 
synthesis of natural products147,148 and bioactive molecules.149–151 Dicaffeoyl- or Digalloyl 
derivatives of tartrimide have also been reported as HIV integrase inhibitors.152 Generally 
tartrimides are prepared by reaction of amines with O-substituted or unsubstituted tartaric 
acid derivatives in toluene at high temperature for long time.153 Another common protocol 
is three-step synthesis154–156 via O,O-diacyl tartaric acid anhydrides by sequential reaction 
with acid chloride, amine and again acid chloride, which is a multi-step method where the 




Scheme 14. Synthesis of tartrimide from 2º-monoamides 
Scheme 15. One-pot two step synthesis of tartrimides from tartaric acid anhydride 
Table 15. Tartrimide synthesis 













As discussed in section 7.1.6, reaction of O,O-diacetyl 2º-monoamides with thionyl 
chloride at higher temperature was observed to provide cyclic tartrimide based on MS 
analysis within 15 minutes, however the product could not be isolated. Considering the 
importance of the series, we sought to develop the observation into an easier and faster 
protocol for tartrimide synthesis. 
As reaction of O,O-diacetyl 2º-monoamide with 4 equiv. of thionyl chloride in THF at 80 
ºC provided only a tiny amount of tartrimide (detectable only on MS), it clearly suggested 
need of more thionyl chloride for completion of the reaction. Therefore, a reaction (Scheme 
14) was carried out using thionyl chloride as the solvent, which gave the desired tartrimides 
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in just 20 minutes. However, an attempt of isolation by evaporation of thionyl chloride 
resulted in deacetylation and gave mixture of products. Hence, the products were isolated 
by precipitation in pentane, which provided product H1 in good yields.  
An attempt to integrate the reaction with monoamide synthesis step as a one-pot synthesis 
was also successful as shown in Scheme 15. Reactions of tartaric acid anhydride were 
carried out with 1º-amines. Upon completion, solvent DCM was evaporated with nitrogen 
flow up to dryness, and thionyl chloride was added as the new solvent. Upon reflux for 20 
min at 80 ºC, each reaction mixure (entries H2 to H4 in Table 15) was poured in pentane. 
The precipitates were filtered and washed with pentane, and then dried in air. The reaction 
mixtures that did not precipitate were subjected to crystallization in pentane at -20 ºC, and 
the crystals were filtered followed by washing with cold pentane and drying in air. Overall, 
the tartrimides were obtained in good yields in shorter time with easy isolation. 
 
7.2. Library properties 
As discussed in the introduction (chapter 2), the properties of library-compounds should 
be reasonably favourable for their use in drug discovery process. Further, as mentioned in 
section 3.4.3, TABs were considered rather fragment-like, amenable to extension via 
substituted fragments on both variable positions. Hence, only a small virtual library (Figure 
22) with 20 amine varieties for R1 and 6 amine varieties of R2 was created and analyzed 
for distribution of properties.  
 Diversifiability 
TABs offer two places for substitutions, which makes them diversifiable fragments. 
Further, considering the huge varieties of commercially available amines, the possible 
diversification potential remains high. Moreover, it is also possible to derivatize the vicinal 
hydroxyl groups in order to introduce further diversification.  
 Diversity 
As for NSDs and DKPs, the diversity of the virtual library of TABs fragments was also 
analyzed with respect to various physicochemical parameters such as molecular weight, 
AlogP, number of rotatable bonds and polar surface area. It can be observed from Figure 
23 that the virtual library shows promising distribution patterns for various parameters, 




Figure 22. Virtual library generation for TABs 
 Ease of synthesis 
As described in N-substituted dipeptide and DKP libraries, ease of synthesis is an important 
factor for chemoprospecting. The synthesis of TABs requires 5 steps. The first step is short 
and easy to scale-up. As the product is isolated with precipitation, no column 
chromatography is required. The second to fifth steps can be carried out as one-pot 
synthesis, which makes them possible to integrate with a parallel synthesis assembly. The 
overall yield is medium. Products are usually highly polar, which makes isolation with 
column chromatography difficult. Reverse phase chromatography, however, may be very 









Figure 23. Distribution of a few properties for the virtual library of TABs 
 
 Cost and availability of starting materials 
The main starting materials for TABs library are tartaric acid and amines. Tartaric acid is 
quite cheap and commercially available. However, unnatural isomers of tartaric acid are 
not cheap in pure enantiomeric forms.  On the other hand, amines are commercially 
available in wide varieties, and most of them are cheap. 
7.3. Bioactivity studies 
The TABs library was tested on assays such as anti-microbial assays, viability assays on 
cancer cell-lines and anti-oxidant activity assay at MarBio and was also subjected to kinase 
profiling, but no compound showed any significant activity. The tartrimide series was 
synthesized only recently, and will be tested on various platforms in future.  

























As described in section 6.1.2, microwave assisted cyclization of dipeptide esters to piperazine-2,5-
diones revealed strong substitution effects resulting in significantly higher times required for 
reaction completion, and relatively low yields for substrates with bigger substitutions. The objective 
of the theoretical studies was to rationalize such substitution effects in terms of energetics. This 
rationalization would enable analysis of such effects for different substitution patterns along with 
stereochemical considerations with a potential applicability to determine synthesizability and 
thereby compound selection. The theoretical studies were carried out using density functional 
theory (DFT) on both stages: the cis/trans isomerization of dipeptide esters and cyclization by attack 




8. Cis/trans isomerization in NMA and GGMe 
This chapter will introduce theoretical studies on cis/trans isomerization in secondary amides. 
Therefore, the discussion in this chapter will focus on primary understanding of the secondary amide 
geometries in terms of stationary points such as optimized minimum energy trans and cis 
geometries as well as transition state geometries using a small secondary amide prototype N-
methylacetamide (NMA) and a peptidic prototype Glycylglycine methyl ester (GGMe). The detailed 
cis/trans isomerization process will be discussed in terms of minimum energy reaction paths via 
transition states and corresponding geometry changes for NMA and GGMe, and the applicability to 
bigger substituted systems will be established. This chapter will prepare the reader for the discussion 
on cis/trans isomerization in substituted peptidic systems. 
8.1. Introduction 
 Cis/trans isomerization in secondary amides 
Due to partial double bond character of the C-N bond in amide bond, the free rotation 
around the bond is hindered by a relatively high energy barrier, resulting in cis and trans 
isomers where trans is energetically favoured over cis.157–160 A majority of cis peptide 
bonds have been observed to be tertiary amide bonds (i.e. preceding prolyl residues) as the 
relative stability of corresponding cis and trans conformations would be similar.160–162 
Conversely, secondary (i.e. non-prolyl) cis peptide bonds are rare but they do occur162–164 
and play a key role in various biological functions, such as chemo-mechanical cycle of 
motor proteins165, protein folding166–168 and catalytic activity169 of enzymes such as 
cyclophilin A. Moreover, cis/trans isomerization is also involved in cascade dissociation 
of peptide cation radicals170, and hence is important for peptide sequencing. From a 
synthetic chemistry point of view, cis/trans isomerization is an essential step for cyclization 
reactions of peptides, such as formation of piperazine-2,5-diones.171 In the drug discovery 
area, cis/trans isomerization is also linked with efficacy and selectivity of peptidomimetics, 
hence attempts have been made to tailor the flexibility of the rotamers and overall 
conformations by introducing constraints such as intramolecular hydrogen bonding and/or 
steric bulk.172,173  
 Theoretical studies  
While cis/trans isomerization has been a subject of interest for chemists since 1950s174–179, 
effective theoretical studies have become possible only rather recently. QM methods on 
secondary cis/trans isomerizations have been employed to explain and predict rotational 
barrier values in agreement with experimental values180,181, and studies have been carried 
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out to understand different phenomena such as role of conjugation182 and solvent effects 
with molecular dynamics183. The theoretical studies with ab initio methods on secondary 
amide prototypes184–186 have highlighted the importance of pyramidalization of amide 
nitrogen along with two transition state geometries. These studies described two transition 
states interchanging though a high-energy saddle point of 2nd order along with a reaction 
coordinate path involving the more stable transition state, however a discussion on 
changing planarity and hybridization state of amide nitrogen was lacking. Following this, 
Mantz et al. described187 cis/trans isomerization using force-field methods by generation 
of an ensemble of transition state geometries, which described plausible hybridization 
change for amide nitrogen around ω dihedral values between 90º-110º. However, the 
observations from force-field methods indicated a single path for cis/trans isomerization 
passing through both transition states via the high-energy saddle point of 2nd order, 
requiring further clarity on geometry changes during the isomerization. Hence, a fresh 
relook with assessment on the reaction path(s), corresponding geometry changes and the 
relevance/importance of the high-energy 2nd order saddle point can provide more details 
about geometry changes. 
In addition, it has been observed experimentally188,189 that moieties on both sides of amide 
bond may affect the cis/trans isomerization process. Therefore, it seemed interesting to 
replicate such studies on bigger moieties, such as dipeptides or their derivatives, to assess 
the effect of peptide backbone on isomerization. Juxtaposing observations on a small amide 
prototype such as N-methylacetamide (NMA) with that on a model dipeptide scaffold 
would provide an excellent foundation for such studies. A dipeptide ester scaffold, owing 
to the use in pro-drugs and peptidomimetics190–193 and as a precursor of piperazine-2,5-
diones via cyclization where cis/trans isomerization is an important step, can serve as a 
valuable model dipeptide scaffold not only for understanding of isomerization in peptide 
chains, but also in peptidomimetic drug design and synthetic chemistry. Overall, such 
studies can provide a realistic view on cis/trans isomerization in peptidic systems that may 
serve as a basis for further studies with larger systems.  
In this context, our theoretical assessment on cis/trans isomerization in NMA and a 





Figure 24. NMA and GGMe structures, atom numbers and different measures 
8.2. Stationary points in NMA and GGMe 
 Optimized trans and cis geometries 
The optimized minimum energy geometries of NMA and GGMe were found to be in an 
extended form, albeit with the “peptide backbone” slightly offset from complete planarity 
(Figure 25). A weak N-H-N hydrogen bond (2.24 Å) between N-terminal nitrogen and the 
hydrogen attached to amide nitrogen appeared to contribute to further stabilization of trans 
geometry of GGMe as evident from shorter C-N amide bond length than that in NMA 
(Table 16). The optimized trans and cis geometries of NMA appear more planar than those 
reported previously at SCF and MP2 levels though the relative stabilities of trans and cis 
geometries are in excellent agreement.186 
Table 16. Optimized minimum energy geometries of NMA and GGMe in cis and trans form 







NMA Trans 178.7 176.8 1.366 121.7 0.0 0.0 
NMA Cis 5.3 3 1.370 127.1 2.3 2.2 
GGMe Trans 178.3 180.7 1.354 121.5 0.0 0.0 
GGMe Cis 0.1 -0.1 1.367 127 4.6 4.5 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 




Figure 25. Trans (left) and cis (right) optimized energy minimum geometries of NMA (above) and 
GGMe (below). 
 Transition state geometries (TSGs) for NMA and GGMe 
For trans to cis isomerization, the rotation of amide bond in terms of ω dihedral would be 
from ~180º to ~0 (= 360º), which can occur in both directions, i.e. 180º - 270º - 360º 
(positive direction) or 180º - 90º - 0º (negative direction). Similarly, the rotation from cis 
to trans in terms of ω dihedral would be from ~0º to ~±180º, which can occur either 0º - 
90º - 180º (positive direction) or 0º - (-90º) - (-180º) (negative direction). Owing to the 
symmetry of NMA and GGMe, it would be sufficient to describe the isomerization between 
~0º to ~180º via positive ω values.  
Instead of creating reasonable transition state geometries for transition state search 
manually, we chose to use generate such reasonable geometries using a relaxed coordinate 
scan (RCS) protocol along the ω dihedral, and the energy barrier geometries thus obtained 
were used for transition state search. The RCS along the ω dihedral from trans isomer led 
to syn energy barrier geometry (EBG – an optimized RCS geometry near the energy barrier) 
near ω = ~60º, while the trajectory starting from the cis isomer led to anti EBG near ω = 
~120º. The syn and anti terms represent the orientation of the lone electron pair of 
pyramidalized nitrogen with respect to C=O bond. The transition state geometries (TSGs 
– obtained with QST transition state search, with one imaginary frequency) were found to 
be in agreement with previous studies186,187, and also extremely similar to the EBGs, 
confirming the validity of the EBGs (Table 17). Henceforth, EBGsyn will refer to the syn 
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EBGs, TSsyn will refer to syn TSGs, EBGanti will refer to the anti EBGs and TSanti will refer 
to anti TSGs. 
Table 17. Comparison of energy barrier geometries and transition state geometries 








NMA -  EBGanti 122.6 60.3 1.455 112.2 -32.5 18.4 16.3 
0.0008 
NMA -  TSant 122.6 60.7 1.455 112.2 -32.4 18.6 16.3 
NMA -   EBGsyn 59.7 114.2 1.449 115.3 29.0 21.8 19.6 
0.0027 
NMA -  TSsyn 60 115.1 1.449 115.2 29.2 21.9 19.6 
GGMe -  EBGanti 118.3 56.6 1.449 113.1 -31.9 19.5 17.4 
0.0031 
GGMe -  TSanti Rota I 118.1 56.1 1.449 113.1 -31.8 19.6 17.4 
GGMe -  EBGsyn 61 110.3 1.451 117.2 26.7 25.4 23.5 
0.0131 
GGMe -  TSsyn Rota I 60.7 106.5 1.449 117.8 25.4 25.3 23.5 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 




Figure 26. Rotations around the rotatable bonds generate local saddle points corresponding to the 
transition state rotamers. 
As a small molecule with only methyl groups beyond the amide moiety, NMA does not 
have asymmetric rotatable bonds, or substitutions that would generate multiple local 
minima rotamers for a coordinate (such as ω) pertaining to cis/trans isomerization, hence a 
single geometry can represent a particular optimized state such as trans, cis, or a transition 
state. However, this is not the case for bigger systems such as GGMe as multiple rotatable 
bonds with substituted carbons outside amide moiety (Figure 26) give rise to multiple local 
transition state rotamers. Accordingly, reasonable rotamer geometries were generated from 
TSanti Rotamer I and TSsyn Rotamer I, and subjected to transition state search protocols. 
Thus, a total of 14 rotamers of TSanti and TSsyn (7 of each type) were chosen (Table 18 and 
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Figure 27). Rotamer I for TSanti and rotamer VII for TSsyn were found to be most stable 
among them, and will be used for further discussion on transition state geometries (Figure 
28 and Table 19). It is also important to note that there may exist more transition state 
rotamers of GGMe. 
















I 19.6 17.4 57.4 -179.3 118.1 158.2 158.8 56.1 
II 20.4 24.0 149.4 173.1 115.4 158.8 158.4 54.3 
III 24.4 22.0 -156.4 77.6 118.5 161.1 157.1 55.1 
IV 21.7 18.9 -178.4 -40.4 122.7 156.0 160.8 58.6 
V 20.5 18.2 70.6 -176.8 115.8 -76.0 -158.1 46.3 
VI 24.6 30.0 -162.2 89.8 116.6 -70.5 -159.5 46.4 
VII 23.5 45.0 -57.8 47.3 112.8 92.1 -159.7 52.3 
















I 25.3 23.5 -86.0 62.2 60.7 -89.5 174.2 106.6 
II 24.4 22.4 58.4 60.3 63.6 -93.1 172.7 115.7 
III 23.5 21.5 -32.3 -166.5 63.4 -98.7 175.7 116.1 
IV 25.1 23.0 -171.4 -8.9 64.5 -124.4 -175.4 116.4 
V 26.2 24.0 -86.2 42.3 56.6 -161.0 -155.8 110.8 
VI 28.5 26.5 -83.8 60.7 62.8 -88.0 -23.2 107.5 
VII 23.3 20.8 56.5 179.0 61.3 -95.3 172.3 115.9 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 






Figure 27. Transition state rotamers for GGMe. Seven rotamers for TSanti 120 (upper) and seven 





Figure 28. Transition state geometries for NMA and GGMe in gas phase.  
Table 19. Comparison of transition state geometries of NMA and GGMe 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 
 
Figure 29. Steric bulk caused by atoms neighbouring the amide moiety, and repulsion between C=O 
bond and lone N-electron pair lead to significant strain in syn geometries. 
Interestingly, the pyramidal character of amide nitrogen in syn and anti TSGs differs in 
terms of bond angle ∠CNC and improper dihedral angle τ (Table 19). The values for ∠CNC 
were observed to be ~112-113º for anti TSG, which is close to expected value of 109º for 







NMA TSanti 122.6 60.7 1.455 112.2 -32.4 18.6 16.3 
NMA TSsyn 60 115.1 1.449 115.2 29.2 21.9 19.6 
GGMe TSanti I 118.1 56.1 1.449 113.3 -32.0 19.5 17.4 
GGMe TSsyn VII 61.3 115.9 1.450 116.3 29.3 23.3 20.8 
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sp3 hybridized pyramidal nitrogen, but for syn TSG, the values were higher, at ~115-116º. 
Similarly, while the values of τ for anti TSG remained at ~32º, close to expected values of 
33-34º for sp3 pyramidalized nitrogen, those for syn TSG were at ~29º. The strained 
geometry for syn TSG clearly reflects the effect of steric bulk due to the proximity of atoms 
in neighbourhood of amide moiety (Figure 29). This strain, together with the repulsion 
between C=O bond and lone pair of electron, results in significant destabilization of the 
geometry. This destabilization makes syn TS more unstable by ~3-4 kcal/mol compared to 
anti TS.  
 Molecular orbitals 
Although molecular orbital analysis on transition state geometries is complicated by the 
mixing of several molecular orbitals, the molecular orbital HOMO-10 on syn RBGs (and 
syn TSGs as well) of GGMe provided a relatively clear view. It is apparent from Figure 30 
that the angle between two planes containing C=O π orbital and orbital with N-lone pair is 
90º – implying lack of overlap. This further confirms the complete pyramidalization of the 
amide nitrogen at the energy barrier and explains the increase in C-N bond length to 1.45-
1.46 Å compared to 1.35-1.37 Å in energy minimized cis or trans geometries. 
 
Figure 30. The molecular orbital HOMO-10 of TSsyn of GGMe showing 90º angle between two 
planes of C=O π orbital and orbital with N-lone pair. 
8.3. Geometry changes during cis/trans isomerization 
 Reaction paths and geometry changes in cis/trans isomerization 
The most important feature of the cis/trans isomerization is the progression of changes of 
the effective atomic orbital hybridization of the amide nitrogen. Cis and trans geometries 
have a planar sp2 amide nitrogen, but a pyramidal sp3 hybridization state characterizes both 
transition states. Previous studies186,187 suggested an inversion of sp3 pyramidal nitrogen in 
terms of interchange between syn and anti transition states via a high-energy 2nd order 
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saddle point with ω = ±90º. However, no reaction coordinate path connecting the two 
transition states via the saddle point with planar nitrogen was established. Based on the 
geometry changes shown by our intrinsic reaction coordinate (IRC) study, we describe here 
a significantly different and more detailed account of reaction paths with corresponding 
geometry changes driving the cis/trans isomerization (Figure 31).  
 
Figure 31. Both paths of cis/trans isomerization and relevant geometries. Ra and Rb represent 
substitutions attached to the carbonyl carbon and amide nitrogen respectively. For simplicity, the 
rotation is shown only for positive ω values between 0º (cis) and 180º (trans). 
 Two reaction paths 
Cis/trans isomerization is a function of both ω and ϴ, and both dihedrals are similar for 
trans and cis geometries (close to ±180º and 0º respectively). However, the values of both 
dihedrals differ substantially for the transition states i.e. ω = ~60º, ϴ = ~120º for TSsyn and 
ω = ~120º, ϴ = ~60º for TSanti. This implies that along the paths to the transition states, the 
two dihedral angles do not change linearly with respect to each other (i.e. rotation about 
the amide C-N bond must involve loss of planarity of at least one of the bonded atoms). 
This results in two different paths via two different transition states for the isomerization. 
Accordingly, Figure 31 details the two distinct paths, path 1 via TSanti and path 2 via TSsyn. 
Because TSanti is more stable transition state, path 1 is energetically more favourable than 
path 2; however, it is also important to note that (as will be discussed later) the relative 
stability of the syn and anti transition states may vary depending on the neighbouring 
substitutions and conformational state of the overall geometry.  
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The isomerizations begin via common reaction paths, characterized mostly by change in 
ω, until a bifurcation point is reached. During the common paths, ϴ values remain close to 
0 or ±180 (for isomerization from cis or trans geometries respectively). This preserves the 
extended π-bonding orbital overlap, in synchrony with atomic orbital hybridization 
changes at the nitrogen atom. These change progressively from sp2 towards sp3 as amide 
nitrogen geometry changes from planar to semiplanar/half-pyramidal at the bifurcation 
point (SPl1 for trans or SPl2 for cis). Here, the paths diverge, and ω and ϴ change 
disproportionately along the two paths to complete the pyramidalization of nitrogen at the 
two respective transition states. Progressing past the transition states, the situation reverses, 
and the path previously characterized by a relatively greater variation of ω now shows 
greater variation of ϴ and vice versa, continuing until the other semiplanar/half-pyramidal 
bifurcation point is reached. So overall, each reaction path is composed of two phases, with 
one phase characterized mostly by changing ω (henceforth referred to as “ω-phase”) and 
the other phase characterized mostly by changing ϴ and very little change in ω (henceforth 
referred to as “ϴ-phase”).  
As the nitrogen becomes pyramidal during the isomerization, the two paths differ 
qualitatively with respect to changes in the planarity of nitrogen as described in terms of 
improper dihedral τ (τ is explained in Figure 24). The ω-phase proceeds from the 
bifurcation point to the transition state through continued progression from half- to full 
pyramidal nitrogen geometries. On the other hand, the ϴ-phase proceeds from the 
bifurcation point to the transition state via inversion of the nitrogen geometry, i.e. first with 
loss of half-pyramidal geometry to become planar (τ = ~0) and then progressing to a full 
pyramidal state with inverted geometry (from positive to negative values of τ and vice 
versa).  
 The ω phase  
The ω phase describes the reaction coordinate paths between SPl1 and TSsyn and between 
SPl2 and TSanti. As mentioned earlier, this phase is characterized by changes of both ω and 
ϴ, although ω changes dominate until close to the transition state, when both change at 
similar rates.  
 The ϴ-phase 
The ϴ-phase describes the reaction coordinate paths between SPl1 and TSanti and between 
SPl2 and TSsyn. This phase is driven almost exclusively by changes in ϴ with small or no 
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change in ω. A drastic change in geometry is observed during this phase as the amide 
nitrogen undergoes inversion, seen as a flip in the hydrogen position. During inversion, the 
geometry of nitrogen changes from pyramidal at the transition state, moves through a 
planar state and becomes semi-pyramidal with inverted geometry at the bifurcation point. 
Correspondingly, its atomic orbital hybridization state changes from the sp3 state, passes 
through an sp2 state (Pl1 or Pl2) and regains a partial sp3 state with an inverted geometry. 
The intermediate geometries with planar nitrogen (Pl1 and Pl2) show the p-orbital of 
nitrogen with its lone pair of electrons in a gauche–like conformation with respect to C=O 
bond. This corresponds well with a chemically intuitive expectation of the lowest energy 
geometry for the planar nitrogen state, although other interactions, such as a steric 
interaction between Ra and Rb in Pl2, may also play a role. This is also in stark contrast to 
the high energy 2nd order saddle point (TSpl) mentioned in previous studies with an eclipsed 
geometry. Instead, the geometries with planar nitrogen Pl1 and Pl2 have partial orbital 
overlap and hence are stabilized geometries compared to respective transition states.  
        
Figure 32. The molecular orbital HOMO-10 of rotamer GGMe TSsyn 60 I shows 90º angle between 
two planes of C=O π orbital and orbital with lone N-electron pair, whereas the same orbital of 
corresponding SPl2 bifurcation point geometry showing restored overlap between the two orbitals. 
As the hydrogen-flip (pyramidal inversion) approaches the bifurcation points (SPl1 and 
SPl2), the overlap of orbitals continues to increase and stabilizes the geometries in both 
paths (Figure 32). Conversely, in the reverse direction, reaching the transition state from a 
bifurcation point via ϴ-phase requires progressively higher energy geometries as 
decreasing overlap progresses through inversion to the transition state with little or no 
change in ω.  This, in turn, explains why RCS on ω dihedral from trans geometry leads to 
syn EBG, while from cis geometry leads to anti EBG in its attempt to find local minimum 




Figure 33. Contour map for ω and ϴ dihedral coordinates for cis/trans isomerization of NMA. The 
black marks represent IRC geometries from path 1 and path 2. The minimized coordinate scan 
geometries for the creation of contour were generated using MMFFs force-field, while energy 
values for the generated geometries were calculated at B3LYP/6-31G**++ level. 
8.4. Cis/trans isomerization in NMA 
The IRC study showed that cis/trans isomerization in NMA precisely follows the scheme 
described above (Figure 31) and its corresponding geometry changes. Figure 33 illustrates 
the IRC paths for cis/trans isomerization in NMA and important geometric measurements 
of the relevant geometries have been tabulated in Table 20. The Newman projections of 












NMA – trans 1.366 121.68 178.72 -176.78 2.56 0.00 0.0 
NMA – cis 1.370 127.14 5.27 -3.08 -4.32 2.3 2.2 
NMA – TSanti 1.455 112.20 122.64 60.75 -32.42 18.7 16.3 
NMA – Pl1 1.383 120.07 143.50 147.61 -2.18 7.7 7.4 
NMA – SPl1 1.377 120.33 149.57 184.80 16.59 2.4 1.3 
NMA – TSsyn 1.449 115.20 60.00 115.18 29.25 21.9 19.7 
NMA – Pl2 1.395 122.02 46.83 42.13 -0.92 12.9 12.7 
NMA – SPl2 1.386 122.77 44.43 -2.29 -23.68 4.8 3.6 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level.  
 
 
Figure 34. Plot showing the geometries and corresponding energy changes for both isomerization 
paths for NMA with change in ω dihedral. 
During the ϴ-phase, as a result of nitrogen inversion and hydrogen flip in path 1 (via TSanti), 
the ϴ dihedral shows a drastic change, from ~60º to ~180º, while ω changes only from 
~120º to ~150º. For path 2 (via TSsyn), the change in ω during nitrogen inversion is even 
smaller, from ~60º to ~45º, while ϴ changes from ~120º to ~0º. The geometries Pl1 and 
Pl2 are significantly more stable (by ~9 kcal/mol for path 1 and by ~7 kcal/mol for path 2) 
than the corresponding transition states due to partial restoration of overlap unlike the high-
energy saddle point of 2nd order TSpl (Figure 33). As the geometry approaches bifurcation 
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point geometries SPl1 and SPl2, it remains within 2-5 kcal/mol of the energy minimum 
geometry. 
From Figure 33, path 1 and path 2 geometries along the common path might appear to 
follow slightly different paths in terms of ω and ϴ. However, a closer look reveals that the 
geometries differ only in the orientation of one or both methyl groups attached to the amide 
moiety, with no real energy barrier for interconversion (Figure 35). In other words, the 
geometries along the common path are easily interconvertible between path 1 and path 2, 
essentially implying the common path.  
 
Figure 35. Path 1 and path 2 geometries of NMA along the common path show easily 
interconvertible geometries. 
8.5. Cis/trans isomerization in GGMe and applicability to peptidic systems 
As discussed in section 8.2.2, larger systems such as GGMe and other peptidic systems 
contain asymmetric rotatable bonds or substitutions, and corresponding energy landscapes 
of (much) greater dimensionality. Thus, transition state saddle points (such as TSsyn and 
TSanti with energy maxima along ω pertaining to cis/trans isomerization) occur multiply for 
the multiple geometries of the larger system. This greatly complicates the study of cis/trans 
isomerization paths. The energy surface with respect to ω and ϴ dihedrals differs for each 
rotamer and may involve coupled rotations of rotatable bonds. However, the rotamers may 
be classified according to the degree to which they interfere (couple) with the isomerization 
transition; coupling may arise from electronic influence on the peptide bond itself. As the 
simplest form of a dipeptide, GGMe introduces only rotamers with relatively weak 
coupling to ω rotation. Thus, cis/trans isomerization may be studied by considering 





Figure 36. (A) Four path-1 (left) and four path-2 (right) IRC geometries generated from TSanti and 
TSsyn rotamers of GGMe respectively are plotted in terms of ω and ϴ dihedrals. In order to facilitate 
the comparison, the grey-scale path-2 IRC geometries have been superimposed on coloured path-1 
IRC geometries, and vice versa. (B) All eight IRC paths are plotted in terms of ω, ϴ and τ dihedrals, 
showing change in planarity of nitrogen during isomerization with clear inversion of nitrogen in ϴ-
phases of both paths. (C) The plot shows relative energy change for all IRC paths along with change 







Because the IRC path generation method follows only the two decreasing energy paths 
from the transition state, and because rotamer interconversion would usually involve an 
additional energy barrier, IRC generation from a specific TS rotamer will lead to a specific 
pair of trans and cis rotamers. The process identifies the geometries and reaction paths for 
isomerization for each GGMe rotamer, and so describes TSsyn, TSanti, Pl1, Pl2 SPl1 and 
SPl2 for each specific rotamer. The set of isomerization paths thus generated represents a 
sampling of the full energy landscape with greatly simplified dimensionality, suitable for 
study of the range of variation created by the rotamer set. 
In this study, eight of the fourteen rotamers generated for TSanti and TSsyn (see Figure 36) 
were chosen for IRC analysis (four for each TS type). The analysis confirms that each 
transition state rotamer leads to a pair of trans and cis rotamers and path specific to the 
chosen TS rotamer. As illustrated in Figure 36, the overall geometry and corresponding 
energies of all rotamers differ significantly because of the conformational differences, but 
the IRC paths show very similar geometry changes within the amide moiety throughout the 
isomerization path. 
 
Figure 37. Two IRC paths connecting the same trans and cis rotamers of GGMe show both the IRC 
paths following the described isomerization scheme on peptidic systems.   
Significantly, as shown in Figure 37, it was also observed that for a corresponding TSsyn 
(or TSanti) rotamer pair, the IRC paths lead to identical pairs of trans and cis rotamers, 
replicating the full reaction path as seen for NMA. Thus, the GGMe set of IRC paths shows 
all the salient characteristics of the NMA path described above: a common path until a 
bifurcation point, splitting into ω- and ϴ- phases leading to transition states, continuation 
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to another bifurcation point of the opposite isomer via ϴ and ω phases on two separate 
paths, and completion of the isomerization via a common path. 
 
9. Cis/trans isomerization in substituted GGMe derivatives 
Based on the understanding of cis/trans isomerization in secondary amides in the previous chapter, 
this chapter now describes effects of substitution patterns on the energetics of minimum energy 
geometries as well as of cis/trans isomerization. 
After detailed study of isomerization paths and geometry changes in the previous chapter, 
it was evident that a small prototype such as NMA has limited applicability to represent 
larger systems, especially with respect to structural factors and energetics, owing to 
existence of multiple rotamers and asymmetry around the molecular backbone in larger 
systems. On the other hand, a peptidic prototype such as GGMe can suitably represent the 
isomerization and the complexities arising out of a bigger molecular backbone, and can be 
used as the primary scaffold to generate models structures with different substitution 
patterns in order to assess and compare the steric effect of the substitution patterns.  
As different side chains and substitutions have different extent of steric effect, the study of 
the role of steric effect becomes complex. Further, bigger and bulkier side chains and 
substitutions lead to more number of atoms and interactions with potentially more 
asymmetry and flexibility, and hence substantially higher CPU time for QM studies along 
with interference of other factors such as resonance and hydrogen bonding. Hence, such a 
study requires a representative substitution-group that can serve as a small and symmetrical 
yet bulky group, devoid of any resonance or hydrogen bonding effects. With the the A 
value > 4194,195 and ef value = 1.2
196,197, tert-butyl group can be as an ideal choice for the 
bulky substitution as it fits all these criteria. In synthetic chemistry, it is a common practice 
to use tert-butyl group as a bulky substitution to analyse the effect of steric bulk.198–200 
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9.1. Model structures   
 
Figure 38. Model structure and the substitution positions 
As shown in Figure 38, there are four available positions for substitutions. Among the four, 
two are alpha carbons of amino acids and are thus chiral centers. In line with natural amino 
acids, the default configuration of substitution at alpha carbons was kept as the S-
configuration. However, when both chiral centers had substitutions (i.e. neither R2 nor R3 
was hydrogen), the R2 configuration was kept constant (S), and both isomers with different 
configurations (R and S) of R3 were included. Hence, along with compounds with the 
natural S-configuration, two compounds with unnatural R-configuration at the alpha carbon 
were also included. R4 forms a distant moiety, which would not be a part of “conventional” 
dipeptide structure, and may not be expected to exert significant steric effect on the peptide 
structure, so only one variation of R4 was included. Thus, a total of 11 model structures 
with different substitution patterns of tert-butyl groups were generated as described in 
Table 21.  
Table 21. Model structures and their substitutions 
Compound R1 R2 R3 R4 
N0000 (GGMe) H H H Me 
N0001 H H H t-Bu 
N0010 H H S-t-Bu Me 
N0100 H S-t-Bu H Me 
N0110 H S-t-Bu S-t-Bu Me 
N0120 H S-t-Bu R-t-Bu Me 
N1000 t-Bu H H Me 
N1010 t-Bu H S-t-Bu Me 
N1100 t-Bu S-t-Bu H Me 
N1110 t-Bu S-t-Bu S-t-Bu Me 
N1120 t-Bu S-t-Bu R-t-Bu Me 
 
9.2. Comparison of trans isomers using additive principle 
In order to assess the magnitude of steric factors in terms of energy (stE), the energy values 
calculated based on additive principle194 for tert-butyl substituted structures (calE) were 




Figure 39. Using additive principle to assess the magnitude of steric bulk in terms of energy 
explained with examples of N0100 and N1110. 
Table 22. Calculation of tert-Bu additive energy in the gas phase 
Compound optE Attachment point tert-Bu additive energy kcal/mol (Etb) 
NH3 -35508.975 
sp3 nitrogen EtbN = -98709.131 
tert-Bu-NH2 -134218.106 
CH4 -25437.531 
sp3 carbon EtbC = -98712.134 
tert-Bu-CH3 -124149.665 
Table 23. Calculation of tert-Bu additive energy in the water phase 
Compound optE Attachment point tert-Bu additive energy kcal/mol (Etb) 
NH3 -35514.577 
sp3 nitrogen EtbN = -98707.646 
tert-Bu-NH2 -134222.223 
CH4 -25436.175 
sp3 carbon EtbC = -98711.962 
tert-Bu-CH3 -124148.137 
As explained in Figure 39A, the energy difference between methane and neopentane was 
taken to represent the additive energy value of tert-butyl substitution on an sp3-carbon 
(Etb
C) while the energy difference between ammonia and tert-butylamine was taken to 
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represent the additive energy value of tert-butyl substitution on pyramidal sp3-nitrogen of 
amino group (Etb
N). Both values were calculated for both gas and water phases (Table 22 
and Table 23). Then, as described in Figure 39B, energy value for optimized minimum 
energy geometry of N0000 (GGMe) i.e. optEN0000 was taken as the basis for the calculations 
of other compounds having tert-butyl substitutions on alpha carbon or amino nitrogen. For 
each compound, the additive energy value (calE) was determined by addition of 
corresponding additive energy values of tert-butyl group (Etb) – depending on the atom of 
attachment (carbon or nitrogen), number of tert-butyl groups and the phase (gas or water). 
The steric effect (stE) was calculated as the difference between  calE and the energy values 
for optimized minimum energy geometries of respective compounds (optE) in respective 
phase i.e. gas or water phases (Table 24 and Table 25). 





Bu- on sp3 
Nitrogen 
No. of t-






N0000t -333806.071   -333806.071 0 
N0010t -432516.46  1 -432518.205 1.745 
N0100t -432515.901  1 -432518.205 2.304 
N0110t -531225.709  2 -531230.339 4.63 
N0120t -531225.494  2 -531230.339 4.845 
N1000t -432514.375 1  -432515.202 0.827 
N1010t -531224.575 1 1 -531227.336 2.761 
N1100t -531222.518 1 1 -531227.336 4.818 
N1110t -629932.315 1 2 -629939.47 7.155 
N1120t -629931.92 1 2 -629939.47 7.55 

















N0000t -16.33 -381811.506   -381811.506 0 
N0010t -16.85 -480519.643  1 -480523.468 3.825 
N0100t -14.86 -480518.077  1 -480523.468 5.391 
N0110t -16.1 -579224.507  2 -579235.43 10.923 
N0120t -12.66 -579225.518  2 -579235.43 9.912 
N1000t -11.16 -480518.478 1  -480519.152 0.674 
N1010t -15.97 -579226.192 1 1 -579231.114 4.922 
N1100t -13.47 -579222.324 1 1 -579231.114 8.79 
N1110t -11.49 -677932.254 1 2 -677943.076 10.822 




Figure 40. Calculated steric effect for trans-isomers in gas phase and water phase using additive 
principle 
The trend, as shown in Figure 40, suggests that adding a bulky substitution to an alpha 
carbon results in a considerable steric effect. The bulky substitution on the N-terminal alpha 
carbon has slightly larger impact than that on the C-terminal alpha carbon. A bulky 
substitution on the N-terminal amino nitrogen also leads to a steric effect that is consistently 
present across corresponding pairs, becoming stronger with bulk on alpha carbons. This 
steric effect seen in terms of energies is also reflected in strained geometries, and is stronger 
when using the polarizable continuum model (the water phase).  
9.3. Comparison of cis isomers 
 Relative energy compared to minimum energy trans-geometry 
Table 26 and Table 27 describe the relative energies of minimum energy cis geometries in 
gas and water phases respectively, along with corresponding equilibrium constant 
estimates. Interestingly, the relative energy values of minimum energy geometries of most 
cis isomers (compared to minimum energy geometry of trans isomers) were found to be 
higher in the gas phase than in water phase (Figure 41). This may be attributed partially to 
the fact that the trans-isomers in water phase already have much higher energy than 
corresponding gas phase structures as revealed in steric factor calculations with additive 
principles for trans isomers. Further, the solvation energy values for most cis isomers are 
higher (i.e. more negative) than corresponding trans isomers by 2-3 kcal/mol. This 










N0000t N0010t N0100t N0110t N0120t N1000t N1010t N1100t N1110t N1120t
Calculated steric effect kcal/mol
Calculated steric effect Kcal/mol (Gas Phase) Calculated steric effect Kcal/mol (Water Phase)
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which may, in turn, be attributed to the higher dipole moment of cis isomers compared to 
trans isomers, as evident from Figure 42. 








N0000c 4.63 4.51 4.91E-04 
N0001c 4.31 4.24 7.83E-04 
N0010c 5.23 4.78 3.16E-04 
N0100c 5.12 4.76 3.22E-04 
N0110c 6.17 5.82 5.42E-05 
N0120c 4.96 4.76 3.22E-04 
N1000c 5.02 5.25 1.41E-04 
N1010c 5.67 5.78 5.84E-05 
N1100c 5.17 4.92 2.49E-04 
N1110c 7.52 7.62 2.61E-06 
N1120c 7.52 7.65 2.48E-06 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 
c Equilibrium constant estimated at 298.15 K based on ΔG.  











N0001c -18.53 1.881 1.98 3.54E-02 
N0000c -19.43 2.035 2.01 3.36E-02 
N0010c -17.85 2.967 2.73 9.96E-03 
N0100c -16.88 2.107 2.23 2.33E-02 
N0110c -15.67 1.385 1.66 6.08E-02 
N0120c -14.7 2.797 2.18 2.53E-02 
N1000c -19.86 2.788 2.57 1.30E-02 
N1010c -18.63 3.345 3.14 4.95E-03 
N1100c -14.35 3.919 3.69 1.96E-03 
N1110c -11.87 7.666 7.88 1.68E-06 
N1120c -11.76 4.86 4.94 2.39E-04 
a Water phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-
311G-3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 




Figure 41. Energies of minimum energy geometries of cis isomers relative to that of trans-isomers 
 
 
Figure 42. Comparison of dipole moment and solvation energy for trans and cis isomers 
 
 Steric factor effect calculation 
Table 28 and Table 29 describe the calculation of steric effect on cis-isomers based on the 
additive principle in gas and water phases respectively. The steric effect calculation based 
on the additive principle shows a trend similar to that for the trans-isomers (Figure 43) as 












N0000c N0001c N0010c N0100c N0110c N0120c N1000c N1010c N1100c N1110c N1120c
Energy relative to trans isomer kcal/mol






























































































































   
   





Dipole moment and solvation energy (kcal/mol)
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No. of t-Bu- on 
sp3 Nitrogen 






N0000c -333801.441   -333801.441 0 
N0010c -432511.233  1 -432513.575 2.342 
N0100c -432510.785  1 -432513.575 2.79 
N0110c -531219.543  2 -531225.709 6.166 
N0120c -531220.53  2 -531225.709 5.179 
N1000c -432509.352 1  -432510.572 1.22 
N1010c -531218.91 1 1 -531222.706 3.796 
N1100c -531217.348 1 1 -531222.706 5.358 
N1110c -629924.792 1 2 -629934.84 10.048 
N1120c -629924.4 1 2 -629934.84 10.44 




No. of t-Bu- on 
sp3 Nitrogen 






N0000c -333819.556   -333819.556 0 
N0010c -432526.761  1 -432531.518 4.757 
N0100c -432526.055  1 -432531.518 5.463 
N0110c -531233.207  2 -531243.48 10.273 
N0120c -531232.806  2 -531243.48 10.674 
N1000c -432525.775 1  -432527.202 1.427 
N1010c -531232.932 1 1 -531239.164 6.232 
N1100c -531228.49 1 1 -531239.164 10.674 
N1110c -629934.673 1 2 -629951.126 16.453 
N1120c -629934.711 1 2 -629951.126 16.415 
 







N0000c N0010c N0100c N0110c N0120c N1000c N1010c N1100c N1110c N1120c
Calculated steric effect kcal/mol
Calculated steric effect Kcal/mol (Gas Phase)
Calculated steric effect Kcal/mol (Water Phase)
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9.4. Energy barrier comparison 
The calculation of energy barriers for substituted derivatives of GGMe is a complex task. 
As we have seen in case of GGMe (chapter 8), the existence of multiple rotamers makes it 
difficult to identify every possible transition state. In case of GGMe, however, the lack of 
substitutions on α-carbons still simplifies the calculation significantly, as the isomerization 
study along the rotation coordinate ω between 180º and 0º suffices due to the symmetry. 
This becomes more complex with the introduction of substitutions and stereospecificity at 
α-carbons, which introduces asymmetry along the rotation coordinates, such as the ω-
dihedral, resulting in different energy barriers for rotation along the positive vs negative 
directions of rotation (see section 8.2.2), with simultaneous existence of multiple rotamers. 
Therefore, the number of possible transition states conformations increases enormously.  
In order to simplify this complex problem, it was necessary to use a specific method to 
enable comparison among same type of geometries for different compounds. Such a 
comparison can provide information about the overall effect of substitution patterns, if not 
for specific conformers. From the examples of NMA and GGMe, it became evident (see 
Table 17) that the energy barrier geometries obtained with step wise RCS provides a 
reasonably accurate estimation of transition states and corresponding energies. Therefore, 
we decided to find energy barrier geometries (EBGs) to estimate energy barrier values. For 
compounds without substitutions on α-carbon, the calculation in one direction (between 0º 
and 180º, or between 180º (= -180º) and 360º (= 0º) was sufficient. However, for other 
substituted compounds, calculation in both directions was carried out. Correspondingly, 
from trans isomers, syn EBGs were obtained close to ω = ±60º and from cis isomers, anti 
EBGs were obtained close to ω = ±120º.  
Table 30 and Table 31 describe energy barrier values corresponding to syn/anti EBGs in 
gas phase and water phase respectively. It is evident that the energy barrier value strongly 
depends on the direction of rotation for compounds with substitution on chiral α-carbons, 
and in such cases, the energy difference between same types of energy barrier geometries 





Table 30. Energy barrier values corresponding to syn and anti EBGs generated from optimized 
minimum energy trans and cis geometries, respectively, in the gas phase.  
Cpd 
Anti120GP Anti-120GP Syn60GP Syn-60GP 
ΔGeff 
Rate 
constant kc ΔEa ΔGb ΔEa ΔGb ΔEa ΔGb ΔEa ΔGb 
N0000 19.53 17.46 19.53 17.45 25.46 23.53 25.26 23.56 17.45 1.01E+00 
N0001 19.45 17.40 19.45 17.38   25.37 23.47 17.38 1.13E+00 
N0010 24.22 22.48 19.34 17.42 25.22 23.75 27.99 25.85 17.42 1.06E+00 
N0100 20.96 18.38 20.51 18.15 26.30 24.36 25.26 22.94 18.15 3.08E-01 
N0110 25.64 23.98 19.76 18.02 23.98 22.37 28.18 26.43 18.02 3.84E-01 
N0120 19.99 17.73 24.92 23.00 27.33 25.13 29.92 28.30 17.73 6.24E-01 
N1000 19.55 18.01 19.82 18.27   25.09 22.61 18.01 3.89E-01 
N1010 24.33 23.44 20.10 18.72 24.95 23.68 27.80 26.05 18.72 1.18E-01 
N1100 21.54 19.17 20.59 18.58 26.61 24.35 25.40 23.64 18.58 1.48E-01 
N1110 26.08 24.54 20.15 18.60 28.29 27.29 34.39 32.74 18.60 1.45E-01 
N1120 21.43 19.36 26.18 23.42 30.79 29.04 23.68 22.48 19.36 3.98E-02 
a Gas phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-311G-
3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 
c Reaction rate constant estimated with Eyring equation from ΔGeff .  
Table 31. Energy barrier values corresponding to syn and anti EBGs generated from optimized 
minimum energy trans and cis geometries, respectively, in the water phase 
Cpd 
Anti120WP Anti-120WP Syn60WP Syn-60WP 
ΔGeff 
Rate 
constant kc ΔEa ΔGb ΔEa ΔGb ΔEa ΔGb ΔEa ΔGb 
N0000 19.18 16.81 19.18 16.83 24.29 21.70   16.81 2.95E+00 
N0001 19.27 17.14 19.22 17.14   26.50 24.31 17.14 1.69E+00 
N0010 25.40 23.65 19.03 17.08 29.42 27.05 24.23 21.98 17.08 1.86E+00 
N0100 22.45 19.95 20.66 18.68 23.31 21.13 26.09 24.04 18.68 1.25E-01 
N0110 25.13 23.41 19.32 17.84 22.23 20.59 20.47 18.76 17.84 5.23E-01 
N0120 26.44 24.12 26.55 24.23 23.39 20.82 26.51 24.48 20.82 3.38E-03 
N1000 22.30 19.56 22.35 19.68   23.86 21.02 19.56 2.85E-02 
N1010 26.60 24.56 19.00 17.29 29.60 27.45 24.29 22.06 17.29 1.31E+00 
N1100 22.54 19.97 23.71 21.35 26.50 24.03 23.04 21.02 19.97 1.43E-02 
N1110 29.46 27.62 24.53 23.10 29.24 28.14 30.37 28.81 23.10 7.25E-05 
N1120 23.15 21.02 27.71 25.62 26.65 24.73 23.78 22.37 21.02 2.42E-03 
a Water phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-
311G-3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 
c Reaction rate constant estimated with Eyring equation from ΔGeff . 
However, considering the minimum value energy barrier as the “real” barrier, it appears 
that bulky substitution patterns only marginally affect the energy barrier values in gas 
phase, as the most substituted compounds N1110 and N1120 show an increase in the 
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energy barrier of just 2 kcal/mol compared to N0000 (GGMe). On the other hand, the effect 
of bulky substitution patterns becomes significant in the water phase, and can show an 
increase in energy barrier by up to 5 kcal/mol. Interestingly, a syn EBG was found to be 
more stable than both anti EBGs in case of compound N0120 in water phase.   
Overall, bulky substitutions affect cis/trans isomerization in two ways: by making the cis 
isomer more unstable and thereby shifting the equilibrium towards the trans isomer, and 
by increasing the reaction barrier height and thereby decreasing the reaction rate. As both 
effects discourage trans to cis isomerization, compounds with bulky substitutions are 
expected to take longer and/or require higher temperatures for the same. Moreover, as trans 
to cis isomerization is an essential step in cyclization of dipeptides to piperazine-2,5-
diones, it is certain that the slow isomerization would also result in decelerated dipeptide 
cyclization. 
10. Cyclization of dipeptide esters to piperazine-2,5-diones 
10.1. Water catalyzed cyclization mechanism 
When the amide bond of the dipeptide ester acquires a cis orientation, the nucleophilic 
nitrogen of the N-terminal amino group can come in proximity of the electrophilic carbonyl 
carbon of the C-terminal ester group. The reaction then occurs in two steps. In the first step, 
the nucleophilic amino group attacks the electrophilic carbonyl carbon of the ester group 
and generates an alcohol intermediate. In the second step, the alkoxy part of the ester group 
leaves as a corresponding alcohol. For synthesis of our biofocussed chemoprospecting 
library of piperazine-2,5-diones, the cyclization of dipeptide esters (see section 6.1.2) was 
carried out using water as a solvent, without any other reagent.  
As described by Xia et al.201, it is likely that water plays an important role as a catalyst in 
the cyclization, as explained in Scheme 16. Both steps of the reaction occur via two 
different six-membered transition states with direct involvement of a water molecule. In 
the first step, a water molecule accepts a hydrogen atom from amino nitrogen, and donates 
a hydrogen atom to the carbonyl oxygen, creating an alcohol intermediate. In the second 
step, a water molecule accepts a hydrogen atom from the carbonyl carbon and donates a 
hydrogen atom to the leaving alkoxy group to generate corresponding alcohol and product 
piperazine-2,5-dione. During the course of the reaction, the carbonyl carbon changes from 
sp2 to sp3 hybridized state, resulting in a tetrahedral geometry in the first step, and regains 
sp2 hybridized state in the second step. The authors observed that the first step is rate 
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determining, with its transition state (TS1) having the highest energy for the complete 
cyclization reaction. Further, the cyclization reaction up to TS1 is reversible, capable of 
regenerating the trans isomer of N-substituted dipeptide ester. However, once the reaction 
intermediate (INTMDT) is formed, its stabilization is achieved through removal of leaving 
group (alkoxy part of ester group) and formation of piperazine-2,5-diones via the second 
transition state (TS2). TS2 is more stable than TS1, and does not affect the reaction rate 
significantly. Therefore, for analysis of substitution effects on reaction, it is sufficient to 
perform theoretical studies on TS1 only.  
 
Scheme 16. Water catalyzed cyclization of a dipeptide ester to a piperazine-2,5-dione 
10.2. Model structures 
                       
Figure 44. Dipeptide ester and corresponding piperazine-2,5-dione scaffolds with corresponding 
substitution positions 
With intramolecular cyclization, the dipeptide ester scaffold cyclizes to piperazine-2,5-
dione scaffold (Figure 44). In order to study the cyclization reaction, the model structures 
used for trans-cis isomerization studies were used along with their analogues with tert-Bu 
groups as methyl group replacements. The pattern of substituents was also kept same. Thus, 
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a total of 19 model structures with different substitution patterns were generated, as 
described in Table 32. 





R1 R2 R3 
N0000 D000 H H H 
N0010 D001 H H S-t-Bu 
N0100 D010 H S-t-Bu H 
N0110 D011 H S-t-Bu S-t-Bu 
N0120 D012 H S-t-Bu R-t-Bu 
N1000 D100 t-Bu H H 
N1010 D101 t-Bu H S-t-Bu 
N1100 D110 t-Bu S-t-Bu H 
N0030 D003 H H S-Me 
N0300 D030 H S-Me H 
N0330 D033 H S-Me S-Me 
N0340 D034 H S-Me R-Me 
N3000 D300 Me H H 
N3030 D303 Me H S-Me 
N3300 D330 Me S-Me H 
N3330 D333 Me S-Me S-Me 
N3340 D334 Me S-Me R-Me 
N1110 D111 t-Bu S-t-Bu S-t-Bu 
N1120 D112 t-Bu S-t-Bu R-t-Bu 
 
As the reaction site of the rate-determining step (C-N bond formation) is “crowded” with 
local substitutions and a water molecule, we expected that methyl substitutions already 
should be sufficient to demonstrate the role of steric factor, requiring significantly less 
computational resources compared to tert-butyl group calculations. Therefore, while the 
geometries for trans, cis isomer, reaction intermediate and corresponding piprazine-2,5-
dione were optimized for all 19 model structures, the transition state search and reaction 
coordinate studies were performed mostly with model structures having methyl group 
substitutions, and only two model structures with tert-butyl substitutions were used. For 
the synthesized compounds, the steric bulk size of most of the amino acid side chains is 
intermediate, between the bulk of methyl and tert-butyl groups, hence the observations for 
model structures from this study can be correlated to synthesized compounds. As the 
reaction occurs in water phase, all the calculations were performed for water phase only.  
108 
 


























N0000 D000 2.03 1.98 15.90 41.10 11.70 15.02 -5.50 -15.09 
N0030 D003 2.03 1.44 17.15 37.42 11.58 15.61 -6.30 -16.06 
N0300 D030 2.84 2.61 17.73 43.84 12.67 17.04 -5.17 -14.90 
N0330 D033 3.59 3.34 18.94 44.49 12.14 16.47 -6.39 -16.06 
N0340 D034 3.68 3.46 17.48 43.74 13.70 17.85 -5.75 -15.51 
N0010 D001 2.97 2.73   16.19 20.63 -6.37 -15.74 
N0100 D010 2.11 2.23   12.19 16.66 -7.97 -17.00 
N0110 D011 1.39 1.66   16.54 21.29 -6.94 -16.03 
N0120 D012 2.80 2.18   18.89 22.57 -6.25 -16.04 
N3000 D300 2.67 2.10 18.29 43.31 13.42 17.15 -6.05 -16.08 
N3030 D303 3.13 2.90 17.93 43.56 13.80 17.82 -6.91 -17.30 
N3300 D330 3.38 2.79 19.56 44.63 15.42 19.23 -6.36 -16.65 
N3330 D333 4.17 3.72 
22.09 (S)  47.49 16.24 20.30 
-6.58 -16.87 
22.75 (R) 47.98 15.81 19.65 
N3340 D334 2.82 2.47 
20.88 (S) 46.33 15.80 19.85 
-6.97 -17.51 
22.95 (R) 43.06 17.20 21.22 
N1000 D100 2.79 2.57   26.06 29.67 1.69 -8.66 
N1010 D101 3.35 3.14   32.07 36.55 1.71 -8.62 
N1100 D110 3.92 3.69   30.35 34.31 4.07 -6.74 
N1110 D111 7.67 7.88 
52.84 (S) 79.54 42.28 47.23 
15.16 4.55 
48.14 (R) 74.54 43.67 49.14 
N1120 D112 4.86 4.94 
45.28 (S) 71.98 40.89 45.84 
10.62 0.41 
58.16 (R) 86.14 38.98 43.59 
a Water phase energy relative to the minimum energy trans geometry, calculated in kcal/mol at B3LYP/6-
311G-3DF-3PD++ level. 
b Relative free energy at 298.15 K relative to minimum energy trans geometry, calculated in kcal/mol at 
B3LYP/CC-PVTZ(-F)++ level. 
10.3. Cyclization energetics 
The relative energies of relevant geometries for water catalyzed cyclization are shown in 
Table 33. It is evident that even a small moiety such as the methyl group causes a significant 
steric effect, destabilizing the geometries, especially transition state TS1. This 
destabilization is observed to become stronger with increasing number of substitutions. 
From D000 (unsubstituted piperazine-2,5-dione) to D333 (all 3 methyl substitutions, with 
two S-methyl), the cis, TS1 and  intermediate (INTMDT) geometries are further 
destabilized, by 2, 6 and 5 kcal/mol respectively, discouraging the cyclization reaction at 
each transformation step. For the structure with triply substituted tert-butyl group, the TS1 
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energy barrier values were found to be unrealistically high, at more than 45 kcal/mol, 
demonstrating the extent of destabilization with bigger and bulkier substitutions.  
Overall, the theoretical studies clearly demonstrate the strong effect of steric factor for the 
cyclization reaction. These results were correlated with the experimental results obtained 
for DKP library synthesis.  
11. Rationalization of experimental results 
As described in section 6.1.2, the experimental results had shown a strong steric effect on 
two reaction parameters: yield and reaction time. The theoretical studies of both stages, 
cis/trans isomerization and cyclization to piperazine-2,5-dione also demonstrated that 
increasing bulk of substitution exerts steric effect in both reaction stages.    
Because the theoretical studies were carried out on model compounds, it was necessary to 
categorize the library synthesis reactions according to the most relevant model structures. 
The model compounds subjected to theoretical studies had two type of substitutions: 
methyl and tert-butyl, and most of the substitutions in the synthesized compounds are 
moderate in terms of bulk; often greater than methyl, but smaller than tert-butyl. Therefore, 
for the calculation, the categorization was done using following criteria. 
1) All compounds had substitution on one nitrogen. All substitutions on nitrogen were 
greater than methyl, but still not as bulky as tert-butyl, so only D3xx categories 
were considered. 
2) The compounds with at least one hydrogen substitution were categorized into 
relevant D3x0 or D30x categories depending on the other substitutions.  
3) The compounds with at least one methyl substitution were categorized into relevant 
D330 or D303 or D333, depending on the other substitutions.  
4) The compounds with all substitutions bigger than hydrogen or methyl were 
classified in a new category D333+, indicating that all substitutions are greater than 
methyl.  
Using this categorization protocol, library synthesis reactions were categorized in 5 





















Glycine Glycine 20 78 D300 
25 75 
 
Glycine Glycine 30 72 D300 
 
Glycine D-Tryptophan 30 65 D303 
30 61.6 
 
Glycine L-Tryptophan 30 61 D303 
 
Glycine L-Tyrosine 30 59 D303 
 


































L-Alanine 90 58 D333 
 
L-Alanine L-Tryptophan 180 47 D333 
 


















Table 35. Correlation of theoretcal energetics with reaction time and yield 
Title Title 















N3000 D300 2.669 18.294 13.418 -6.052 25 75 
N3030 D303 3.126 17.93 13.804 -6.909 30 61.6 
N3300 D330 3.383 19.564 15.424 -6.359 42 59.5 
N3330 D333 4.173 
22.09 (S) 16.245 
-6.579 130 53.6 
22.75 (R) 15.81 
 D333+     140 47.6 
N1110 D111 7.666 
52.84 (S) 42.281 
15.16   
48.14 (R) 43.67 
 
As shown in Table 35, the categorization of available library synthesis examples provided 
a clear trend of increasing substitution effect with more and bigger substitutions. It is 
evident that the substitution effect is reflected for both stages, cis/trans isomerization as 
well as cyclization, and it discourages the overall cyclization reaction in both stages. The 
high activation energies for each category also explains the need of carrying out the 
reaction at high temperature, and the increase in the required time. The decrease in the yield 
is secondary to the increase in the required time, and may be attributed to plausible side 
reactions such as hydrolysis and degradation of the ester with increase in time. Thus, the 
theoretical studies satisfactorily rationalize the strong substitution effects observed during 
synthesis of piperazine-2,5-dione library. From a larger perspective, such theoretical 























12. Biofocussed chemoprospecting: synergizing best 
approaches in early phase drug discovery 
As a part of this PhD research work, a “Biofocussed chemoprospecting” approach – a 
hybrid approach for design and synthesis of hit-finding libraries was developed. The 
essence of the approach is to use diverse, yet “bio-like” compounds for efficient hit-finding. 
Biofocussing enhances hit-rates; upfront chemical synthesis enables the choice of efficient 
protocols and diversification potential, and the screening approaches enable discovery of 
novel therapeutic targets and mechanisms. Integration of informatics and theoretical 
methods promise to aid the optimization of property profiles for chemical library design. 
Congruent to the research goals described in chapter 4, three diverse libraries based on 
biomolecules such as linear and cyclic dipeptides, and tartaric acid were designed. Virtual 
libraries corresponding to the scaffolds were generated, and their physicochemical 
properties and drug likeness were analysed computationally.  
This enabled property filtering and optimization of qualities such as diversity of 
physicochemical properties, drug likeness, ease of synthesis, low cost and “bio-likeness” 
for efficient selection of compounds. The compounds providing optimum diversity of 
scaffolds, substitutions and physicochemical properties were selected.  
Using conventional or novel protocols, easy and short synthetic routes for the library 
synthesis were designed, optimized, and the libraries were synthesized. 
The synthesized libraries were tested for various biological activities. Many of the 
synthesized compounds showed significant bioactivities on different targets based assays 
and cell based assays.   
The N-substituted dipeptide esters showed the most significant bioactivities, including loss 
of viability on cancer cell lines as well as activities on opioid and neurokinin receptors and 
other enzymes such as COX-1,2 and prolyl oligopeptidase. While a primary SAR has been 
generated for the loss of cancer cell-viability, the specific drug target and mechanism 
remain to be identified conclusively. The primary results from SILAC studies have 
provided a good starting point in this direction. Considering that the normal ratio between 
MIC (minimum inhibitory concentration) for cell-based assays and assays on isolated 
target (such as enzymes) usually varies from 100 to 1000 fold, a nanomolar level activity 
may be expected for the target corresponding to the viability loss. The library also provides 
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an opportunity to develop novel molecules with selective activity on other targets such as 
opioid and neurokinin receptors. The multiple optimization opportunities imply significant 
minimization of the investment-risk for commercial partners. Thus, the next logical step is 
to secure the IPRs with a high value patent. The university has claimed the rights and patent 
filing process is in progress, which is expected to be complete before thesis defense. 
The piperazine-2,5-diones have provided interesting hits for anti-cancer activity and 
BRSK1 enzyme inhibition. Though these hits could not be developed further within the 
constraints of this PhD research, they will be important starting points for future research. 
With smaller libraries and screening, the tartaric acid bisamides and related compounds are 
yet to show significant activities. However, the compounds will be tested on broader 
screening platforms to explore the potential bioactivities. 
In sharp contrast to conventional approaches, which use libraries comprising thousands of 
compounds synthesized at a very high cost, the libraries synthesized following the 
biofocussed chemprospecting approach provided hits from small libraries at cheap cost 
with hit-rates comparable to target-based approaches, with additional potential to identify 
novel drug targets and mechanisms.  
In addition, the theoretical QM studies on cis/trans isomerization and cyclization of 
secondary amides using density functional theory were carried out. These studies 
highlighted the geometry changes, including the pyramidalization and inversion of nitrogen 
in cis/trans isomerization, and rationalized the observed substituent effects in cyclization 
reaction. Such studies can be integrated into future efforts to include synthetic efficiency 
as a parameter of library design.  
The success of the approach can be attributed essentially to the efficient library design 
as an outcome of focus on bio-likeness and optimized diversity – the core ideas of the 
biofocussed chemoprospecting approach. 
13. Scientific impact and future directions 
Overall, this PhD research work has been highly interdisciplinary in nature giving diverse 
medicinal chemistry experience, from computer aided drug design (CADD) and 
cheminformatics to library design and synthesis to bioactivity assays to proteomics 
analysis, and has also included theoretical QM studies. This has generated multiple 
opportunities for research publications.  
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Two manuscripts have been published:  
1) The docking studies of known inhibitors of Rho kinase and PKA carried out as a 
part of this research (section 6.4.3) have already been published as a part of a 
publication.202 (See appendix, Paper 1) 
2) A publication describing the biofocussed chemoprospecting approach in detail with 
outline of bioactivities has been published recently.203 (See appendix, Paper 2) 
We expect to submit up to five more manuscripts for publication and potentially a patent 
from this PhD research work as following:  
Three manuscripts describing theoretical chemistry studies: 
1) Density Functional Studies on Cis/Trans Isomerization in Secondary Amides: 
Reaction Paths, Nitrogen Inversion and Relevance to Peptidic Systems (chapter 8) 
– Ready for submission. (See appendix, Paper 3) 
2) Impact of bulky substitutions on minimum energy geometries and cis/trans 
isomerization of secondary amides (chapter 9).  
3) Rationalization of strong steric effects observed in water catalyzed cyclization of 
dipeptide esters to piperazine-2,5-diones using density functional methods (chapter 
10 and 11). 
After a decision on patent filing for the N-substituted dipeptide ester series, the following 
two manuscripts can be submitted:  
1) Anticancer activity of N-substituted dipeptide esters  
2) Opioid and/or neurokinin receptor activity of N-substituted dipeptide esters (This 
will require a small study, which we hope to complete before thesis defense) 
The research carried out on tartaric acid bisamides and related compounds has also created 
opportunities for two publications, although these require more work before submission: 
1) One-pot synthesis of tartaric acid bisamides  
2) One-pot synthesis of 2o-monoamides of tartaric acid and cyclic tartrimides, 
along with their hydrolysis products.  
A good indicator of a successful research is how it inspires further research. We hope that 
it is evident that this PhD thesis has generated wide range of opportunities for further 

















14. Computational chemistry 
14.1. Computational chemistry – General information 
The structure of compounds were generated using MarvinSketch module of JChem suite 
(ChemAxon, Budapest, Hungary), ChemSketch software (ACD labs, Toronto, Ontario, 
Canada) or ChemDraw module of ChemBioOffice (Perkin Elmer, Massachusetts, USA). 
The virtual combinatorial libraries were generated using Markush enumerator plugin of 
JChem suite. Docking and related studies such as protein preparation, ligand preparation, 
homology modelling were performed in Maestro module204 of Schrödinger software suite 
(Schrödinger, LLC. New York City, USA) using default settings unless specified otherwise. 
Cheminformatic analysis was carried out using Canvas module of Schrödinger software 
suite and DataWarrior software (developed by Actelion Pharmaceuticals Ltd, Allschwil, 
Switzerland). Theoretical QM studies were carried out using Jaguar program in Maestro 
module of Schrodinger suite on Stallo supercomputer using default settings unless 
specified otherwise. 
14.2. Chemoinformatics analysis of libraries 
Virtual libraries for both series were generated using the JChem software suite. 
Chemoinformatics analysis of virtual libraries and synthesized compounds was carried out. 
Properties such as molecular weight, AlogP, hydrogen bond donor and acceptors, number 
of rotatable bonds, polar surface area, toxicity were calculated using the Canvas module of 
Schrodinger Suite, and their distribution was analysed. Drug likeness and clogP were 
estimated with Datawarrior software. 
14.3. Cost calculation 
As a standard, the necessary amount of starting materials to carry out reaction at 1 mmol 
scale was calculated considering the mole equivalents. The estimated costs include only 
the cost of aldehyde, amino acid and amino acid esters. Based on the amount, the prices for 
each starting material were generated as per commercial catalogues of Sigma-Aldrich (St. 
Louis, MO, USA) and other suppliers (if not available from Sigma-Aldrich). From the cost 
of each starting material, the costs for all compounds from both virtual libraries were 
estimated. The costs of isolation, purification or characterization costs were not included 
because such calculations would be unpredictable and can show huge variation from one 
reaction to another. 
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4-pyridaldehyde 745 100 107 934.58 667.56 1.12 
3-pyridaldehyde 417 100 107 934.58 667.56 0.62 
2-pyridaldehyde 160 25 107 233.64 166.89 0.96 
4-hydroxybenzaldehyde 318 50 122 409.84 292.74 1.09 
3-hydroxybenzaldehyde 309 100 122 819.67 585.48 0.53 
2-hydroxybenzaldehyde 209 100 122 819.67 585.48 0.36 
Thiophene-2-carboxaldehyde 103 25 112 223.21 159.44 0.65 
Thiophene-3-carboxaldehyde 1090 10 112 89.29 63.78 17.09 
Furan-2-carboxaldehyde 235 116a 96 1208.33 863.10 0.27 
Furan-3-carboxaldehyde 485 5 96 52.08 37.20 13.04 
Imidazole-4-carboxaldehyde 724 5 96 52.08 37.20 19.46 
4-(1-imidazolyl)-
benzaldehyde 
1291 5 172 29.07 20.76 62.17 
N-methyl-Imidazole-2-
carboxaldehyde 
351 1 110 9.09 6.49 54.05 
N-methyl-Imidazole-5-
carboxaldehyde 
1137 1 110 9.09 6.49 175.10 
4-anisaldehyde 464 100 136 735.29 525.21 0.88 
3-anisaldehyde 136 25 136 183.82 131.30 1.04 
2-anisaldehyde 391 100 136 735.29 525.21 0.74 
4-(N,N-
dimethylamino)benzaldehyde 
269 100 149 671.14 479.39 0.56 
Quinoline-3-carboxaldehyde 3279 5 157 31.85 22.75 144.14 
Isoquinoline-5-
carboxaldehyde 
937 1 157 6.37 4.55 205.95 
Indole-3-carboxaldehyde 741 25 145 172.41 123.15 6.02 
Indole-5-carboxaldehyde 1165 5 145 34.48 24.63 47.30 
aPrice for 100 mL quantity, density = 1.16, therefore 116 g. 







NOK per 1 mmol 
reaction 
Glycine 268 100 75 1333.33 0.20 
L-Alanine 642 100 89 1123.60 0.57 
L-Serine 892 100 105 952.38 0.94 
L-valine 293 25 117 213.68 1.37 
L-leucine 170 25 131 190.84 0.89 
L-isoleucine 250 10 131 76.34 3.28 
L-tyrosine 471 100 181 552.49 0.85 
L-phenylalanine 800 100 165 606.06 1.32 
L-cysteine 501 100 121 826.45 0.61 
L-threonine 464 25 119 210.08 2.21 
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L-methionine 583 100 149 671.14 0.87 
L-tryptophan 348 25 204 122.55 2.84 
L-histidine 319 25 155 161.29 1.98 
L-asparagine 218 25 132 189.39 1.15 
L-glutamine 624 100 146 684.93 0.91 
L-aspartic acid 176 100 133 751.88 0.23 
L-glutamic acid 204 100 147 680.27 0.30 
L-arginine 595 1000 174 5747.13 0.10 
L-lysine 370 25 146 171.23 2.16 
D-Alanine 1275 25 89 280.90 4.54 
D-Serine 659 25 105 238.10 2.77 
D-valine 355 5 117 42.74 8.31 
D-leucine 986 10 131 76.34 12.92 
D-isoleucine 6910 1 131 7.63 905.21 
D-tyrosine 952 5 181 27.62 34.46 
D-phenylalanine 350 5 165 30.30 11.55 
D-cysteine 2779 1 121 8.26 336.26 
D-threonine 468 5 119 42.02 11.14 
D-methionine 380 5 149 33.56 11.32 
D-tryptophan 370 5 204 24.51 15.10 
D-histidine 1266 5 155 32.26 39.25 
D-asparagine 
monohydrate 
1152 25 150 166.67 6.91 
D-glutamine 662 1 146 6.85 96.65 
D-aspartic acid 712 25 133 187.97 3.79 
D-glutamic acid 510 5 147 34.01 14.99 
D-arginine 737 1 174 5.75 128.24 
D-lysine 871 1 146 6.85 127.17 
 
 Cost calculations for amino acid esters 












Glycine methyl ester HCl 256 100 125.5 796.81 0.32  
L-Alanine methyl ester HCl 1024 25 139.5 179.21 5.71  
L-Serine methyl ester HCl 358 5 155.5 32.15 11.13  
L-valine methyl ester HCl 476 10 167.6 59.67 7.98  
L-leucine methyl ester HCl 444 25 181.6 137.67 3.23  
L-isoleucine methyl ester HCl 522 5 181.6 27.53 18.96  
L-tyrosine methyl ester HCl 430 25 231.6 107.94 3.98  
L-phenylalanine ethyl ester HCl 452 10 229.7 43.54 10.38  
L-cysteine ethyl ester HCl 473 25 185.6 134.70 3.51  
L-threonine methyl ester HCl 3196 5 169.6 29.48 108.41  
L-methionine methyl ester HCl 952 25 199.7 125.19 7.60  
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L-tryptophan methyl ester HCl 546 5 254.7 19.63 27.81  
L-histidine methyl ester diHCl 850 25 242 103.31 8.23  
L-asparagine tert-butyl ester HCl 1105 1 224.7 4.45 248.29  
L-glutamine methyl ester HCl 403 0.25 196.6 1.27 316.92  
L-aspartic acid dimethyl ester HCl 719 5 197.6 25.30 28.41  
L-glutamic acid dimethyl ester HCl 544 10 211.6 47.26 11.51  
L-arginine methyl ester diHCl 413 5 261 19.16 21.56  
L-lysine methyl ester diHCl 846 25 247 101.21 8.36  
D-Alanine methyl ester HCl 484 5 139.5 35.84 13.50  
D-Serine methyl ester HCl 451 5 155.5 32.15 14.03  
D-valine methyl ester HCl 793 5 167.6 29.83 26.58  
D-leucine methyl ester HCl 676 5 181.7 27.52 24.57 Chemimpex 
D-isoleucine methyl ester HCl 1885 1 145 6.90 273.33 SCBT 
D-tyrosine methyl ester HCl 177 5 231.7 21.58 8.20 Chemimpex 
D-phenylalanine methyl ester HCl 543 5 215.7 23.18 23.43  
D-cysteine methyl ester HCl 420 1 171.6 5.83 72.07 TCI 
D-threonine methyl ester HCl 814 5 169.6 29.48 27.61 Chemimpex 
D-methionine methyl ester HCl 308 5 199.7 25.04 12.30 Chemimpex 
D-tryptophan methyl ester HCl 1134 5 254.7 19.63 57.77  
D-histidine methyl ester diHCl 386 1 242 4.13 93.41 TCI 
D-asparagine methyl ester HCl 3565 5 182.6 27.38 130.19 Oakwood 
D-glutamine methyl ester HCl 591 1 196.6 5.09 116.19 Fluorochem 
D-aspartic acid dimethyl ester HCl 686 5 197.6 25.30 27.11 Chemimpex 
D-glutamic acid dimethyl ester HCl 257 5 211.6 23.63 10.88 Chemimpex 
D-arginine methyl ester diHCl 480 1 261 3.83 125.28 TCI 
D-lysine methyl ester diHCl 865 5 233 21.46 40.31  
 
14.4. General docking protocols 
 Protein preparation and grid generation 
The crystal structures were downloaded from the PDB. Using the protein preparation 
wizard, the target structures were first preprocessed, missing side chains were added if 
required, water molecules were removed unless they were important as H-bond bridges 
between two or more side chains. Het-states were generated with the S2 state chosen by 
default. H-bonds were optimized, followed by restrained minimization. Receptor grids 
were usually generated with such minimized protein structures unless mentioned 
specifically for unminimized ones. The active site was identified with the native ligand 
molecules. In absence of native ligand, the key active site residues such as residues from 
hinge and DFG loop for kinases were specified. During docking, all rotatable groups were 
allowed to rotate. 
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 Receptor grid generation for homology models 
The model structure (from which the homology model was to be created) was downloaded 
from PDB after identification from a blast homology search using the target sequence. The 
incompatible residues were noted and the model was built using “knowledge based model 
building”. After the model was created, the proper loops were subjected to loop refinement. 
The homology model thus generated was then subjected to H-bond optimization and 
restrained minimization. Unless specified otherwise, the receptor grid was generated for 
model structures after minimization. As the homology models are devoid of any native 
ligand, the active site was specified with key amino acid residues of active sites such as 
Val123, Asp184 in PKA and its analogues in other kinases. During docking, all rotatable 
groups were allowed to rotate. 
 Docking procedure 
Native ligands from crystal structures were usually extracted from respective crystal 
structures and were subjected to LigPrep application along with virtual library of 
compounds to generate rotamers and charge variants. The docking was carried out without 
any constraints. For small scale docking studies (ligands < 1000), a virtual screening 
workflow was used with specifying all receptor grids on which the docking was to be 
performed. All poses were kept after docking using “high throughput virtual screening” 
(HTVS) mode and “standard precision” (SP) mode sequentially. The poses were finally 
subjected to “extra precision” (XP) mode and the best pose was kept for each ligand 
structure. For large scale docking studies (ligands > 1000), each docking step on each 
receptor grid was carried out separately and only one pose for each ligand was kept after 
HTVS, SP and XP modes each.   
14.5. QM studies 
 Generation of structures 
The structures were initially generated as 2D structures with trans orientations using 
MarvinSketch program, ChemAxon and were imported to the Maestro module of 
Schrodinger suite from which all further studies were performed. The cis geometries were 
generated by manual adjustment of ω dihedral.  
 Conformational search 
Initial conformers sets for all geometries were generated with the MacroModel205 
conformational search algorithm using MMFFs force-field.  
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 Geometric optimization 
This and all further studies were performed using Jaguar206,207 program. The 
conformational search conformers were subjected to geometric optimization at B3LYP/6-
31G**++ level with maximum grid density and “accurate” accuracy level of SCF. 
Frequency analyses were carried out to confirm convergence to optimized minimum 
energy geometries with no imaginary frequencies. For NMA, “tight” convergence criteria 
were required to locate the optimized geometry. For all structures, only the minimum 
energy conformers were used for further studies.  
 Relaxed coordinate scan (RCS) 
The optimized cis and trans geometries of NMA and N-substituted dipeptide esters were 
subjected to relaxed coordinate scan (RCS) on ω dihedral coordinate at at B3LYP/6-
31G**++ level with maximum grid density and “accurate” accuracy level of SCF. The 
optimized geometry at each step was used to generate the starting geometry for the next 
step. Each RCS was performed in three rounds, with 15º, 2º and 0.125º for rounds 
progressively closer to the rotation barrier. The energy barrier geometries (EBGs) were 
identified and used as plausible transition state geometries (TSGs) for subsequent transition 
state searches.  
 Transition state search 
Transition state search was carried out using Quadratic Synchronous Transit (QST) 
method208 along reactant-product path at B3LYP/6-31G**++ level with maximum grid 
density and “accurate” accuracy level of SCF. For transition state search for cis-trans 
isomerization, EBGs obtained from RCS were used as the plausible transition state input, 
while optimized trans and cis geometries were used as reactants and products respectively. 
For transition state search for cyclization reaction, plausible transition state geometries 
were manually generated from minimum energy conformers of corresponding 
intermediates. Frequency analyses were carried out to confirm convergence to a single 
imaginary frequency (corresponding to the vibration connecting reactant and product 
geometries) for optimized TSGs. From the syn and anti TSGs of GGMe, 12 more transition 
state rotamers (six of each type) were created by manual torsional adjustment of rotatable 
bonds, and were used for QST transition state search to locate other transition state 
rotamers. Thus, total 14 transition state rotamers of GGMe were generated. For cyclization 
reaction, both stereoisomers (S and R) at ester carbonyl carbon of TS1 and intermediate 
were generated for triply substituted compounds (D111, D112, D333, D334). 
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 Intrinsic reaction coordinates (IRC) 
The reaction paths linking the reactant and product geometries via TSGs were established 
with mass weighted intrinsic reaction coordinate analysis209 in both forward and reverse 
directions at B3LYP/6-31G**++ level with maximum grid density and “accurate” 
accuracy level of SCF. The step-size were varied from 0.1 to 2.0. Initially each IRC study 
was carried out to generate 20 IRC points in both directions, then, if necessary, further 
downhill IRC study were continued till clear IRC paths were established. 
 Single point energy calculations 
Accurate single point energies were calculated for all optimized geometries, energy barrier 
geometries and transition state geometries at the B3LYP/6-311G-3DF-3PD++ level with 
maximum grid density and “accurate” accuracy level of SCF. Vibrational analyses were 
carried out at the B3LYP/CC-PVTZ(-F)++ level and the free energy values obtained for 
298.15 K were used to calculate free energy changes. 
 NMA contour generation 
The coordinate scan geometries of NMA for the creation of contour were generated using 
MMFFs force-field along ω dihedral values between 0º - 180º and ϴ dihedral values 
between (-10)º to 190º with 2º increments. Once the geometries were generated, their single 
point energies were calculated at the B3LYP/6-31G**++ level. 
15. Synthetic chemistry – General 
Unless mentioned specifically, all reagents and solvents were purchased and used as 
received without further purification. The reactions were monitored by thin-layer 
chromatography (TLC) analysis on precoated Merck® silica gel 60 F254 TLC aluminum 
sheets and/or mass spectrometry. The spots on TLC were visualized by exposure to 
ultraviolet (UV) light (254 nm), or by staining with iodinated silica gel powder, or 5% 
ninhydrin solution in ethanol followed by heating. Column chromatography was carried 
out using silica gel 60 (230-400 mesh), while preparative thin layer chromatography 
(PTLC) was performed on precoated Merck® silica gel 60 F254 TLC aluminum sheets. For 
TLC as well as column chromatography, 0-100 % of ethylacetate in pentane or 0-15 % of 
methanol in DCM were used as common mobile phase to elute compounds in increasing 
order of polarity. NMR spectra were recorded at 400 MHz (1H NMR) and at 100 MHz (13C 
NMR) using Varian spectrometer. The chemical shifts are expressed in ppm relative to 
TMS or to the literature value of the residual solvent peak. The high resolution mass 
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spectrometric analysis (HRMS) were carried out on an LTQ Orbitrap XL (Thermo 
Scientific, Bremen, Germany) using positive mode ESI. The IR spectra were taken using 
Varian 7000e FT-IR spectrometer. Microwave assisted reactions were carried out using 
Biotage® Initiator 300 W instrument, keeping fixed hold time ON.  
15.1. General procedure for synthesis of N-substituted amino acids (Series A) 
Representative protocol for A1: Reaction of pyridine-3-carboxaldehyde with glycine 
Pyridine-3-carboxaldehyde (1.498 g, 14 mmol, 1.4 equiv.) was added to a stirred solution 
of glycine (750 mg, 10 mmol, 1 equiv.) in methanol (20 mL), neutralized with finely 
powdered NaOH (420 mg, 10.5 mmol, 1.05 equiv.). After imine formation for 30 min at 
room temperature, the solution was cooled on an ice-bath and NaBH4 pellets (494 mg, 13 
mmol, 1.3 equiv.) were added. The reaction mixture was stirred under inert N2 atmosphere 
for 2 hours at 0 oC followed by acidification with 37 % aq. HCl up to pH = 5.97 i.e. 
isoelectric point of glycine. The solvent was then distilled off at reduced pressure. The solid 
mixture was triturated with acetone and filtered. The residue after filtration was dried in air 
only for 2 min after it was found to be extremely hygroscopic. Hence, the residue (with 
some acetone) giving 4.78 g crude product. The attempts to remove salts with water-wash 
resulted in considerable loss of product, hence the product was used in next step without 
further purification. 
15.2. General procedure for synthesis of N-substituted dipeptides (Series B) 
Representative protocol for B1: Coupling of A1 with glycine methyl ester 
hydrochloride 
A1 (478 mg crude product, 1 mmol, 1 equiv.) was mixed in acetonitrile (3 mL) into which, 
triethylamine (484.8 mg, 4.8 mmol, 4.8 equiv.) and HBTU (455 mg, 1.2 mmol, 1.2 equiv.) 
were slowly added sequentially. After 10 min stirring at room temperature, glycine methyl 
ester hydrochloride (125.5 mg, 1 mmol, 1 equiv.) was added. The reaction mixture was 
stirred for about 20 min at room temperature and was monitored on TLC. After completion, 
the solvent was evaporated under reduced pressure. The crude reaction mixture was 
purified using column chromatography with silica gel as stationary phase and 0-3 % 
methanol in DCM as mobile phase to yield 157 mg desired product and 27.2 mg of the 
cyclic dimer (symmetrical DKP) side product. The product was further purified on 
preparative TLC using 10 % methanol in DCM as the mobile phase.  
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15.3. General procedure for synthesis of cyclic dimers (Series C) 
Representative protocol for C2: Dimerization of A2 
A2 (141 mg crude product, 0.5 mmol, 1 equiv.) was mixed in acetonitrile (2 mL) into 
which, triethylamine (242 mg, 2.4 mmol, 4.8 equiv.) and HBTU (228 mg, 0.6 mmol, 1.2 
equiv.) were slowly added sequentially. The reaction mixture was stirred for 24 hours at 
room temperature and was monitored on TLC. After completion, the solvent was 
evaporated under reduced pressure. The crude reaction mixture was purified using column 
chromatography with silica gel as stationary phase and 0-2 % methanol in DCM as mobile 
phase to yield 27.8 mg of the cyclic dimer (cyclic dimer) product D2. The product was 
further purified on preparative TLC using 8 % methanol in DCM as the mobile phase. 
15.4. General procedure for microwave assisted cyclization (Series D) 
Representative protocol for D1: Microwave assisted cyclization of B1 
52 mg of B1 was mixed in 3 mL of water in a 2-5 mL microwave vial. The mixture was 
heated under microwave irradiation with 300 W power for 20 minutes at 200 oC and 20 
atm pressure. After completion, the solvent was evaporated to dryness under reduced 
pressure and the crude mixture was subjected to column chromatography with silica gel as 
the stationary phase and 0-4 % methanol in DCM as the mobile phase to yield 35 mg of 
desired compound. On a small scale, the product was further purified using 10 % methanol 
in DCM as the mobile phase. 
15.5. General procedure for synthesis of tartaric acid anhydrides (E) 
Representative protocol for E1: Synthesis of (3R,4R)-2,5-dioxotetrahydrofuran-3,4-
diyl diacetate 
A solution of 100 µL conc. sulphuric acid in acetic anhydride (9.29 mL, 98.4 mmol, 4.92 
equiv.) was added to a 50 mL single neck RBF containing L-(+)-tartaric acid (3.0 g, 20 
mmol, 1.0 equiv.) at room temperature and was stirred until dissolved. The mixture was 
then heated at 135-137 oC under reflux for 10 min. The reaction mixture showed change in 
colour to light orange-brown. After 10 min, the reaction mixture was poured into a dry 
beaker cooled under ice-bath and the product was allowed to crystallize for 1 hour. The 
crystallized product was filtered, washed with benzene (20 mL) and cold diethylether (20 
mL) and then was dried in vacuum to afford 3.02 g product. 
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15.6. General procedure for synthesis of tartaric acid monoamides (F) 
Representative protocol for F1: Synthesis of (2R,3R)-2,3-diacetoxy-4-oxo-4-(pyridin-
3-ylamino)butanoic acid 
3-aminopyridine (564 mg, 6.0 mmol, 1.0 equiv.) was added portion-wise to a solution of 
A1 (1.36 g, 6.3 mmol, 1.05 equiv.) in 10 mL DCM at room temperature. The reaction 
mixture was stirred for 2 hours and monitored on TLC. On completion, the solvent was 
evaporated under reduced pressure and the crude mixture was washed 3 times with 10 mL 
ether each, followed by drying under vacuum to provide 2.037 g crude product, which was 
used for further reactions. 
15.7. General procedure for synthesis of tartaric acid bisamides (G) 
Representative protocol for G1: Synthesis of (2R,3R)-2,3-dihydroxy-4-morpholino-4-
oxo-N-(pyridin-3-yl)butanamide 
Under inert argon atmosphere, the solution of F1 (303 mg, 1 mmol, 1 equiv.) in thionyl 
chloride (2 mL) was stirred in a 10 mL RBF for 30 min at room temperature. The solvent 
was then evaporated under argon flow up to dryness. Then to the RBF, dry THF was added 
keeping the inert atmosphere intact and stirred for 5 min. Then, 3-aminopyridine (94 mg, 
1 mmol, 1 equiv.) was added to the mixture under argon bed. The reaction mixture was 
again stirred for 30 min at room temperature and monitored on TLC. On completion, the 
solvent was evaporated again to dryness under argon flow. Then 28 % aq. ammonium 
hydroxide solution (2 mL) was added and reaction mixture was again stirred for 2 hours at 
room temperature and monitored on TLC. After completion, the solvent was evaporated 
under reduced pressure up to dryness. The crude product was then purified with column 
chromatography using silica gel 60 (230-400 mesh) as the stationary phase and 0-4 % 
methanol in DCM as the mobile phase, to give 79 mg of product.  
15.8. General procedure for synthesis of tartrimides (H) 
Representative protocol for H1: Synthesis of (3R,4R)-2,5-dioxo-1-(pyridin-4-
ylmethyl)pyrrolidine-3,4-diyl diacetate 
In a 10 mL RBF, 5 mL thionyl chloride was mixed with F5 (65 mg, 0.2 mmol, 1 equiv.) 
under inert argon atmosphere. Keeping the inert atmosphere intact, the mixture was heated 
at 80 oC reflux for 20 min. After 20 min, the reaction mixture was slowly poured in a beaker 
containing 50 mL pentane cooled with ice-bath and allowed to precipitate for 1 hour. After 
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1 hour, the precipitates were filtered and were washed 3 times with pentane (10 mL each), 
followed by drying under air to afford 42.3 mg product. 
15.9. Spectral data report 
 Series A: N-substituted amino acids 
A1: (Pyridin-3-ylmethyl)glycine 
1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 8.44 (d, J = 4.9 Hz, 1H), 7.88 (d, J = 7.8 
Hz, 1H), 7.42 (dd, J = 7.9, 5.0 Hz, 1H), 3.82 (s, 2H), 3.18 (s, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 175.16, 149.75, 148.15, 137.12, 136.01, 123.75, 54.16, 
51.10. 
A2: (Pyridin-3-ylmethyl)-L-alanine 
1H NMR (400 MHz, Methanol-d4) δ 8.71 (d, J = 2.3 Hz, 1H), 8.60 (dd, J = 4.9, 1.6 Hz, 
1H), 8.04 (dt, J = 7.9, 2.1 Hz, 1H), 7.53 (dd, J = 7.9, 4.9 Hz, 1H), 4.31 (d, J = 13.1 Hz, 
1H), 4.23 (d, J = 13.1 Hz, 1H), 3.63 (q, J = 7.1 Hz, 1H), 1.54 (d, J = 7.1 Hz, 4H). 
13C NMR (100 MHz, Methanol-d4) δ 172.86, 150.16, 149.53, 138.51, 128.72, 124.11, 
104.99, 57.90, 15.06. 
A3: (Pyridin-3-ylmethyl)-L-phenylalanine – HCl salt 
1H NMR (400 MHz, D2O) δ 8.77 (d, J = 2.1 Hz, 1H), 8.75 (dt, J = 5.9, 1.2 Hz, 1H), 8.57 
(dq, J = 8.3, 1.5 Hz, 1H), 8.01 (dd, J = 8.2, 5.9 Hz, 1H), 7.32 – 7.21 (m, 3H), 7.21 – 7.15 
(m, 2H), 4.40 (s, 2H), 4.05 (dd, J = 7.2, 6.1 Hz, 1H), 3.25 – 3.11 (m, 2H). 
13C NMR (100 MHz, D2O) δ 171.55, 148.53, 142.64, 142.35, 134.22, 130.96, 129.37, 
129.10, 127.88, 127.78, 63.09, 46.60, 35.61. 
A5: (Pyridin-4-ylmethyl)-L-phenylalanine – HCl salt 
1H NMR (400 MHz, D2O) δ 8.79 – 8.72 (m, 2H), 8.01 (dt, J = 5.8, 0.8 Hz, 2H), 7.33 – 7.26 
(m, 3H), 7.24 (dd, J = 7.8, 1.8 Hz, 2H), 4.53 (s, 2H), 4.37 – 4.26 (m, 1H), 3.39 – 3.22 (m, 
2H). 
13C NMR (100 MHz, D2O) δ 170.43, 150.92, 141.86, 133.64, 129.38, 129.20, 128.09, 




1H NMR (400 MHz, DMSO-d6) δ 8.45 (dt, J = 4.9, 1.3 Hz, 1H), 7.68 (td, J = 7.7, 1.8 Hz, 
1H), 7.27 – 7.18 (m, 7H), 3.89 (d, J = 14.7 Hz, 1H), 3.77 (d, J = 14.6 Hz, 1H), 3.44 (dd, J 
= 7.3, 6.0 Hz, 1H), 3.01 (dd, J = 13.8, 6.0 Hz, 1H), 2.90 (dd, J = 13.7, 7.3 Hz, 1H). 
13C NMR (100 MHz, DMSO-d6) δ 174.55, 159.47, 149.07, 138.74, 136.80, 129.64, 128.42, 
126.54, 122.37, 122.25, 62.65, 52.86, 38.79. 
A7: (Thiophen-2-ylmethyl)-L-phenylalanine 
1H NMR (400 MHz, DMSO-d6) δ 7.35 (dd, J = 5.1, 1.3 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.21 
– 7.17 (m, 3H), 6.91 (dd, J = 5.1, 3.4 Hz, 1H), 6.88 (d, J = 3.4 Hz, 1H), 3.95 (d, J = 14.2 
Hz, 1H), 3.78 (d, J = 14.2 Hz, 1H), 3.38 (t, J = 6.7 Hz, 1H), 2.87 (qd, J = 13.6, 6.7 Hz, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 174.83, 143.76, 138.47, 129.72, 128.46, 127.01, 126.66, 
125.53, 125.41, 61.64, 46.06, 38.75. 
A8: (Furan-2-ylmethyl)-L-phenylalanine 
1H NMR (400 MHz, DMSO-d6) δ 7.56 – 7.49 (m, 1H), 7.20 (ddt, J = 15.2, 12.3, 7.3 Hz, 
7H), 6.37 – 6.31 (m, 1H), 6.16 (d, J = 3.2 Hz, 1H), 3.75 (d, J = 14.6 Hz, 1H), 3.63 (d, J = 
14.3 Hz, 1H), 3.38 (t, J = 6.6 Hz, 1H), 2.91 (dd, J = 13.7, 6.2 Hz, 1H), 2.84 (dd, J = 13.7, 
7.0 Hz, 1H). 
13C NMR (100 MHz, DMSO-d6) δ 174.70, 153.96, 142.26, 138.66, 129.60, 128.40, 126.53, 
110.64, 107.27, 61.95, 44.26, 38.84. 
A10: (3-Hydroxybenzyl)-L-phenylalanine  
1H NMR (400 MHz, DMSO-d6) δ 7.27 – 7.20 (m, 4H), 7.20 – 7.14 (m, 1H), 7.04 (t, J = 7.7 
Hz, 1H), 6.72 (t, J = 2.1 Hz, 1H), 6.66 (dd, J = 8.1, 2.7 Hz, 2H), 3.69 (d, J = 13.4 Hz, 1H), 
3.57 (d, J = 13.3 Hz, 1H), 3.40 (t, J = 6.6 Hz, 1H), 2.98 (dd, J = 13.8, 6.3 Hz, 1H), 2.90 
(dd, J = 13.8, 6.9 Hz, 1H). 
13C NMR (100 MHz, DMSO-d6) δ 172.74, 157.93, 138.35, 138.11, 129.75, 129.63, 128.52, 
126.71, 119.62, 116.20, 115.09, 62.30, 50.58, 37.65. 
A11: (Pyridin-4-ylmethyl)glycine 
1H NMR (400 MHz, DMSO-d6) δ 8.52 (d, J = 5.0 Hz, 2H), 7.40 (d, J = 5.0 Hz, 2H), 3.90 
(s, 2H), 3.16 (s, 2H). 
13C NMR (100 MHz, DMSO-d6) δ 171.07, 150.01, 146.37, 123.97, 50.31, 50.13. 
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A12: (Pyridin-4-ylmethyl)-L-alanine  
1H NMR (400 MHz, D2O) δ 8.50 (d, J = 5.4 Hz, 2H), 7.43 (d, J = 5.4 Hz, 2H), 4.19 (s, 2H), 
3.65 (q, J = 7.2 Hz, 1H), 1.43 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, D2O) δ 174.50, 149.36, 141.32, 124.64, 57.94, 48.28, 15.19. 
A13: (Pyridin-4-ylmethyl)-D-alanine  
1H NMR (400 MHz, D2O) δ 8.57 – 8.42 (m, 2H), 7.52 – 7.38 (m, 2H), 4.20 (s, 2H), 3.66 
(q, J = 7.2 Hz, 1H), 1.44 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, D2O) δ 174.50, 149.35, 141.34, 124.67, 57.95, 48.29, 15.22. 
A14: ((1H-indol-5-yl)methyl)-L-alanine 
1H NMR (400 MHz, DMSO-d6) δ 11.41 (s, NH), 7.64 (s, 1H), 7.46 – 7.29 (m, 2H), 7.20 
(d, J = 8.3 Hz, 1H), 6.39 (s, 1H), 4.06 (t, J = 8.7 Hz, 2H), 3.19 (q, J = 7.2 Hz, 1H), 1.31 (d, 
J = 7.0 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 172.07, 136.21, 127.97, 126.56, 123.77, 123.11, 122.18, 
111.90, 101.46, 56.58, 50.02, 16.30. 
A15: ((1H-indol-5-yl)methyl)-D-alanine 
1H NMR (400 MHz, DMSO-d6) δ 11.39 (s, NH), 7.63 (s, 1H), 7.44 – 7.30 (m, 2H), 7.20 
(dd, J = 8.2, 1.7 Hz, 1H), 6.47 – 6.34 (m, 1H), 4.14 – 4.00 (m, 2H), 3.19 (q, J = 7.1 Hz, 
1H), 1.31 (d, J = 7.0 Hz, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 171.55, 136.22, 127.96, 126.58, 123.46, 123.13, 122.26, 
111.90, 101.47, 56.50, 49.91, 16.14. 
 Series B: N-substituted dipeptide esters 
B1: Methyl 2-(2-(pyridin-3-ylmethylamino)acetamido)acetate 
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 2.3 Hz, 1H), 8.47 (d, J = 4.9 Hz, 1H), 7.67 (dt, 
J = 8.4, 1.8 Hz, 1H), 7.25 (dd, J = 7.8, 4.9 Hz, 1H), 4.04 (d, J = 5.3 Hz, 2H), 3.80 (s, 2H), 
3.72 (s, 3H), 3.34 (s, 2H), 2.89 (s, NH). 
13C NMR (100 MHz, CDCl3) δ 171.39, 170.32, 149.56, 148.72, 136.13, 134.44, 123.58, 
52.37, 51.49, 50.99, 40.70. 
IR (neat): 1745, 1659, 1207, 842, 712 cm–1 
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MS (ESI): m/z = 238.1185 (MH+), calculated for C11H16O3N3 = 238.1186 
B3: (S)-methyl 2-(3-phenyl-2-(pyridin-3-ylmethylamino)propanamido)acetate  
1H NMR (400 MHz, CDCl3) δ 8.47 (dd, J = 4.9, 1.7 Hz, 1H), 8.40 – 8.33 (m, 1H), 7.71 (t, 
J = 5.8 Hz, 1H), 7.45 – 7.39 (m, 1H), 7.35 – 7.23 (m, 2H + CDCl3), 7.21 – 7.12 (m, 3H), 
4.17 (dd, J = 18.3, 6.2 Hz, 1H), 4.01 (dd, J = 18.3, 5.1 Hz, 1H), 3.80 – 3.77 (m, 4H), 3.57 
(d, J = 13.5 Hz, 1H), 3.41 (dd, J = 9.9, 4.1 Hz, 1H), 3.25 (dd, J = 14.0, 4.1 Hz, 1H), 2.73 
(dd, J = 13.9, 9.9 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 173.65, 170.31, 149.45, 148.61, 137.04, 135.76, 134.44, 
128.97, 128.89, 127.11, 123.43, 63.19, 52.35, 49.88, 40.76, 39.19. 
IR (neat): 1750, 1668, 1208, 702 cm–1 
MS (ESI): m/z = 328.1655 (MH+), calculated for C18H22O3N3 = 328.1656 
B5: (S)-methyl 3-(1H-indol-3-yl)-2-((S)-2-(pyridin-3-ylmethylamino)propanamido)-
propanoate 
1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 4.8 Hz, 1H), 8.33 – 8.23 (m, 1H + NH), 7.63 
(d, J = 8.7 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.28 (ddd, J = 7.4, 5.6, 1.6 Hz, 1H + CDCl3), 
7.16 – 6.97 (m, 3H), 6.95 – 6.88 (m, 1H), 4.89 (dt, J = 8.6, 5.5 Hz, 1H), 3.66 – 3.58 (m, 
4H), 3.52 (d, J = 13.1 Hz, 1H), 3.35 – 3.21 (m, 2H), 3.14 (q, J = 6.9 Hz, 1H), 1.18 (d, J = 
6.9 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 174.31, 172.41, 149.48, 148.56, 136.12, 135.82, 134.84, 
127.62, 123.38, 122.66, 122.26, 119.59, 118.69, 111.27, 110.06, 57.99, 52.32, 52.16, 
49.68, 27.53, 19.46. 
IR (neat): 2918, 1741, 1661, 743 cm–1 
MS (ESI): m/z = 381.1918 (MH+), calculated for C21H25O3N4 = 381.1921 
B6: (R)-methyl 3-(1H-indol-3-yl)-2-((S)-3-phenyl-2-(pyridin-3-ylmethylamino)propa-
namido)propanoate 
1H NMR (400 MHz, CDCl3) δ 8.41 (dd, J = 4.7, 1.8 Hz, 1H), 8.19 (s, NH), 8.08 – 8.00 (m, 
1H), 7.64 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.26 (qdd, J = 6.7, 4.9, 2.9 Hz, 
3H+CDCl3), 7.15 – 7.11 (m, 3H), 7.08 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.02 (dd, J = 7.9, 
4.7 Hz, 1H), 6.99 – 6.93 (m, 1H), 6.87 (d, J = 2.4 Hz, 1H), 4.96 (dt, J = 7.8, 6.1 Hz, 1H), 
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3.76 (d, J = 1.1 Hz, 3H), 3.40 (dd, J = 14.9, 5.5 Hz, 1H), 3.34 – 3.27 (m, 1H), 3.27 – 3.20 
(m, 3H), 3.16 (d, J = 13.7 Hz, 1H), 2.70 (dd, J = 13.2, 9.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 173.07, 172.41, 149.27, 148.35, 137.25, 136.10, 135.32, 
134.44, 129.02, 128.80, 127.57, 126.96, 123.21, 122.58, 122.31, 119.69, 118.58, 111.25, 
110.06, 63.08, 52.42, 52.29, 49.35, 38.86, 27.33. 
IR (neat): 1742, 1661, 1512, 743 cm–1 
MS (ESI): m/z = 457.2237 (MH+), calculated for C27H29O3N4 = 457.2234 
B8: (S)-methyl 2-(3-phenyl-2-(pyridin-4-ylmethylamino)propanamido)acetate 
1H NMR (400 MHz, CDCl3) δ 8.42 – 8.31 (m, 2H), 7.63 (t, J = 5.9 Hz, NH), 7.29 – 7.16 
(m, 3H), 7.14 – 7.06 (m, 2H), 6.90 (d, J = 5.4 Hz, 2H), 4.07 (dd, J = 18.3, 6.1 Hz, 1H), 3.94 
(dd, J = 18.3, 5.1 Hz, 1H), 3.76 – 3.65 (m, 4H), 3.51 (d, J = 14.5 Hz, 1H), 3.29 (dd, J = 
9.9, 4.0 Hz, 1H), 3.16 (dd, J = 13.9, 4.0 Hz, 1H), 2.66 (dd, J = 13.9, 9.9 Hz, 1H), 1.86 (s, 
1H). 
13C NMR (100 MHz, CDCl3) δ 172.61, 169.30, 148.78, 147.01, 136.07, 128.02, 127.88, 
126.11, 121.75, 62.08, 51.32, 50.04, 39.74, 38.29. 
IR (neat): 1750, 1670, 1206, 701 cm–1 
MS (ESI): m/z = 328.1657 (MH+), calculated for C18H22O3N3 = 328.1656 
B9: (R)-methyl 3-(1H-indol-3-yl)-2-((S)-3-phenyl-2-(thiophen-2-ylmethylamino)-
propanamido)propanoate 
1H NMR (400 MHz, CDCl3) δ 7.98 (s, NH), 7.68 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 7.9 Hz, 
1H), 7.30 (dd, J = 8.3, 7.2 Hz, 1H), 7.23 (dt, J = 8.7, 3.5 Hz, 2H), 7.19 – 7.14 (m, 1H), 7.13 
(dt, J = 6.4, 1.5 Hz, 2H), 7.11 – 7.07 (m, 2H), 6.90 (d, J = 2.5 Hz, 1H), 6.82 (dd, J = 5.1, 
3.4 Hz, 1H), 6.52 (dd, J = 3.5, 1.3 Hz, 1H), 5.00 – 4.87 (m, 1H), 3.72 (s, 3H), 3.48 (d, J = 
1.7 Hz, 2H), 3.39 – 3.24 (m, 3H), 3.18 (dd, J = 14.0, 4.4 Hz, 1H), 2.73 (dd, J = 14.0, 9.6 
Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 173.25, 172.42, 142.70, 137.26, 136.10, 129.08, 128.72, 
127.48, 126.84, 126.58, 124.85, 124.41, 122.59, 122.25, 119.66, 118.63, 111.16, 110.22, 
62.66, 52.35, 52.29, 46.63, 38.87, 27.61. 
IR (neat): 3330, 1741, 1658, 1511, 1456, 743, 701 cm–1 
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MS (ESI): m/z = 462.1848 (MH+), calculated for C26H28O3N3S = 462.1846 
B11: (S)-methyl 3-(4-hydroxyphenyl)-2-((S)-3-phenyl-2-(thiophen-2-ylmethylamino)-
propanamido)propanoate 
1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 9.1, 2.5 Hz, 1H), 7.30 – 7.17 (m, 2H + CDCl3), 
7.13 (t, J = 3.6 Hz, 1H), 7.06 (d, J = 7.0 Hz, 2H), 6.98 – 6.90 (m, 2H), 6.86 (dt, J = 5.5, 2.8 
Hz, 1H), 6.80 – 6.72 (m, 2H), 6.67 (d, J = 3.7 Hz, 1H), 4.93 (ddq, J = 8.0, 5.9, 3.4, 2.8 Hz, 
1H), 3.83 (dd, J = 14.2, 2.4 Hz, 1H), 3.76 – 3.63 (m, 4H), 3.40 (dt, J = 10.5, 3.4 Hz, 1H), 
3.12 (dt, J = 14.6, 3.3 Hz, 1H), 3.00 (ddt, J = 16.6, 14.1, 5.5 Hz, 2H), 2.50 (ddd, J = 12.2, 
9.5, 2.4 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 173.78, 171.97, 155.74, 142.26, 136.83, 130.26, 129.04, 
128.76, 126.96, 126.88, 126.69, 125.32, 124.66, 115.62, 62.59, 52.80, 52.40, 46.68, 38.81, 
37.43. 
IR (neat): 3329, 2361, 1743, 1652, 1515, 1221, 700 cm–1 
MS (ESI): m/z = 439.1687 (MH+), calculated for C24H27O4N2S = 439.1686 
B12: (S)-methyl 2-((S)-2-(furan-2-ylmethylamino)-3-phenylpropanamido)-3-(1H-
indol-3-yl)propanoate 
1H NMR (400 MHz, CDCl3) δ 9.31 (d, J = 2.6 Hz, NH), 7.95 (d, J = 8.6 Hz, 1H), 7.55 (d, 
J = 7.9 Hz, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.31 – 7.18 (m, 4H + CDCl3), 7.14 (t, J = 7.4 Hz, 
1H), 7.07 (dd, J = 7.3, 2.1 Hz, 2H), 6.95 (d, J = 2.4 Hz, 1H), 6.22 (dd, J = 3.1, 1.8 Hz, 1H), 
5.90 (d, J = 3.2 Hz, 1H), 5.03 (dt, J = 8.7, 5.9 Hz, 1H), 3.67 (d, J = 18.7 Hz, 4H), 3.51 (d, 
J = 14.9 Hz, 1H), 3.42 (dd, J = 9.5, 4.1 Hz, 1H), 3.36 (dd, J = 9.0, 5.8 Hz, 2H), 3.07 (dd, J 
= 13.9, 4.1 Hz, 1H), 2.58 (dd, J = 14.0, 9.5 Hz, 1H), 1.96 (s, NH). 
13C NMR (100 MHz, CDCl3) δ 173.44, 172.37, 152.63, 141.82, 137.07, 136.37, 129.03, 
128.67, 127.62, 126.85, 123.11, 121.86, 119.23, 118.55, 111.49, 110.03, 109.51, 107.22, 
62.15, 52.64, 52.24, 44.42, 38.86, 27.81. 
IR (neat): 3326, 1741, 1658, 1510, 741, 701 cm–1 
MS (ESI): m/z = 446.2066 (MH+), calculated for C26H28O4N3 = 446.2074 
B14: (S)-methyl 2-(2-(furan-2-ylmethylamino)-3-phenylpropanamido)acetate 
133 
 
1H NMR (400 MHz, CDCl3) δ 7.77 (s, NH), 7.37 – 7.18 (m, 4H), 7.18 – 7.03 (m, 2H), 6.24 
(d, J = 5.9 Hz, 1H), 6.02 (d, J = 3.2 Hz, 1H), 4.06 (qt, J = 18.1, 5.6 Hz, 2H), 3.83 – 3.66 
(m, 4H), 3.66 – 3.51 (m, 1H), 3.44 (dt, J = 9.7, 3.9 Hz, 1H), 3.19 (dd, J = 13.9, 4.1 Hz, 1H), 
2.71 (qd, J = 9.7, 8.0, 3.6 Hz, 1H), 1.92 (s, NH). 
13C NMR (100 MHz, CDCl3) δ 173.96, 170.28, 152.51, 141.98, 137.09, 128.97, 128.74, 
126.89, 110.03, 107.42, 62.39, 52.25, 44.78, 40.76, 39.16. 
IR (neat): 3340, 1750, 1668, 1207, 700 cm–1 
MS (ESI): m/z = 317.1498 (MH+), calculated for C17H21O4N2 = 317.1496 
B15: (S)-methyl 2-((S)-2-(furan-2-ylmethylamino)-3-phenylpropanamido)-
propanoate 
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.2 Hz, 1H), 7.30 – 7.27 (m, 1H), 7.25 – 7.22 
(m, 2H), 7.16 – 7.08 (m, 2H), 6.24 (dd, J = 3.2, 1.9 Hz, 1H), 6.08 – 6.02 (m, 1H), 4.62 (dq, 
J = 8.3, 7.2 Hz, 1H), 3.82 – 3.75 (m, 1H), 3.74 (s, 3H), 3.59 (d, J = 14.8 Hz, 1H), 3.41 (dd, 
J = 9.6, 4.0 Hz, 1H), 3.15 (dd, J = 14.0, 4.0 Hz, 1H), 2.71 (dd, J = 13.9, 9.5 Hz, 1H), 1.71 
(s, NH), 1.39 (d, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 173.27, 173.05, 152.61, 141.90, 137.02, 129.00, 128.65, 
126.84, 110.00, 107.33, 62.16, 52.30, 47.41, 44.58, 39.16, 18.31. 
IR (neat): 3336, 2925, 1743, 1668, 1507, 1149, 741, 701 cm–1 
MS (ESI): m/z = 331.1652 (MH+), calculated for C18H23O4N2 = 331.1652 
B16: (S)-methyl 2-(2-(3-hydroxybenzylamino)-3-phenylpropanamido)acetate 
1H NMR (400 MHz, Chloroform-d) δ 7.92 (t, J = 5.8 Hz, 1H), 7.34 – 7.25 (m, 3H), 7.22 – 
7.14 (m, 2H), 7.11 (t, J = 7.8 Hz, 1H), 6.78 – 6.70 (m, 1H), 6.64 – 6.57 (m, 2H), 4.18 (dd, 
J = 18.3, 6.2 Hz, 1H), 4.01 (dd, J = 18.3, 5.1 Hz, 1H), 3.78 (s, 3H), 3.71 (d, J = 13.6 Hz, 
1H), 3.55 (d, J = 13.6 Hz, 1H), 3.44 (dd, J = 9.7, 4.1 Hz, 1H), 3.24 (dd, J = 13.9, 4.1 Hz, 
1H), 2.76 (dd, J = 13.9, 9.7 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 174.61, 170.47, 156.30, 140.67, 137.18, 129.68, 129.15, 
128.82, 126.97, 119.78, 114.90, 114.29, 62.81, 52.44, 52.22, 40.86, 39.14. 
IR (neat): 3332, 1749, 1654, 1213, 699 cm–1 




B17: (S)-methyl 2-((S)-2-(3-hydroxybenzylamino)-3-phenylpropanamido)propanoate 
1H NMR (400 MHz, Chloroform-d) δ 7.89 (d, J = 8.3 Hz, 1H), 7.25 – 7.16 (m, 3H), 7.11 
– 7.06 (m, 2H), 7.02 (t, J = 7.8 Hz, 1H), 6.69 – 6.60 (m, 1H), 6.60 – 6.56 (m, 1H), 6.53 (d, 
J = 7.5 Hz, 1H), 4.64 – 4.50 (m, 1H), 3.67 (s, 3H), 3.62 (d, J = 13.5 Hz, 1H), 3.47 (d, J = 
13.5 Hz, 1H), 3.31 (dd, J = 9.3, 4.0 Hz, 1H), 3.11 (dd, J = 13.9, 4.0 Hz, 1H), 2.68 (dd, J = 
13.9, 9.3 Hz, 1H), 1.33 (d, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.70, 173.63, 156.29, 156.27, 140.75, 137.12, 129.68, 
129.65, 129.21, 128.78, 126.96, 119.87, 114.95, 114.26, 62.65, 52.55, 52.17, 47.57, 39.13, 
18.50. 
IR (neat): 3325, 1743, 1651, 1453, 1217, 1156, 699 cm–1 
MS (ESI): m/z = 357.1809 (MH+), calculated for C20H25O4N2 = 357.1809 
B18: (S)-methyl 2-((S)-2-(3-hydroxybenzylamino)-3-phenylpropanamido)-3-(1H-
indol-3-yl)propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.47 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.20 
(d, J = 6.7 Hz, 3H), 7.11 – 6.95 (m, 6H), 6.61 (dd, J = 7.7, 2.4 Hz, 1H), 6.51 (s, 1H), 6.37 
(d, J = 7.4 Hz, 1H), 4.79 (t, J = 6.5 Hz, 1H), 3.66 (s, 3H), 3.39 (d, J = 13.0 Hz, 1H), 3.29 – 
3.21 (m, 4H), 2.85 (dd, J = 13.7, 5.8 Hz, 1H), 2.64 (dd, J = 13.7, 7.7 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 174.51, 172.17, 156.97, 140.57, 137.05, 136.64, 
128.93, 128.89, 128.07, 127.28, 126.33, 123.16, 121.11, 119.03, 118.48, 117.85, 114.71, 
113.50, 111.02, 108.88, 62.70, 52.64, 51.35, 51.31, 38.71, 27.06. 
IR (neat): 3327, 2361, 1740, 1653, 1456, 740, 700 cm–1 
MS (ESI): m/z = 472.2238 (MH+), calculated for C28H30O4N3 = 472.2231 
B19: (S)-methyl 2-((S)-2-(3-hydroxybenzylamino)-3-phenylpropanamido)-3-(4-
hydroxyphenyl)propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.27 – 7.16 (m, 3H), 7.09 (dd, J = 7.4, 1.7 Hz, 2H), 
7.06 – 7.00 (m, 1H), 6.96 – 6.90 (m, 2H), 6.72 – 6.65 (m, 2H), 6.65 – 6.59 (m, 1H), 6.57 
(d, J = 2.6 Hz, 1H), 6.52 – 6.45 (m, 1H), 4.71 – 4.62 (m, 1H), 3.67 (d, J = 1.1 Hz, 3H), 3.46 
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(d, J = 13.0 Hz, 1H), 3.32 (s, 2H), 3.00 (dd, J = 14.0, 5.3 Hz, 1H), 2.88 (dd, J = 13.8, 7.3 
Hz, 2H), 2.71 (dd, J = 13.6, 7.7 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 174.72, 171.98, 157.34, 156.47, 140.79, 137.29, 
130.09, 129.15, 129.10, 128.28, 127.01, 126.52, 119.20, 115.20, 114.97, 113.79, 62.95, 
53.41, 51.54, 51.49, 39.13, 36.48. 
IR (neat): 3322, 1741, 1650, 1540, 1220,734 cm–1 
MS (ESI): m/z = 449.2079 (MH+), calculated for C26H29O5N2 = 449.2071 
B20: (R)-methyl 3-(1H-indol-3-yl)-2-((S)-3-phenyl-2-(pyridin-4-ylmethylamino)-
propanamido)propanoate 
1H NMR (400 MHz, CDCl3) δ 8.84 (s, NH), 8.32 – 8.21 (m, 2H), 7.65 (d, J = 7.9 Hz, 1H), 
7.52 (d, J = 7.8 Hz, 1H), 7.31 – 7.19 (m, 3H + CDCl3), 7.15 – 7.09 (m, 3H), 7.06 (t, J = 7.6 
Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.59 (d, J = 5.2 Hz, 2H), 5.01 – 4.91 (m, 1H), 3.75 (s, 
3H), 3.40 (dd, J = 15.0, 5.4 Hz, 1H), 3.29 (dd, J = 15.0, 6.6 Hz, 1H), 3.25 – 3.16 (m, 3H), 
3.12 (d, J = 14.8 Hz, 1H), 2.68 (dd, J = 14.8, 10.7 Hz, 1H), 1.86 (s, NH). 
13C NMR (100 MHz, CDCl3) δ 173.17, 172.48, 149.36, 148.27, 137.24, 136.20, 129.05, 
128.82, 127.61, 127.01, 122.65, 122.53, 122.17, 119.57, 118.46, 111.36, 109.73, 63.08, 
52.44, 52.42, 50.48, 39.03, 27.29. 
IR (neat): 3309, 2361, 2337, 1741, 1659, 740, 701 cm–1 
MS (ESI): m/z = 457.2231 (MH+), calculated for C27H29O3N4 = 457.2234 
B21: (S)-methyl 3-(1H-indol-3-yl)-2-(2-(pyridin-4-ylmethylamino)acetamido)-
propanoate 
1H NMR (400 MHz, CDCl3) δ 9.04 (s, NH), 8.44 – 8.35 (m, 2H), 7.62 (d, J = 8.3 Hz, 1H), 
7.52 (d, J = 7.9 Hz, 1H), 7.34 – 7.27 (m, 1H), 7.18 – 7.10 (m, 1H), 7.10 – 7.02 (m, 1H), 
6.93 (d, J = 2.7 Hz, 1H), 6.90 (d, J = 5.2 Hz, 2H), 4.96 (dt, J = 8.2, 5.3 Hz, 1H), 3.70 (d, J 
= 1.0 Hz, 3H), 3.60 – 3.43 (m, 2H), 3.40 – 3.27 (m, 2H), 3.25 – 3.18 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 172.39, 171.03, 149.62, 148.38, 136.24, 127.69, 122.85, 
122.75, 122.13, 119.49, 118.40, 111.43, 109.61, 52.48, 52.32, 52.16, 51.79, 27.38. 
IR (neat): 3323, 1740, 1662, 1518, 1213, 744 cm–1 





1H NMR (400 MHz, CDCl3) δ 8.84 (s, NH), 8.45 – 8.37 (m, 2H), 7.60 (d, J = 8.2 Hz, 1H), 
7.56 – 7.48 (m, 1H), 7.34 – 7.27 (m, 1H), 7.14 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.06 (ddd, J 
= 8.0, 7.0, 1.1 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.93 – 6.89 (m, 2H), 4.97 (dt, J = 8.3, 5.4 
Hz, 1H), 3.71 (s, 3H), 3.62 – 3.53 (m, 1H), 3.49 (dd, J = 15.2, 3.6 Hz, 1H), 3.40 – 3.28 (m, 
2H), 3.23 (s, 2H). 
13C NMR (100 MHz, CDCl3) δ 172.37, 170.97, 149.67, 148.33, 136.20, 127.70, 122.77, 
122.74, 122.18, 119.53, 118.43, 111.40, 109.71, 52.43, 52.38, 52.18, 51.81, 27.39. 
IR (neat): 3315, 1741, 1661, 1519, 1216, 744 cm–1 
MS (ESI): m/z = 367.1775 (MH+), calculated for C20H23O3N4 = 367.1765 
B23: Methyl 2-(2-(pyridin-4-ylmethylamino)acetamido)acetate 
1H NMR (400 MHz, Methanol-d4) δ 8.47 (d, J = 5.1 Hz, 2H), 7.46 (d, J = 5.1 Hz, 2H), 4.00 
(s, 2H), 3.85 (s, 2H), 3.73 (d, J = 1.4 Hz, 3H), 3.31 (s, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 173.21, 170.41, 150.25, 148.61, 123.48, 51.38, 50.66, 
40.17, 39.02. 
IR (neat): 3322, 1745, 1663, 1211 cm–1 
MS (ESI): m/z = 238.1189 (MH+), calculated for C11H16O3N3 = 238.1186 
B25: (R)-methyl 2-((S)-2-((1H-indol-5-yl)methylamino)propanamido)-3-(1H-indol-3-
yl)propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.53 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 7.6 Hz, 2H), 7.27 
(d, J = 8.3 Hz, 1H), 7.19 (d, J = 3.1 Hz, 1H), 7.12 – 7.05 (m, 2H), 7.01 (ddd, J = 8.1, 6.8, 
1.2 Hz, 1H), 6.93 (dd, J = 8.3, 1.7 Hz, 1H), 6.36 (dd, J = 3.3, 1.0 Hz, 1H), 4.78 (dd, J = 
8.1, 5.4 Hz, 1H), 3.71 (s, 3H), 3.65 (d, J = 12.6 Hz, 1H), 3.50 (d, J = 12.6 Hz, 1H), 3.19 
(dd, J = 14.7, 7.9 Hz, 2H), 1.11 (d, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 176.33, 172.39, 136.66, 135.52, 129.43, 127.97, 
127.31, 124.38, 123.05, 121.79, 121.08, 119.76, 118.44, 117.82, 111.00, 110.59, 109.08, 
100.86, 56.50, 52.74, 51.96, 51.32, 27.10, 18.03. 
IR (neat): 3402, 1737, 1672, 1369, 1166 cm–1 
137 
 
MS (ESI): m/z = 419.2076 (MH+), calculated for C24H27O3N4 = 419.2083 
B26: (R)-methyl 2-((R)-2-((1H-indol-5-yl)methylamino)propanamido)-3-(1H-indol-3-
yl)propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.58 – 7.51 (m, 1H), 7.35 – 7.27 (m, 2H), 7.24 (d, J = 
8.3 Hz, 1H), 7.18 (d, J = 3.0 Hz, 1H), 7.12 – 7.05 (m, 2H), 7.05 – 6.97 (m, 1H), 6.87 (dd, 
J = 8.6, 1.7 Hz, 1H), 6.37 – 6.30 (m, 1H), 4.81 (d, J = 5.4 Hz, 1H), 3.68 (s, 3H), 3.53 (d, J 
= 12.4 Hz, 1H), 3.46 (d, J = 12.4 Hz, 1H), 3.28 – 3.22 (m, 1H), 3.18 (q, J = 6.8 Hz, 1H), 
1.16 (d, J = 6.9 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 176.30, 172.36, 136.63, 135.49, 129.40, 127.94, 
127.28, 124.35, 123.02, 121.77, 121.05, 119.73, 118.41, 117.80, 110.97, 110.56, 109.05, 
100.83, 56.47, 52.71, 51.93, 51.29, 27.08, 18.00. 
IR (neat): 3257, 2929, 1594, 1354, 1023,742 cm–1 
MS (ESI): m/z = 419.2077 (MH+), calculated for C24H27O3N4 = 419.2083 
B27: (R)-methyl 2-((S)-2-(3-hydroxybenzylamino)-3-phenylpropanamido)-3-(1H-
indol-3-yl)propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.48 (dt, J = 7.9, 1.0 Hz, 1H), 7.31 (dt, J = 8.2, 1.0 
Hz, 1H), 7.16 (dd, J = 5.0, 1.9 Hz, 3H), 7.08 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.05 – 7.02 
(m, 2H), 7.02 – 6.96 (m, 2H), 6.90 (s, 1H), 6.62 (ddd, J = 8.2, 2.5, 1.0 Hz, 1H), 6.54 – 6.49 
(m, 1H), 6.43 (dt, J = 7.5, 1.4 Hz, 1H), 4.72 (dd, J = 7.8, 5.5 Hz, 1H), 3.68 (s, 3H), 3.43 (d, 
J = 13.1 Hz, 1H), 3.32 (d, J = 5.7 Hz, 1H), 3.27 – 3.17 (m, 2H), 3.10 (dd, J = 14.7, 7.8 Hz, 
1H), 2.88 (dd, J = 13.5, 6.3 Hz, 1H), 2.71 (dd, J = 13.5, 7.6 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 174.76, 172.41, 157.03, 140.58, 137.11, 136.67, 
128.95, 128.83, 128.06, 127.18, 126.32, 123.02, 121.13, 119.01, 118.49, 117.71, 114.70, 
113.56, 111.00, 108.90, 62.37, 52.87, 51.36, 51.18, 38.86, 26.89. 
IR (neat): 3331, 1740, 1652, 1456, 1218, 744 cm–1 





1H NMR (400 MHz, Methanol-d4) δ 7.30 – 7.17 (m, 6H), 7.17 – 7.12 (m, 2H), 7.12 – 7.06 
(m, 2H), 7.02 (t, J = 7.8 Hz, 1H), 6.62 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H), 6.58 – 6.52 (m, 1H), 
6.48 (dt, J = 7.5, 1.5 Hz, 1H), 4.73 (dd, J = 8.5, 5.5 Hz, 1H), 4.13 (qd, J = 7.2, 3.2 Hz, 2H), 
3.43 (d, J = 13.0 Hz, 1H), 3.30 – 3.25 (m, 2H), 3.11 (dd, J = 13.8, 5.5 Hz, 1H), 2.98 (dd, J 
= 13.8, 8.4 Hz, 1H), 2.88 (dd, J = 13.6, 5.9 Hz, 1H), 2.68 (dd, J = 13.6, 7.8 Hz, 1H), 1.20 
(t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 174.46, 171.16, 157.05, 140.54, 137.09, 136.43, 
128.96, 128.93, 128.89, 128.16, 128.10, 126.62, 126.37, 118.99, 114.76, 113.56, 62.70, 
53.37, 53.08, 51.31, 37.47, 37.14, 13.04. 
IR (neat): 3327, 1736, 1652, 1454, 1280, 1198, 782, 699 cm–1 
MS (ESI): m/z = 447.2282 (MH+), calculated for C27H31O4N2 = 447.2278 
B29: (R)-methyl 2-((S)-2-(3-hydroxybenzylamino)-3-phenylpropanamido)-3-phenyl-
propanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.24 – 7.16 (m, 6H), 7.09 (tt, J = 6.1, 1.7 Hz, 4H), 
7.03 (t, J = 7.8 Hz, 1H), 6.64 (ddd, J = 8.1, 2.6, 1.0 Hz, 1H), 6.56 (t, J = 2.0 Hz, 1H), 6.51 
(dt, J = 7.6, 1.3 Hz, 1H), 4.69 (dd, J = 8.5, 5.5 Hz, 1H), 3.70 (s, 3H), 3.49 (d, J = 13.3 Hz, 
1H), 3.37 – 3.32 (m, 1H), 3.26 (d, J = 13.2 Hz, 1H), 3.09 (dd, J = 13.9, 5.6 Hz, 1H), 2.90 
(ddd, J = 13.6, 7.4, 4.0 Hz, 2H), 2.72 (dd, J = 13.6, 7.9 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 174.74, 171.83, 157.11, 140.57, 137.14, 136.44, 
128.98, 128.86, 128.78, 128.21, 128.13, 126.58, 126.38, 118.93, 114.72, 113.61, 62.42, 
53.27, 51.38, 51.27, 37.48, 36.86. 
IR (neat): 3326, 1740, 1650, 1454, 1203 cm–1 
MS (ESI): m/z = 433.2125 (MH+), calculated for C26H29O4N2 = 433.2122 
B30: Methyl (2S)-3-(1H-indol-3-yl)-2-[(2S)-3-phenyl-2-{[(thiophen-2-yl)methyl]-
amino}propanamido]propanoate 
1H NMR (400 MHz, Chloroform-d) δ 8.19 (s, 1H), 7.85 (d, J = 8.7 Hz, 1H), 7.54 (d, J = 
7.9 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.33 – 7.18 (m, 4H), 7.18 – 7.07 (m, 4H), 6.92 (d, J 
= 2.4 Hz, 1H), 6.86 (dd, J = 5.1, 3.5 Hz, 1H), 6.62 (d, J = 3.4 Hz, 1H), 5.01 (dt, J = 8.7, 5.7 
Hz, 1H), 3.83 (d, J = 14.1 Hz, 1H), 3.72 (d, J = 18.1 Hz, 4H), 3.48 – 3.25 (m, 3H), 3.10 
(dd, J = 13.9, 4.0 Hz, 1H), 2.59 (dd, J = 13.9, 9.3 Hz, 1H). 
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13C NMR (101 MHz, CDCl3) δ 173.09, 172.30, 142.62, 137.15, 136.14, 129.15, 128.75, 
127.67, 126.94, 126.62, 125.12, 124.53, 122.71, 122.24, 119.60, 118.78, 111.24, 110.21, 
62.57, 52.38, 52.32, 46.70, 38.74, 27.80. 
IR (neat): 3327, 1741, 1659, 1577, 1439 cm–1 
MS (ESI): m/z = 462.1841 (MH+), calculated for C26H28O3N3S = 462.1846 
B31: Methyl (2S)-3-(1H-indol-3-yl)-2-[(2S)-3-phenyl-2-{[(pyridin-3-yl)methyl]-
amino}propanamido]propanoate 
1H NMR (400 MHz, Methanol-d4) δ 8.38 – 8.29 (m, 1H), 8.15 (s, 1H), 7.46 (d, J = 7.9 Hz, 
1H), 7.32 (d, J = 8.1 Hz, 1H), 7.29 – 7.14 (m, 6H), 7.14 – 7.05 (m, 3H), 7.04 – 6.95 (m, 
2H), 3.69 (s, 3H), 3.40 – 3.34 (m, 1H), 3.30 – 3.27 (m, 1H), 3.25 (d, J = 6.5 Hz, 2H), 2.92 
(dd, J = 13.6, 5.7 Hz, 1H), 2.73 (dd, J = 13.6, 7.5 Hz, 1H). 
13C NMR (101 MHz, MeOD) δ 174.35, 172.20, 148.37, 147.08, 137.16, 136.74, 136.62, 
135.69, 129.04, 128.10, 127.32, 126.41, 123.63, 123.29, 121.20, 118.60, 117.95, 111.08, 
108.88, 63.15, 52.49, 51.43, 48.37, 38.73, 26.91. 
IR (neat): 3320, 2929, 1745, 1666, 1521, 1462, 747 cm–1 
MS (ESI): m/z = 457.2230 (MH+), calculated for C27H29O3N4 = 457.2234 
B32: Methyl (2S)-3-hydroxy-2-[(2S)-2-{[(3-hydroxyphenyl)methyl]amino}-3-phenyl-
propanamido]butanoate 
1H NMR (400 MHz, Methanol-d4) δ 7.33 – 7.13 (m, 5H), 7.04 (dd, J = 9.1, 7.2 Hz, 1H), 
6.66 – 6.57 (m, 3H), 4.45 (d, J = 2.6 Hz, 1H), 4.33 (qd, J = 6.4, 2.6 Hz, 1H), 3.73 (s, 3H), 
3.49 (d, J = 12.9 Hz, 1H), 3.43 (dd, J = 8.6, 4.9 Hz, 1H), 3.08 (dd, J = 13.7, 4.9 Hz, 1H), 
2.85 – 2.75 (m, 1H), 1.12 (d, J = 6.4 Hz, 3H). 
13C NMR (101 MHz, MeOD) δ 175.49, 170.95, 157.21, 140.66, 137.16, 129.01, 128.88, 
128.26, 126.50, 119.04, 114.90, 113.69, 66.94, 62.78, 57.38, 51.64, 51.49, 39.02, 19.04. 
IR (neat): 3339, 2929, 1752, 1655, 1525, 1462, 1283 cm–1 
MS (ESI): m/z = 387.1919 (MH+), calculated for C21H27O5N2 = 387.1914 
 




1H NMR (400 MHz, Methanol-d4) δ 8.54 (d, J = 2.2 Hz, 2H), 8.49 (dd, J = 5.0, 1.6 Hz, 
2H), 7.86 – 7.79 (m, 2H), 7.43 (dd, J = 7.9, 4.9 Hz, 2H), 4.66 (s, 4H), 4.07 (s, 4H). 
13C NMR (100 MHz, Methanol-d4) δ 164.70, 148.68, 148.21, 136.86, 132.23, 124.04, 
49.12, 46.36. 
IR (neat): 1653, 1422, 715, 640 cm–1 
MS (ESI): m/z = 297.1342 (MH+), calculated for C16H17O2N4 = 297.1346 
 
C2: (3S,6S)-3,6-dimethyl-1,4-bis(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.51 (d, J = 2.5 Hz, 2H), 8.47 (dd, J = 5.0, 1.7 Hz, 
2H), 7.79 (dt, J = 8.0, 2.1 Hz, 2H), 7.42 (dd, J = 7.9, 4.9 Hz, 2H), 4.91 (d, J = 15.4 Hz, 
2H), 4.47 (d, J = 15.4 Hz, 2H), 4.12 (q, J = 7.0 Hz, 2H), 1.55 (d, J = 7.0 Hz, 6H). 
13C NMR (100 MHz, Methanol-d4) δ 167.82, 148.35, 148.09, 136.47, 133.19, 124.07, 
56.47, 45.25, 18.43. 
IR (neat): 1654, 1481, 1429, 828 cm–1 
MS (ESI): m/z = 325.1662 (MH+), calculated for C18H21O2N4 = 325.1659 
C3: (3S,6S)-3,6-dibenzyl-1,4-bis(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.52 – 8.36 (m, 2H), 8.26 (s, 2H), 7.59 (d, J = 7.7 Hz, 
2H), 7.34 (td, J = 19.5, 17.5, 7.1 Hz, 8H), 7.08 (d, J = 7.4 Hz, 4H), 5.05 (d, J = 15.2 Hz, 
2H), 4.24 (t, J = 5.0 Hz, 2H), 4.02 (d, J = 15.3 Hz, 2H), 2.93 – 2.78 (m, 2H), 2.37 (dd, J = 
14.1, 6.0 Hz, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 166.37, 148.56, 148.15, 136.61, 136.59, 132.51, 
129.42, 128.67, 127.14, 123.99, 61.56, 45.39, 38.28. 
IR (neat): 1658, 1425, 843 cm–1 
MS (ESI): m/z = 477.2293 (MH+), calculated for C30H29O2N4 = 477.2285 
C4: (3S,6S)-3,6-dibenzyl-1,4-bis(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.57 – 8.35 (m, 4H), 7.38 – 7.32 (m, 4H), 7.32 – 7.25 
(m, 2H), 7.17 – 7.12 (m, 4H), 7.12 – 7.07 (m, 4H), 5.07 (d, J = 15.9 Hz, 2H), 4.28 (dd, J = 
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6.2, 4.6 Hz, 2H), 4.02 (d, J = 15.9 Hz, 2H), 2.90 (dd, J = 14.4, 4.6 Hz, 2H), 2.39 (dd, J = 
14.4, 6.3 Hz, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 166.41, 149.02, 146.33, 136.51, 129.43, 128.69, 
127.16, 122.89, 61.88, 47.02, 38.35. 
IR (neat): 1660, 1601, 1459, 1414, 702 cm–1 
MS (ESI): m/z = 477.2286 (MH+), calculated for C30H29O2N4 = 477.2285 
C5: (3S,6S)-3,6-dibenzyl-1,4-bis(thiophen-2-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, CDCl3) δ 7.35 (dd, J = 8.2, 6.5 Hz, 4H), 7.29 (d, J = 7.1 Hz, 2H), 7.22 
(dd, J = 5.3, 1.3 Hz, 2H), 7.12 – 7.06 (m, 4H), 6.88 (dd, J = 5.1, 3.4 Hz, 2H), 6.70 (d, J = 
3.4 Hz, 2H), 5.31 (d, J = 15.2 Hz, 2H), 4.23 (dd, J = 6.7, 4.3 Hz, 2H), 3.77 (d, J = 15.3 Hz, 
2H), 2.92 (dd, J = 14.2, 4.3 Hz, 2H), 2.39 (dd, J = 14.2, 6.6 Hz, 2H). 
13C NMR (100 MHz, CDCl3) δ 165.49, 137.64, 136.80, 129.68, 128.94, 127.60, 127.41, 
126.60, 126.32, 60.45, 42.49, 38.93. 
IR (neat): 1654, 1454, 699 cm-1 
MS (ESI): m/z = 487.1545 (MH+), calculated for C26H27O2N2S2 = 487.1508 
C8: 1,4-bis(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.56 – 8.44 (m, 2H), 7.48 – 7.31 (m, 2H), 4.68 (s, 2H), 
4.11 (d, J = 2.2 Hz, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 164.83, 149.09, 146.13, 123.00, 49.47, 47.97. 
IR (neat): 1664, 1604, 1479, 1417, 1334 cm–1 
MS (ESI): m/z = 297.1350 (MH+), calculated for C16H17N4O2 = 297.1351 
 Series D: Piperazine-2,5-diones  
D1: 1-(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.55 (s, 1H), 8.49 (d, J = 4.8 Hz, 1H), 7.83 (d, J = 7.9 
Hz, 1H), 7.45 (dd, J = 7.9, 5.0 Hz, 1H), 4.67 (s, 2H), 4.03 (s, 2H), 3.97 (s, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 166.55, 165.41, 148.59, 148.15, 136.81, 132.38, 
124.06, 48.86, 46.57, 44.22. 
142 
 
IR (neat): 1662, 1476, 1327 cm–1 
MS (ESI): m/z = 206.0921 (MH+), calculated for C10H12O2N3 = 206.0924 
D2: (S)-6-methyl-1-(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.53 (d, J = 2.6 Hz, 1H), 8.47 (dd, J = 4.9, 1.6 Hz, 
1H), 7.81 (dt, J = 8.0, 2.0 Hz, 1H), 7.42 (dd, J = 7.9, 4.9 Hz, 1H), 4.99 (d, J = 15.4 Hz, 
1H), 4.39 (d, J = 15.4 Hz, 1H), 4.17 (d, J = 17.7 Hz, 1H), 4.01 – 3.83 (m, 2H), 1.46 (d, J = 
7.0 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 169.97, 165.79, 148.38, 148.06, 136.50, 133.26, 
124.01, 56.48, 44.98, 43.84, 16.32. 
IR (neat): 1649, 1466, 1322, 711 cm–1 
MS (ESI): m/z = 220.1086 (MH+), calculated for C11H14O2N3 = 220.1086 
D3: (S)-6-benzyl-1-(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.55 (dd, J = 2.1, 1.0 Hz, 1H), 8.48 (dd, J = 4.9, 1.6 
Hz, 1H), 7.87 – 7.79 (m, 1H), 7.48 – 7.39 (m, 1H), 7.35 – 7.27 (m, 3H), 7.20 – 7.13 (m, 
2H), 5.27 (d, J = 15.2 Hz, 1H), 4.30 – 4.16 (m, 2H), 3.43 (dd, J = 17.7, 0.7 Hz, 1H), 3.36 
– 3.28 (m, 2H), 3.20 (dd, J = 14.1, 3.7 Hz, 1H), 2.46 – 2.34 (m, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 168.43, 166.04, 148.64, 148.19, 136.71, 134.71, 
132.87, 129.86, 128.39, 127.46, 124.07, 61.18, 44.74, 43.22, 36.27. 
IR (neat): 1656, 1455, 1324, 702 cm–1 
MS (ESI): m/z = 296.1398 (MH+), calculated for C17H18O2N3 = 296.1399 
D4: (3S,6S)-6-benzyl-3-methyl-1-(pyridin-3-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.57 (d, J = 2.5 Hz, 1H), 8.48 (dd, J = 4.9, 1.6 Hz, 
1H), 7.85 (dt, J = 8.0, 1.9 Hz, 1H), 7.43 (dd, J = 7.9, 4.9 Hz, 1H), 7.34 – 7.25 (m, 3H), 7.14 
(dt, J = 6.0, 1.6 Hz, 2H), 5.33 (d, J = 15.1 Hz, 1H), 4.34 (d, J = 15.2 Hz, 1H), 4.26 (dd, J = 
4.7, 3.4 Hz, 1H), 3.86 (q, J = 7.1 Hz, 1H), 3.38 (dd, J = 14.3, 4.7 Hz, 1H), 3.25 (dd, J = 
14.2, 3.6 Hz, 1H), 0.42 (d, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 168.11, 166.39, 148.76, 148.14, 136.80, 134.96, 
132.77, 130.16, 128.46, 127.27, 124.05, 60.67, 50.64, 44.63, 35.96, 19.09. 
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IR (neat): 1655, 1454, 1425, 1321, 704 cm–1 
MS (ESI): m/z = 310.1552 (MH+), calculated for C18H20O2N3 = 310.1550 
D5: (3S,6S)-3-((1H-indol-3-yl)methyl)-6-methyl-1-(pyridin-3-ylmethyl)piperazine-
2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.39 (s, 2H), 7.57 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 7.9 
Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.27 (d, J = 6.3 Hz, 1H), 7.08 (d, J = 9.2 Hz, 2H), 7.02 
(t, J = 7.6 Hz, 1H), 4.71 (d, J = 15.4 Hz, 1H), 4.40 (d, J = 4.6 Hz, 1H), 4.16 (d, J = 15.5 
Hz, 1H), 3.67 (q, J = 7.7 Hz, 1H), 3.20 – 3.14 (m, 1H), 1.32 – 1.27 (m, 1H), 0.33 (d, J = 
7.0 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 168.62, 167.00, 148.19, 147.70, 136.43, 136.39, 
133.03, 127.66, 124.47, 123.84, 121.23, 118.82, 118.56, 110.94, 107.98, 56.38, 55.60, 
45.15, 29.68, 16.86. 
IR (neat): 3287, 1656, 1112, 611 cm–1 
MS (ESI): m/z = 349.1657 (MH+), calculated for C20H21O2N4 = 349.1659 
D6: (3R,6S)-3-((1H-indol-3-yl)methyl)-6-benzyl-1-(pyridin-3-ylmethyl)piperazine-
2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.34 – 8.27 (m, 1H), 8.23 (d, J = 2.3 Hz, 1H), 7.50 (d, 
J = 8.0 Hz, 1H), 7.33 (dt, J = 16.4, 7.4 Hz, 4H), 7.14 (dd, J = 7.4, 1.9 Hz, 2H), 7.07 (t, J = 
7.6 Hz, 1H), 6.99 – 6.87 (m, 3H), 6.60 – 6.49 (m, 1H), 5.26 (d, J = 15.3 Hz, 1H), 4.06 (d, 
J = 15.3 Hz, 1H), 3.81 (t, J = 3.9 Hz, 1H), 3.28 – 3.20 (m, 2H), 3.09 (dd, J = 14.1, 3.2 Hz, 
1H), 2.97 – 2.85 (m, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 167.65, 167.45, 148.25, 147.71, 136.27, 135.84, 
134.45, 132.17, 129.97, 128.28, 127.47, 127.42, 124.14, 123.89, 121.03, 118.77, 118.55, 
110.77, 107.78, 60.16, 53.98, 43.61, 36.01, 27.70. 
IR (neat): 1668, 1454, 1425, 743, 703 cm–1 





1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 8.46 (d, J = 4.8 Hz, 1H), 7.74 (dt, J = 
8.0, 1.8 Hz, 1H), 7.40 (dd, J = 7.9, 4.9 Hz, 1H), 6.98 (d, J = 8.1 Hz, 2H), 6.71 (d, J = 8.1 
Hz, 2H), 4.77 (d, J = 15.3 Hz, 1H), 4.43 – 4.31 (m, 2H), 3.78 (q, J = 7.0 Hz, 1H), 3.22 (dd, 
J = 14.0, 4.1 Hz, 1H), 2.90 (dd, J = 13.9, 4.5 Hz, 1H), 0.64 (d, J = 7.0 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 168.68, 166.43, 156.91, 148.55, 147.87, 136.72, 
133.19, 131.29, 125.60, 123.82, 115.13, 56.50, 55.89, 45.47, 38.67, 17.41. 
IR (neat): 1652, 1514, 1463 cm–1 
MS (ESI): m/z = 326.1497 (MH+), calculated for C18H20O3N3 = 326.1499 
D8: (S)-6-benzyl-1-(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 2H), 7.33 (tdd, J = 6.7, 4.5, 1.7 Hz, 5H), 7.24 
– 7.13 (m, 2H), 5.28 (d, J = 15.9 Hz, 1H), 4.30 – 4.11 (m, 2H), 3.49 (d, J = 17.7 Hz, 1H), 
3.30 – 3.26 (m, 1H), 3.21 (dd, J = 14.1, 3.9 Hz, 1H), 2.52 (d, J = 17.5 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 168.43, 166.17, 149.14, 146.54, 134.77, 129.82, 
128.40, 127.43, 122.85, 61.65, 46.33, 43.33, 36.39. 
IR (neat): 1665, 1456, 1415, 1325 cm–1 
MS (ESI): m/z = 296.1396 (MH+), calculated for C17H18O2N3 = 296.1394 
D9: (3R,6S)-3-((1H-indol-3-yl)methyl)-6-benzyl-1-(thiophen-2-ylmethyl)piperazine-
2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 7.42 (d, J = 7.9 Hz, 1H), 7.30 (dd, J = 7.6, 4.0 Hz, 
2H), 7.25 (td, J = 6.7, 5.7, 4.1 Hz, 3H), 7.10 – 7.02 (m, 3H), 7.00 – 6.94 (m, 1H), 6.92 (s, 
1H), 6.85 (dd, J = 5.2, 3.5 Hz, 1H), 6.69 (d, J = 3.4 Hz, 1H), 5.31 (d, J = 15.2 Hz, 1H), 
4.35 (d, J = 15.2 Hz, 1H), 4.00 (t, J = 4.0 Hz, 1H), 3.25 (dd, J = 14.1, 4.7 Hz, 1H), 3.13 – 
2.98 (m, 3H), 2.88 (t, J = 5.0 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 168.04, 167.03, 137.65, 136.54, 134.58, 129.89, 
128.24, 127.36, 127.33, 126.35, 125.72, 123.85, 121.02, 118.44, 118.40, 110.74, 107.80, 
104.99, 60.04, 53.51, 41.52, 36.03, 27.60. 
IR (neat): 3346, 1678, 1454, 738, 701 cm–1 




1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 3.0 Hz, 1H), 7.33 – 7.23 (m, 3H + CDCl3), 7.10 
– 7.05 (m, 2H), 7.01 (dd, J = 3.5, 1.3 Hz, 1H), 6.95 (dd, J = 5.1, 3.5 Hz, 1H), 5.53 (dd, J = 
15.0, 0.9 Hz, 1H), 4.25 (t, J = 4.3 Hz, 1H), 4.16 (d, J = 15.1 Hz, 1H), 3.95 – 3.83 (m, 1H), 
3.33 – 3.18 (m, 2H), 0.58 (d, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 166.76, 166.56, 137.41, 134.84, 130.21, 128.83, 127.95, 
127.59, 126.81, 126.46, 59.58, 51.13, 41.90, 36.72, 20.66. 
IR (neat): 3241, 2361, 1682, 1655, 1454, 1321, 701 cm–1 
MS (ESI): m/z = 315.1170 (MH+), calculated for C17H19O7N2S = 315.1167 
D11: (3S,6S)-3-((1H-indol-3-yl)methyl)-6-benzyl-1-(furan-2-ylmethyl)piperazine-2,5-
dione 
1H NMR (400 MHz, Methanol-d4) δ 10.45 (s, NH), 7.55 (dd, J = 7.9, 1.2 Hz, 1H), 7.41 
(dd, J = 1.9, 0.8 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.27 – 7.17 (m, 3H), 7.13 (ddd, J = 8.2, 7.0, 
1.2 Hz, 1H), 7.05 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.79 – 6.70 (m, 
2H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 6.15 (d, J = 3.2 Hz, 1H), 5.06 (d, J = 15.5 Hz, 1H), 
4.16 (dd, J = 7.1, 3.9 Hz, 1H), 3.99 (dd, J = 6.1, 4.6 Hz, 1H), 3.70 (d, J = 15.5 Hz, 1H), 
3.03 – 2.91 (m, 1H), 2.70 (dd, J = 14.2, 4.6 Hz, 1H), 2.31 (dd, J = 14.5, 7.0 Hz, 1H), 2.14 
– 2.02 (m, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.27, 166.90, 148.83, 142.67, 136.71, 136.47, 
129.47, 128.34, 127.29, 126.82, 124.19, 121.30, 118.77, 118.31, 111.16, 110.04, 109.53, 
108.55, 60.45, 56.13, 40.22, 38.08, 30.14. 
IR (neat): 3305, 1670, 1455, 744 cm–1 
MS (ESI): m/z = 414.1811 (MH+), calculated for C25H24O3N3 =414.1812 
D12: (3S,6S)-6-benzyl-1-(furan-2-ylmethyl)-3-(4-hydroxybenzyl)piperazine-2,5-
dione 
1H NMR (400 MHz, Methanol-d4) δ 7.49 – 7.43 (m, 1H), 7.35 (dd, J = 8.3, 6.7 Hz, 2H), 
7.30 – 7.23 (m, 1H), 7.13 – 7.06 (m, 2H), 6.89 – 6.81 (m, 2H), 6.77 – 6.69 (m, 2H), 6.38 
(dd, J = 3.2, 1.9 Hz, 1H), 6.32 (d, J = 3.2 Hz, 1H), 5.14 (d, J = 15.5 Hz, 1H), 4.17 – 4.07 
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(m, 2H), 3.97 (dd, J = 8.6, 3.8 Hz, 1H), 3.01 (dd, J = 14.3, 4.9 Hz, 1H), 2.71 (dd, J = 14.2, 
5.0 Hz, 1H), 2.61 (dd, J = 13.8, 3.8 Hz, 1H), 1.55 (dd, J = 13.8, 8.6 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.06, 166.48, 156.32, 148.94, 142.72, 136.06, 
130.43, 129.82, 128.55, 127.06, 126.67, 115.08, 110.16, 109.73, 60.42, 56.96, 40.22, 
39.41, 37.07. 
IR (neat): 3272, 2361, 1669, 1516, 1456, 702 cm–1 
MS (ESI): m/z = 391.1654 (MH+), calculated for C23H23O4N2 =391.1652 
D13: (S)-6-benzyl-1-(furan-2-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 7.52 (d, J = 5.6 Hz, 1H), 7.36 – 7.18 (m, 3H), 7.17 – 
6.99 (m, 2H), 6.51 – 6.34 (m, 2H), 5.06 (d, J = 15.6 Hz, 1H), 4.38 (d, J = 15.5 Hz, 1H), 
4.27 – 4.13 (m, 1H), 3.37 (d, J = 17.7 Hz, 1H), 3.19 (tdd, J = 17.9, 11.2, 4.4 Hz, 2H), 2.34 
(d, J = 17.6 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 168.61, 165.50, 149.10, 142.84, 134.77, 129.86, 
128.31, 127.36, 110.31, 109.78, 60.86, 43.27, 40.12, 36.21. 
IR (neat): 3247, 1660, 1455, 1323, 702 cm–1 
MS (ESI): m/z = 285.1236 (MH+), calculated for C16H17O3N2 = 285.1234 
D14: (3S,6S)-6-benzyl-1-(furan-2-ylmethyl)-3-methylpiperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 7.51 (dd, J = 2.1, 1.1 Hz, 1H), 7.35 – 7.21 (m, 3H), 
7.12 – 7.03 (m, 2H), 6.47 (d, J = 3.3 Hz, 1H), 6.42 (dd, J = 3.3, 1.8 Hz, 1H), 5.21 (d, J = 
15.5 Hz, 1H), 4.39 (d, J = 15.4 Hz, 1H), 4.21 (t, J = 4.1 Hz, 1H), 3.80 (q, J = 7.1 Hz, 1H), 
3.38 – 3.34 (m, 1H), 3.22 (dd, J = 14.2, 3.6 Hz, 1H), 0.39 (dd, J = 7.1, 1.2 Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 167.62, 166.55, 149.06, 142.76, 134.99, 130.13, 
128.36, 127.16, 110.24, 109.82, 60.31, 50.67, 39.93, 35.73, 19.12. 
IR (neat): 3255, 1655, 1453, 1322, 702 cm–1 
MS (ESI): m/z = 299.1393 (MH+), calculated for C17H19O3N2 = 299.1390 
D15: (S)-6-benzyl-1-(3-hydroxybenzyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 7.30 (qd, J = 4.8, 2.2 Hz, 3H), 7.20 – 7.11 (m, 3H), 
6.73 (dq, J = 6.6, 1.5 Hz, 3H), 5.23 (dd, J = 14.9, 1.6 Hz, 1H), 4.14 – 4.06 (m, 1H), 3.99 
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(dd, J = 14.9, 1.6 Hz, 1H), 3.45 (dd, J = 17.5, 1.7 Hz, 1H), 3.25 (ddd, J = 14.0, 4.9, 1.7 Hz, 
1H), 3.13 (ddd, J = 14.0, 4.1, 1.6 Hz, 1H), 2.53 (d, J = 17.6 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 168.78, 165.79, 158.18, 137.02, 134.88, 129.85, 
129.58, 128.33, 127.37, 118.67, 114.81, 114.69, 60.26, 46.61, 43.31, 35.98. 
IR (neat): 3248, 2361, 1652, 1455, 702 cm–1 
MS (ESI): m/z = 311.1396 (MH+), calculated for C18H19O3N2 = 311.1390 
D16: (3S,6S)-6-benzyl-1-(3-hydroxybenzyl)-3-methylpiperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 7.30 (dt, J = 13.5, 6.9 Hz, 3H), 7.23 – 7.05 (m, 3H), 
6.77 (q, J = 7.6 Hz, 3H), 5.38 (d, J = 14.8 Hz, 1H), 4.12 (dd, J = 12.1, 8.2 Hz, 2H), 3.87 
(q, J = 7.0 Hz, 1H), 3.40 – 3.33 (m, 1H), 3.19 (dd, J = 14.3, 3.9 Hz, 1H), 0.45 (d, J = 7.0 
Hz, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 167.91, 166.73, 157.75, 136.95, 135.10, 130.14, 
129.62, 128.42, 127.20, 118.98, 114.64, 114.55, 59.69, 50.75, 46.37, 35.64, 19.22. 
IR (neat): 3203, 2361, 1671, 1454, 705 cm–1 
MS (ESI): m/z = 325.1553 (MH+), calculated for C19H21O3N2 = 325.1547 
D17: (3S,6S)-3-((1H-indol-3-yl)methyl)-6-benzyl-1-(3-hydroxybenzyl)piperazine-2,5-
dione 
1H NMR (400 MHz, Methanol-d4) δ 7.58 (dt, J = 7.8, 1.0 Hz, 1H), 7.35 (dt, J = 8.1, 0.9 
Hz, 1H), 7.28 – 7.18 (m, 3H), 7.14 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.09 – 7.04 (m, 2H), 
7.00 (s, 1H), 6.78 – 6.72 (m, 2H), 6.67 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.51 (t, J = 2.0 Hz, 
1H), 6.46 (dt, J = 7.6, 1.2 Hz, 1H), 5.21 (d, J = 15.0 Hz, 1H), 4.25 (dd, J = 6.9, 3.9 Hz, 
1H), 3.93 – 3.84 (m, 1H), 3.42 (d, J = 15.0 Hz, 1H), 3.01 (ddd, J = 14.6, 4.0, 0.8 Hz, 1H), 
2.69 (dd, J = 14.2, 4.4 Hz, 1H), 2.40 (dd, J = 14.5, 6.9 Hz, 1H), 1.99 (dd, J = 14.2, 6.3 Hz, 
1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.52, 167.18, 157.72, 136.76, 136.73, 136.67, 
129.44, 129.41, 128.36, 127.35, 126.81, 124.23, 121.33, 118.81, 118.68, 118.37, 114.55, 
114.34, 111.19, 108.58, 59.96, 56.22, 46.73, 38.12, 30.14. 
IR (neat): 3317, 2361, 1669, 1456 745, 701 cm–1 




1H NMR (400 MHz, Methanol-d4) δ 7.36 (td, J = 8.5, 7.8, 2.0 Hz, 2H), 7.32 – 7.24 (m, 
1H), 7.13 (ddd, J = 8.0, 4.7, 3.2 Hz, 3H), 6.91 – 6.85 (m, 2H), 6.78 – 6.68 (m, 3H), 6.66 – 
6.60 (m, 2H), 5.30 (dd, J = 15.0, 2.3 Hz, 1H), 4.09 – 4.05 (m, 1H), 4.03 (t, J = 5.3 Hz, 1H), 
3.82 (d, J = 14.9 Hz, 1H), 3.01 (dd, J = 14.3, 4.6 Hz, 1H), 2.70 – 2.57 (m, 2H), 1.65 (dd, J 
= 13.7, 8.5 Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.28, 166.76, 157.70, 156.37, 136.83, 136.22, 
130.49, 129.77, 129.53, 128.58, 127.07, 126.69, 118.87, 115.14, 114.60, 114.46, 59.84, 
57.04, 46.69, 39.40, 37.09. 
IR (neat): 3267, 2361, 1669, 1131, 702 cm–1 
MS (ESI): m/z = 439.1627 (MNa+), calculated for C25H24O4N2Na = 439.1628 
D19: (S)-3-((1H-indol-3-yl)methyl)-1-(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.30 – 8.19 (m, 2H), 7.56 (d, J = 7.9 Hz, 1H), 7.39 (d, 
J = 8.1 Hz, 1H), 7.19 – 7.09 (m, 1H), 7.07 – 6.97 (m, 2H), 6.74 (d, J = 5.4 Hz, 2H), 4.41 
(t, J = 4.0 Hz, 1H), 4.32 (d, J = 15.7 Hz, 1H), 4.23 (d, J = 15.7 Hz, 1H), 3.55 (dd, J = 14.7, 
3.9 Hz, 1H), 3.39 (d, J = 17.4 Hz, 1H), 3.14 (dd, J = 14.7, 4.2 Hz, 1H), 2.70 (d, J = 17.4 
Hz, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.30, 166.18, 148.89, 145.45, 136.55, 127.38, 
124.64, 122.61, 121.43, 118.95, 118.43, 111.03, 107.70, 56.24, 48.59, 48.06, 29.84. 
IR (neat): 3256, 1659, 1417, 1324, 744 cm–1 
MS (ESI): m/z = 335.1503 (MH+), calculated for C19H18O2N4 = 335.1503 
D20: (R)-3-((1H-indol-3-yl)methyl)-1-(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.24 (dd, J = 4.8, 1.6 Hz, 2H), 7.56 (d, J = 8.0 Hz, 
1H), 7.39 (d, J = 8.2 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.07 – 6.97 (m, 2H), 6.78 – 6.68 (m, 
2H), 4.40 (t, J = 4.1 Hz, 1H), 4.32 (d, J = 15.7 Hz, 1H), 4.22 (d, J = 15.7 Hz, 1H), 3.55 (dd, 
J = 14.7, 3.9 Hz, 1H), 3.39 (d, J = 17.4 Hz, 1H), 3.13 (dd, J = 14.7, 4.2 Hz, 1H), 2.77 – 
2.63 (m, 1H). 
13C NMR (100 MHz, Methanol-d4) δ 167.28, 166.18, 148.80, 145.54, 136.47, 127.33, 
124.62, 122.60, 121.42, 118.94, 118.43, 111.02, 107.54, 56.16, 48.46, 47.90, 29.80. 
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IR (neat): 1658, 1417, 1326, 745 cm–1 
MS (ESI): m/z = 335.1506 (MH+), calculated for C19H18O2N4 = 335.1503 
D21: 1-(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.50 (d, J = 4.5 Hz, 2H), 7.34 (dd, J = 4.4, 2.3 Hz, 
2H), 4.67 – 4.63 (m, 2H), 4.06 – 4.02 (m, 2H), 3.99 – 3.95 (m, 2H). 
13C NMR (100 MHz, Methanol-d4) δ 166.54, 165.58, 149.13, 146.15, 122.86, 49.32, 48.13, 
44.25. 
IR (neat): 1664, 1473, 1326 cm–1 
MS (ESI): m/z = 206.0920 (MH+), calculated for C10H12O2N3 = 206.0924 
D22: (S)-3-(4-hydroxybenzyl)-1-(pyridin-4-ylmethyl)piperazine-2,5-dione 
1H NMR (400 MHz, Methanol-d4) δ 8.47 (d, J = 5.7 Hz, 2H), 7.12 (dd, J = 5.1, 2.2 Hz, 
2H), 6.93 (d, J = 8.0 Hz, 2H), 6.62 (d, J = 8.0 Hz, 2H), 4.63 (s, 1H), 4.32 (d, J = 15.6 Hz, 
2H), 3.55 (d, J = 17.4 Hz, 1H), 3.23 – 3.10 (m, 1H), 2.98 – 2.81 (m, 2H). 
13C NMR (100 MHz, Acetone-d6) δ 165.99, 164.57, 156.68, 149.88, 144.82, 131.19, 
126.24, 122.92, 115.18, 56.62, 48.98, 48.17, 39.22. 
IR (neat): 1664, 1514, 1418 cm–1 
MS (ESI): m/z = 312.1348 (MH+), calculated for C17H18O3N3 = 312.1343 
 Tartaric acid anhydride (E) 
E1: (3R,4R)-2,5-dioxotetrahydrofuran-3,4-diyl diacetate 
1H NMR (400 MHz, CDCl3) δ 5.68 (s, 2H), 2.23 (s, 6H). 
13C NMR (100 MHz, CDCl3) δ 169.66, 163.25, 72.04, 20.05. 
 Tartaric acid monoamide (F) 
F1: (2R,3R)-2,3-diacetoxy-4-oxo-4-(pyridin-3-ylamino)butanoic acid 
1H NMR (400 MHz, Methanol-d4) δ 8.76 (d, J = 2.5 Hz, 1H), 8.32 (dd, J = 4.9, 1.5 Hz, 
1H), 8.11 (dt, J = 8.5, 1.9 Hz, 1H), 7.46 (dd, J = 8.4, 4.9 Hz, 1H), 5.72 (d, J = 2.8 Hz, 1H), 
5.69 (d, J = 2.9 Hz, 1H), 2.20 (s, 3H), 2.10 (s, 3H). 
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13C NMR (100 MHz, Methanol-d4) δ 170.01, 169.95, 168.40, 166.14, 144.11, 140.75, 
135.18, 129.08, 124.14, 72.63, 71.15, 19.00, 18.90. 
F2: (2R,3R)-2,3-diacetoxy-4-oxo-4-((pyridin-4-ylmethyl)amino)butanoic acid 
1H NMR (400 MHz, Methanol-d4) δ 8.63 – 8.40 (m, 2H), 7.59 – 7.35 (m, 2H), 5.69 (d, J = 
2.6 Hz, 1H), 5.57 (d, J = 2.6 Hz, 1H), 4.55 (d, J = 16.4 Hz, 1H), 4.46 (d, J = 16.4 Hz, 1H), 
2.17 (s, 3H), 2.07 (s, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 170.08, 169.89, 168.86, 168.04, 151.59, 146.97, 
122.98, 72.64, 71.66, 41.57, 19.08, 19.03. 
F3: (2R,3R)-2,3-diacetoxy-4-morpholino-4-oxobutanoic acid 
1H NMR (400 MHz, Methanol-d4) δ 5.88 – 5.83 (m, 1H), 5.65 – 5.60 (m, 1H), 3.79 – 3.53 
(m, 8H), 2.13 (s, 3H), 2.13 (s, 3H). 
13C NMR (100 MHz, Methanol-d4) δ 170.13, 169.96, 168.08, 165.15, 69.74, 69.61, 66.18, 
66.02, 45.93, 42.65, 18.97, 18.84. 
F4: (2R,3R)-2,3-diacetoxy-4-(diethylamino)-4-oxobutanoic acid 
1H NMR (400 MHz, CDCl3) δ 12.14 (s, 1H), 5.76 (d, J = 4.0 Hz, 1H), 5.52 (d, J = 3.9 Hz, 
1H), 3.49 (td, J = 15.2, 14.4, 7.4 Hz, 1H), 3.36 (dt, J = 14.9, 7.2 Hz, 1H), 3.13 (dq, J = 
14.0, 7.0 Hz, 1H), 3.01 (h, J = 6.9 Hz, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 1.25 (q, J = 4.0 Hz, 
3H), 1.04 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.17, 170.01, 169.04, 165.24, 70.26, 69.36, 42.06, 41.04, 
20.39, 20.38, 13.71, 12.33. 
F5: (2R,3R)-2,3-diacetoxy-4-oxo-4-(piperidin-1-yl)butanoic acid 
1H NMR (400 MHz, Methanol-d4) δ 5.87 (dd, J = 3.6, 0.8 Hz, 1H), 5.58 (dd, J = 3.6, 0.8 
Hz, 1H), 3.63 – 3.43 (m, 4H), 2.12 (s, 3H), 2.12 (s, 3H), 1.72 – 1.49 (m, 6H). 
13C NMR (100 MHz, CDCl3) δ 170.04, 169.92, 168.83, 164.14, 69.97, 68.92, 46.87, 44.01, 
26.06, 25.31, 24.28, 20.44, 20.41. 




1H NMR (400 MHz, Acetic Acid-d4) δ 9.16 (d, J = 13.3 Hz, 1H), 8.76 – 8.60 (m, 1H), 8.60 
– 8.48 (m, 1H), 7.76 (dd, J = 8.6, 4.8 Hz, 1H), 5.17 (d, J = 2.2 Hz, 1H), 4.66 (d, J = 2.2 Hz, 
1H), 3.80 – 3.60 (m, 8H). 
13C NMR (100 MHz, Acetic Acid-d4) δ 171.74, 170.23, 140.10, 136.41, 136.31, 132.73, 
125.89, 72.44, 69.38, 66.15, 66.08, 45.82, 42.85. 
IR (neat): 3315, 1634, 1527, 1424, 1111 cm–1 
MS (ESI): m/z = 296.1245 (MH+), calculated for C13H18O5N3 = 296.1246 
G2: (2R,3R)-2,3-dihydroxy-4-morpholino-4-oxo-N-(pyridin-2-yl)butanamide 
1H NMR (400 MHz, Acetic Acid-d4) δ 8.33 (d, J = 9.0 Hz, 2H), 8.01 (d, J = 8.5 Hz, 1H), 
7.29 (s, 1H), 5.15 (s, 1H), 4.66 (s, 1H), 3.87 – 3.65 (m, 8H). 
13C NMR (100 MHz, Acetic Acid-d4) δ 171.30, 169.92, 149.92, 145.10, 141.02, 120.57, 
115.38, 72.21, 69.70, 69.46, 66.16, 45.71, 42.92. 
IR (neat): 3347, 3195, 1656, 1436, 1389, 1113 cm–1 
MS (ESI): m/z = 296.1246 (MH+), calculated for C13H18O5N3 = 296.1246 
G3: (2R,3R)-N-(2-fluoropyridin-4-yl)-2,3-dihydroxy-4-morpholino-4-oxobutanamide 
1H NMR (400 MHz, Acetic Acid-d4) δ 8.18 (dt, J = 6.2, 3.1 Hz, 1H), 7.64 – 7.47 (m, 2H), 
5.21 (s, 1H), 4.63 (d, J = 7.7 Hz, 1H), 3.79 – 3.69 (m, 8H). 
13C NMR (100 MHz, Acetic Acid-d4) δ 171.48, 170.49, 165.53, 163.16, 149.52, 149.37, 
147.20, 147.08, 112.27, 99.29, 98.88, 72.48, 69.30, 66.08, 52.45, 45.90, 42.94. 
IR (neat): 3194, 1609, 1509, 1264, 1110 cm–1 
MS (ESI): m/z = 314.1150 (MH+), calculated for C13H17O5N3F = 314.1152  
 Cyclic tartrimides (H) 
H1: (3R,4R)-2,5-dioxo-1-(pyridin-4-ylmethyl)pyrrolidine-3,4-diyl diacetate 
1H NMR (400 MHz, Methanol-d4) δ 8.90 – 8.80 (m, 2H), 8.08 (d, J = 6.4 Hz, 2H), 5.76 (d, 
J = 1.1 Hz, 2H), 5.09 (d, J = 3.0 Hz, 2H), 2.18 (s, 6H). 




IR (neat): 3327, 2361, 1740, 1653, 1456, 740, 700 cm–1 
MS (ESI): m/z = 307.0925 (MH+), calculated for C14H15O6N2 = 307.0925 
H2: (3R,4R)-4-(acetyloxy)-1-(4-methylphenyl)-2,5-dioxopyrrolidin-3-yl acetate 
1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.3 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 5.69 (s, 
2H), 2.43 (s, 3H), 2.27 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 170.12, 168.20, 136.07, 129.99, 128.69, 73.17, 20.46, 
17.72. 
IR (neat): 1737, 1518, 1380, 1227, 1201 cm–1 
MS (ESI): m/z = 328.0799 (MNa+), calculated for C15H15O6NNa = 328.0792 
H3: (3R,4R)-4-(acetyloxy)-1-(2,6-dimethylphenyl)-2,5-dioxopyrrolidin-3-yl acetate 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 7.18 (d, J = 7.6 Hz, 2H), 5.69 (s, 2H), 
2.27 (s, 6H), 2.22 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 170.12, 168.20, 136.07, 129.99, 128.69, 73.17, 20.46, 
17.72. 
IR (neat): 1734, 1380, 1223, 1201, 1100 cm–1 
MS (ESI): m/z = 342.0954 (MNa+), calculated for C16H17O6NNa = 342.0948. 
H4: (3R,4R)-1-(4-methoxyphenyl)-2,5-dioxopyrrolidine-3,4-diyl diacetate 
1H NMR (400 MHz, Methanol-d4) δ 7.28 (d, J = 8.9 Hz, 2H), 7.05 (d, J = 8.9 Hz, 2H), 5.88 
(s, 2H), 3.86 (s, 3H), 2.21 (s, 6H). 
13C NMR (101 MHz, Methanol-d4) δ 170.26, 169.55, 160.03, 127.54, 123.83, 113.92, 
72.78, 54.59, 18.85. 
IR (neat): 1734, 1518, 1257, 1231 cm–1 



























































































































































































































































































































































































































































































































16. Bioactivity assays 
Kinase profiling studies were carried out at International centre for kinase profiling.210 Cell 
viability (MTS) assays, anti-oxidant activity (CLPAA) assays, antibacterial activity assays 
and biofilm assays were conducted at MarBio, Tromsø. 
16.1. Cellular lipid peroxidation antioxidant activity (CLPAA) assay 
Approximately 90 000 HepG2 cells per well were seeded in black 96 well plates with clear 
bottoms (# 3603, Corning, NY, USA) and incubated overnight.  The cells were labelled 
with 10 µM C11-BODIPY (#D3861, Invitrogen, Eugene, OR) for 30 min and incubated 
for 1 h with various concentrations of the test compounds. 50 µM Cumene hydroperoxide 
(cumOOH, #247502, Sigma-Aldrich, St.Louis, MO) was added to initiate lipid 
peroxidation and the plate was immediately placed in a Victor3 Plate Reader (Perkin Elmer, 
MA, USA).  Both red (590/7 nm (exitation), 632/45 nm (emission)) and green (485/14 nm, 
520/10 nm) fluorescence was recorded every 3rd minute during ~1 h.  Cells were washed 
with PBS between additions of new reagents. The total reaction volume was 100 μl.  All 
incubations were carried out at 37 ºC with 5 % CO2.  Percent inhibition was calculated 
relative to the positive control (cumOOH without test compound). 
16.2. Cell viability assay (MTS).  
Cell viability was determined by a colorimetric [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay. 
The compounds were tested against three cancer cell lines: human melanoma (A2058 
ATCC CRL-1147), human breast carcinoma (MCF7 ATCC HTB-22), and human colon 
carcinoma (HT29 ATCC HTB-38). In addition, non-malignant lung fibroblasts (MRC5 
ATCC CCL-171) was used as toxicity control.  
The cell lines were seeded in 96-well microtiter plates at 2000 (cancer cell lines) or 4000 
(MRC5) cells/well. After 24 h incubation at 37 ºC in 5 % CO2, the compounds were added 
in triplicates to each cell line to give 50 µM as the test concentration. The plates were 
incubated for 72 h. At the end of the exposure time, 10 µl Cell Titer 96® Aqueous One 
Solution Reagent (Promega, USA) was added to each well, and the plates were incubated 
for 1 h before absorbance was measured using DTX multimode detector (Beckman Coulter, 
INC CA92821 USA) at 485 nm. Cells treated with Roswell Park Memorial Institute-1640 
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medium were used as negative control, and compound effect was quantified as the 
percentage of control absorbance of reduced dye.  
16.3. Antibacterial assay 
The antibacterial activity was tested on five different strains; E. faecalis (ATCC 29212), 
E. coli (ATCC 25922), P. aeruginosa (ATCC 27853), S. aureus (ATCC 25923) and 
Streptococcus agalactiae group B (ATCC 12386). Growth medium with sterile MilliQ 
H2O was used as a negative control while sterile MilliQ H2O and bacteria suspension was 
used as a positive control. Bacteria were transferred from a blood plate to growth medium 
(MH-bullion #275730 Difco Becton Dickinson) for E. coli, P. aeruginosa and S. aureus 
and BHI-bullion (#53286 Sigma Aldrich) for E. faecalis and S. agalactiae gr. B) and 
incubated at 37°C overnight. The following day a part of the bacteria suspension was 
transferred to fresh medium and cultivated in a shaker incubator at 37°C for 1.5 h (E. coli, 
E. faecalis and Streptococcus gr. B) or 2.5 h (S. aureus and P. aeruginosa). The bacteria 
suspension was then diluted 1:100 in medium and added all wells in a 96-well microtiter 
plate (Nunc 167008), followed by test compounds in duplicates. The plates were incubated 
at 37 ºC overnight before growth was assessed visually and photometrical at 600 nm. The 
total reaction volume was 100 μL. Compounds were tested at 50 µM 
16.4. Biofilm inhibition assay 
S. epidermidis  (RP62A 42-77, ATCC 35984) was used to assess the effect of the test 
compounds on biofilm formation. Growth media: tryptic soy broth (TS; #1.05459 Merck, 
Darmstadt, Germany). An overnight culture of S. epidermidis grown in TS was diluted with 
fresh TS containing 1 % glucose (1:100). Aliquots of 50 μL were transferred to a 96-well 
microtiter plate, and 50 μL of test compounds, dissolved in water at ranging concentrations, 
was added. After overnight incubation at 37 °C, the bacterial suspension was carefully 
discarded and the wells washed with water. The plate was dried and the biofilm fixed by 
incubation for 1 h at 55 °C before the surface attached cells were stained with 100 μL of 
0.1 % crystal violet for 5 min. The crystal violet solution was removed and the plate once 
more washed with water and dried at 55 °C for 1 h. After adding 70 μL of 70 % ethanol, 
the plate was incubated at room temperature for 10 min. Biofilm formation was observed 
by visual inspection of the plates. The MIC was defined as the lowest concentration where 
no biofilm formation was visible. A S. epidermidis suspension, diluted with 50 μL of water, 
was used as a positive control, and 50 μL Staphylococcus haemolyticus (clinical isolate 8-
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7A) suspension with 50 μL of water was employed as a negative control. A mixture of 50 
μL water and 50 μL TS was used as assay control. 
16.5. SILAC study 
 SILAC labelling  
The SILAC labeling was performed using the components from the Pierce SILAC 
Quantitation Kit (Fisher Scientific, 89983). 
A2058 cells (ATCC CRL-11147) were grown in one flask with 12C and one flask with 13C 
SILAC Dulbecco’s Modified Eagle Medium, according to the protocol from Thermo 
Scientific. In addition to the supplements provided in the kit, 50 mg/ml proline and 10 
µg/ml gentamicin (Biochrom, A2712) were added to the growth media before sterile 
filtration. The cells were grown in these two media for 2 weeks.  Then the cells were seeded 
in 3 cell cultivation plates (VWR, 734-2043) per growth media, each with 2.2 X 106 cells. 
The cells were incubated overnight at 5 % CO2, 37 ºC. Then 
13C labelled (test) cells were 
incubated for 4 hours with compound B18 (final concentration 5, 2.5 or 0.5 µM). The 12C 
labelled (control) cells were incubated with the same volume of dilution buffer for 4 hours. 
After 4 hours of incubation the cells were washed twice with ice cold PBS. The cells were 
then lysed with 250 µl 2.5 X SDS lysis buffer. By use of a cell scraper, the cell lysate was 
transferred to a LoBind Eppendorf tube. The cell lysates were stored at -20 ºC.  
After thawing the samples on ice, 100 mM DTT (final concentration) was added to the 
samples before the samples were incubated at 95 degree C for 15 min. The lysis buffer 
makes the samples very viscous, and the high temperature makes them liquid again. 10 % 
of the lysate was removed for analysis of 13C incorporation. The rest of the lysate was 
mixed 1:1 for 12C and 13C (i.e. 13C 5 µM B18 with 12C treated with the same amount of 
dilution buffer, and so on).  
The samples were separated on a polyacrylamide gel for SDS-PAGE (Thermo Scientific, 
25204). The samples were run approximately 10 mm into the resolving part of the gel. The 
gel was stained using Simply Blue safe stain (Thermo Scientific, LC 6065) before the 
stained area was cut into 3 slices that were placed into high quality Eppendorf tubes. The 





Gel pieces were subjected to in gel reduction, alkylation, and tryptic digestion using 6 ng/μl 
trypsin (V511A, Promega, Wisconsin, USA).211 OMIX C18 tips (Varian, Inc., Palo Alto, 
CA, USA) was used for sample cleanup and concentration. Peptide mixtures containing 
0.1% formic acid were loaded onto a Thermo Fisher Scientific EASY-nLC1000 system 
and EASY-Spray column (C18, 2µm, 100 Å, 75µm, 50 cm). Peptides were fractionated 
using a 2-100% acetonitrile gradient in 0.1 % formic acid over 200 min at a flow rate of 
250 nl/min. The separated peptides was analysed using a Thermo Scientific Q-Exactive 
mass spectrometer. Data was collected in data dependent mode using a Top10 method.  
 SILAC Quantitation 
Raw files from the Q-Exactive MS were analysed using the quantitative proteomics 
software MaxQuant212 (version 1.5.6.0). SILAC pairs were quantitated in MaxQuant and 
proteins were identified using the built in Andromeda search engine using the Uniprot 
Homo sapiens (Human) database (november.2016). Main search peptide tolerance was set 
to 4.5 ppm and MS/MS mass tolerance was set to 20 ppm. A FDR ration of 0.01 were 
needed to give å protein identification. At least 2 peptides had to be quantitated to give a 
quantitation value.  
Statistical validation of protein regulation was done with the Perseus 1.5.6.0 software. To 
determine significant outliers in the experiments a significance B test was performed. This 
was done with the Benjamini–Hochberg procedure with a FDR of 0.05 on normalized 
ratios. 
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The appendix details the results from various bioactivity screenings performed on the 
libraries synthesized as a part of this research project.  
A. Bioactivity assays 
1. Kinase profiling 
The Kinase profiling of B1 and D8 was carried out at International Centre for Kinase 
























































































































































































































































































































































































































































































































































































B1 did not show very significant inhibition of kinases except minor inhibition of MKK2 
(31 % inhibition) and HIPK1 (28 % inhibition). On the other hand, D8 showed interesting 
























































































































































Kinase profiling for B1 (100 µM)

































































































































































































Kinase profiling for D8 (100 µM)
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Thus, C8 showed 92 % inhibition of brain specific kinase 1 (BRSK1, also known as SAD-
1), 71 % inhibition of TIE2, 66 % inhibition of MAPKAP-K3, 58 % inhibition of PKB-b, 
and 50 % inhibition of MLK1. Surprisingly, it also showed 62 % activation of Lck. The 
inhibitions were very selective, yet scattered. The following kinome tree (Figure 45) 
















































































































































































































































































































































Figure 45. Kinases inhibited by D8 at 100 µM marked in kinome tree - Illustration reproduced 
courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). 
As the inhibition of kinases, especially BRSK1, shown by D8 was significant, it was 
important to determine the IC50 values for the inhibition. Hence, the compound was sent 
again with 2 more similar compounds, D3 and C4, to determine IC50 values. However, this 
time, the results were disappointing as D8 showed only 46 % inhibition at 100 µM 
concentration, resulting IC50 greater than 100 µM, while D3 showed only minor inhibition 




Figure 46. IC50 studies of D8, D3 and C4 on BRSK1 
Despite the less reproducibility, the inhibition shown by D8 is still interesting. As of today, 
BRSK1 still stands as very less explored enzyme. It requires further research to explore its 
importance and applications.  
Along with above three compounds for IC50 studies, three more compounds, D15, D20 and 
D22 were also sent for kinase profiling. One noticeable inhibition was on MAPKAP-K3, 
which, despite weak, was consistent for all four DKP compounds tested. However, the 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Kinase profiling for D20 (100 µM)
















































































































































































































































































































































































































































































































































































































































































































































Overall, the kinase profiling indicated a possibility of hit for specific kinases, which can be 
developed with further research and testing. 
2. Assays on cancer cell lines 
a. Assays on melanoma A2058 cell line 
A2058 melanoma cell line is derived from human skin. It is a common cell line used for 
anti-cancer activity assays. The compounds belonging to all three series were tested on this 
























































































































































































































































































































































































































































N-substituted dipeptide ester compounds













































































































DKP compounds including cyclic dimers

























Compounds from TABs series













































































































N-substituted dipeptide ester compounds








































































































DKP compounds including cyclic dimers
Assay on HT29 colon cancer cell-line (50 µM)























Compounds from TABs series














































































































N-substituted dipeptide ester compounds



































































































DKP compounds including cyclic dimers
Assay on MRC5 lung cell-line (50 µM)
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Compounds from TABs series

















































































































N-substituted dipeptide ester compounds










































































































DKP compounds including cyclic dimers



























Compounds from TABs series
Assay on MCF7 breast cancer cell-line (50 µM)
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A few compounds from N-substituted dipeptide esters (B11, B12, B18, B25 and B28) and 
DKP (D13 and D14) series show significant loss of viability at 50 µM. The compounds 
showing more than 50 % viability loss were then subjected to IC50 studies.  
 
The IC50 value of B18 has been measured at 13.09 µM, while IC50 value of C14 has been 
measured at 43.72 µM for A2058 cell line. The IC50 value for the other compounds and 
cell lines could not be determined due to high variations because of precipitation of 
compounds.  
3. Anti-fouling assay 
As the DKP scaffold was developed from synoxazolidinones, barettin and ianthelline, we 
also expected the compounds to show anti-fouling activity. Currently, the only available 
assay for anti-fouling activity is the bio-film assay. In this assay, the activity of the 
compound is determined by whether it can inhibit the biofilm formation of Staphylococcus 
epidermidis. 
The biofilm assays were carried out at MarBio. To confirm as an active compound, the 
optical density value should come less than or equal to 0.25. However, no compound from 







































4. Cellular lipid peroxidation antioxidant assay (CLPAA) 
CLPAA is used for testing of anti-oxidative effect of compounds. It measures the 
intracellular anti-oxidative protection against free radicals. The assays were carried out at 
MabCent. Compounds from all 3 series were tested. The residual activity less than 50 % is 
























N-substituted dipeptide ester compounds






































































































DKP compounds including cyclic dimers























Compounds from TABs series






5. Anti-bacterial activity assays 
The anti-bacterial assays were carried out at MabCent. Compounds from all three series 
were tested. The assays were done against 5 bacterial species: 
1) Enterococcus faecalis 
2) Escherichia coli 
































N-substituted dipeptide ester compounds




































Cellular Lipid Peroxidation Antioxidant Assay (50 µM)
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Cellular Lipid Peroxidation Antioxidant Assay (50 µM)
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4) Staphylococcus aureus 
5) Streptococcus bovis 
For the antibacterial assays, cell density less than 0.05 is considered an indication of an 
active compound. However, no compound from all three series was found to be active in 
any anti-bacterial assay.  




































N-substituted dipeptide ester compounds







































































































DKP compounds including cyclic dimers



























Compounds from TABs series








































N-substituted dipeptide ester compounds











































































































DKP compounds including cyclic dimers


























Compounds from TABs series
Assay on E Coli (50 µM)
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N-substituted dipeptide ester compounds


















































































































DKP compounds including cyclic dimers































Compounds from TABs series
Assay on Pseudomonas aeruginosa (50 µM)
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N-substituted dipeptide ester compounds

























































































































DKP compounds including cyclic dimers
































Compounds from TABs series
Assay on Staphylococcus aureus (50 µM)
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Cell density less than 0.05 is required to consider a compound as active. Thus, no 





































N-substituted dipeptide ester compounds






















































































































DKP compounds including cyclic dimers
































Compounds from TABs series
Assay on Streptococcus bovis (50 µM)
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6. SILAC studies 
a. Downregulated proteins 
Table 36. Downregulated proteins with significant change 










C: Ratio H/L 
normalized 
0.5 µM B 
significant 
C: Ratio H/L 
normalized 
2.5 µM B 
significant 
C: Ratio H/L 
normalized   
5 µM B 
significant 
FABP7 -0.5621 -0.3640 -0.6763 + + + 
LIMCH1 -0.5074 -0.3293 -0.1321 + +  
PDS5A -0.3963 -0.2584 -0.0140 + +  
UBAP2L -0.2782 -0.1897 -0.0523 + +  
MYH10 -0.5008 -0.3426 0.1881 + +  
ITGAV -0.3043 -0.2144 0.0742 + +  
TAGLN -0.9489 -0.6920 -0.6865 + + + 
MAD1L1 -0.3066 -0.2323 0.0138 + +  
NUP155 -0.2613 -0.2049 -0.0436 + +  
SF3B2 -0.2105 -0.1657 -0.0250 + +  




-0.2514 -0.1992 -0.0963 + +  
PEG10 -0.2421 -0.1980 -0.1218 + +  
ARPC5L -0.4846 -0.3987 -0.0824 + +  
MSH6 -0.2677 -0.2211 0.0410 + +  
MAP4 -0.2307 -0.1954 0.0563 + +  
ANLN -0.3106 -0.2659 -0.0379 + +  
CEP170 -0.4256 -0.3747 -0.0038 + +  
CWC22 -0.4077 -0.3743 -0.6052 + + + 
RBX1 -0.3960 -0.3669 -0.3472 + + + 
CBX3 -0.2604 -0.2479 -0.1395 + +  
DIS3 -0.2088 -0.2279 -0.0177 + +  
TIMP3 -0.5664 -0.6344 -0.3649 + + + 
LAMB1 -0.3160 -0.3616 0.4140 + +  
CDH2 -0.2845 -0.3415 -0.3549 + + + 
SLC7A1 -0.2959 -0.3610 0.2004 + +  
GSN -0.3108 -0.4203 -0.5218 + + + 
ATP1A1 -0.2069 -0.2857 -0.0621 + +  
FLNA -0.1403 -0.2795 0.5093 + +  
HSP90AB2P -0.2117 -0.5089 -0.1183 + + + 
NCOR1 -0.3628 -2.2587 -0.1888 + +  
MANF -0.8355 -0.0998 -0.2980 +  + 
MRPL43 -0.6707 NaN -1.0579 +  + 
SNCA -0.8705 -0.2178 -0.1751 +  + 





-1.4699 -0.0341 -0.3694 +  + 
CAPS -0.9050 NaN -1.2556 +  + 
EIF1; EIF1B -0.2897 0.1209 -0.2657 +  + 
RPLP2 -0.7308 -0.0269 -0.2263 +  + 
RPS10;RPS10P5 -0.2200 -0.0985 -0.1917 +  + 
NUBP1 -0.6034 NaN -0.2983 +  + 
MTPN -0.3305 0.3017 -0.2202 +  + 
ACTC1;ACTA1 -0.2175 -0.0252 -0.2021 +  + 
UBE2L3 -0.4292 -0.0550 -0.1536 +  + 
FABP5 -0.1504 0.0243 -0.2501 +  + 
HSPA14 -0.3443 NaN -0.3578 +  + 
GPNMB -0.2913 -0.1639 -0.2252 +  + 
PFDN5 -0.8685 NaN -0.3107 +  + 
COPS8 -1.2720 0.1849 -0.4648 +  + 
VPS16 -0.2410 -0.1694 -0.4128 +  + 
ACSL1 0.0606 -0.2169 -0.4471  + + 
CALD1 -0.1622 -0.1826 -0.1577  + + 
VKORC1 -0.0842 -0.7549 -0.6919  + + 
PUS1 -0.2180 -0.7775 -0.2791  + + 
PYGL -0.1142 -0.2125 -0.1553  + + 
CRKL -0.2517 -0.2740 -0.3389  + + 
SNW1 -0.0859 -0.2379 -0.2299  + + 
CIRBP -0.0971 -1.7229 -0.5395  + + 
UAP1 -0.1603 -0.2406 -0.3402  + + 
ELMO2 NaN -0.5779 -0.4515  + + 
DPP9 0.1734 -0.7812 -0.4670  + + 
AKAP1 NaN -0.7588 -1.0041  + + 
STAM NaN -0.3678 -0.4854  + + 
CHMP4B NaN -0.3399 -0.4884  + + 
RAI14 -0.0497 -0.7148 -0.5126  + + 
SPCS1 NaN -0.6461 -0.3987  + + 
NaN = The peptides corresponding to the protein could not be identified in both heavy and light media 
samples. 
 
b. Upregulated proteins 
Table 37. Upregulated proteins with significant change 










C: Ratio H/L 
normalized 
0.5 µM B 
significant 
C: Ratio H/L 
normalized 
2.5 µM B 
significant 
C: Ratio H/L 
normalized   
5 µM B 
significant 
RPL36 0.3639 0.1378 -0.0947 + +  
ATP5I 0.4084 0.1932 -0.0865 + +  
RPL39P5; RPL39 0.4193 0.2227 -0.1828 + +  
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TMEM258 0.5213 0.2889 -0.2764 + +  
EXOSC2 0.3619 0.2228 0.1643 + +  
DAD1 0.2844 0.1805 -0.2871 + +  
ACBD3 0.3042 0.1980 -0.0050 + +  
GABARAP; 
GABARAPL1 
0.6808 0.4592 NaN + +  
HSPA1B; 
HSPA1A 
0.2020 0.1375 0.1843 + + + 
SERPINB1 0.3340 0.2434 0.1130 + +  
RPS23 0.3043 0.2238 -0.0605 + +  
SORBS2 0.4691 0.3463 0.0259 + +  
DPM3 0.3275 0.2494 -0.2162 + +  
ROMO1 0.5096 0.3936 NaN + +  
MMP14 0.3975 0.3080 0.3268 + + + 
LMNB2 0.2552 0.1995 0.1511 + +  
FAH 0.2432 0.1911 0.0592 + +  
SEC61G 0.3337 0.2674 -0.4032 + +  
IER3IP1 0.3613 0.2957 -0.2918 + +  
 0.1626 0.1333 -0.1003 + +  
ME1 0.3996 0.3318 0.3717 + + + 
CTSD 0.2683 0.2297 0.2460 + + + 
TMEM59 0.4868 0.4273 -0.2674 + +  
APOBEC3C 0.2292 0.2040 0.2095 + + + 
ANPEP 0.1391 0.1290 0.2989 + + + 
SQSTM1 0.5540 0.5170 0.5628 + + + 
TGM2 0.4270 0.3985 0.5245 + + + 
KYNU 0.3226 0.3024 0.2428 + + + 
RCN1 0.2183 0.2086 0.0303 + +  
SERPINB6 0.1738 0.1692 0.0849 + +  
G6PD 0.2185 0.2203 0.2347 + + + 
KCTD12 0.3465 0.3516 0.2678 + + + 
RPL35A 0.2149 0.2181 0.0072 + +  
AGPAT9 0.5789 0.5943 NaN + +  
AKR1B1 0.3334 0.3449 0.3279 + + + 
IFITM2; IFITM3; 
IFITM1 
0.2499 0.2606 -0.0918 + +  
SNRPG; 
SNRPGP15 
0.3871 0.4088 -0.0110 + +  
ERLIN2 0.2727 0.2915 0.1991 + + + 
SPATA5L1 0.3092 0.3362 -0.0936 + +  
S100A6 0.2965 0.3298 -0.0707 + +  
GCLC 0.3342 0.3733 0.2624 + + + 
MYLK 0.3999 0.4495 0.2707 + +  
SERPINB9 0.2521 0.2862 0.2176 + + + 
FAU 0.2038 0.2320 -0.0504 + +  
HIST2H3A 0.1319 0.1587 -0.0138 + +  
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PGD 0.1551 0.1914 0.1776 + + + 
MGST1 0.1666 0.2058 -0.0654 + +  
HSPE1 0.1528 0.1931 -0.0862 + +  
HMOX1 0.3582 0.4582 0.4652 + + + 
TXN 0.1718 0.2247 -0.0633 + +  
CKB 0.2063 0.2701 0.1794 + +  
RPS28 0.1626 0.2228 -0.1141 + +  
TUBB4A 0.2281 0.3211 -0.0477 + +  
EPHX1 0.1871 0.2800 0.1974 + + + 
USMG5 0.1900 0.2921 -0.0817 + +  
LGALS1 0.1586 0.2449 0.0195 + +  
SDCBP 0.1809 0.2799 0.1519 + + + 
MFF 0.2648 0.4345 NaN + +  
PIGU 0.2954 0.6002 0.0807 + +  
TXNRD1 0.1170 0.1025 0.1406 +  + 
PLOD2 0.1909 0.1328 0.2170 +  + 
RNF40 0.5578 NaN 0.7058 +  + 
ZNF207 0.2994 NaN 0.5037 +  + 
RAB27B 0.5577 NaN 0.5121 +  + 
PTGES 1.0086 NaN 0.4841 +  + 
PAPSS2 0.2463 0.0990 0.2463 +  + 
TFPI2 0.4029 0.2700 0.5492 +  + 
PTDSS1 0.3705 -0.1155 0.3481 +  + 
TRA2B 0.1656 0.1693 0.1747 +  + 
ATL3 0.1685 0.1051 0.1990 +  + 
HTRA1 0.3151 0.1677 0.5779 +  + 
EXOSC4 0.3183 NaN 0.5040 +  + 
SERINC1 0.5131 0.1762 0.3665 +  + 
EBF2 0.0006 0.4249 0.4813  + + 
SDCBP 0.2171 0.2826 0.5773  + + 
AIP 0.2365 0.2535 0.2470  + + 
KPNA6 -0.0616 0.1964 0.2209  + + 
FTL -0.0495 0.3507 0.3473  + + 
NQO1 0.0656 0.1634 0.2085  + + 
PSM8; PSMB8 0.1866 0.2297 0.2313  + + 
GCLM 0.1239 0.2450 0.2468  + + 
TFCP2 NaN 1.0218 0.3476  + + 
DECR1 0.0942 0.2116 0.2221  + + 
RDH11 0.0982 0.2328 0.2675  + + 
NDRG1 0.2290 0.4208 0.4699  + + 
RIC8A 0.1312 0.2888 0.4033  + + 
PLXNA1 NaN 0.5035 0.4231  + + 
NaN = The peptides corresponding to the protein could not be identified in both heavy and light media 
samples.  
 
 
